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Ágrip 
Lungnakrabbamein er þriðja algengasta krabbameinið á Íslandi og það 
krabbamein sem leggur flesta Íslendinga af velli. Sjúklingar læknast sjaldnast án 
skurðaðgerðar og því er markmiðið að beita skurðaðgerð hjá sem flestum 
sjúklingum þegar ábending er til staðar. Skurðmeðferð kemur hinsvegar 
eingöngu til greina hjá þeim sjúklingum sem eru með staðbundið 
lungnakrabbamein og vefjagerðin ekki smáfrumukrabbamein.  
Algengasta vefjagerð þeirra sem gangast undir skurðaðgerð er 
kirtilfrumukrabbamein en flöguþekju- og stórfrumukrabbamein koma þar á eftir. 
Algengasta skurðaðgerðin er blaðnám en stundum er beitt fleyg- eða geiraskurði 
ellegar lungnabrottnámi. Skammtíma- og langtímaárangur skurðaðgerða við 
lungnakrabbameini hefur batnað á síðustu árum og þrátt fyrir að innan við fimmti 
hver lungnakrabbameinssjúklingur læknist í heildina þá er fimm ára lifun þeirra 
sjúklinga sem gangast undir skurðaðgerð vegna staðbundins æxlis í lunganu allt 
að 80%.  
Þessi doktorsritgerð tekur til fjögurra vísindagreina (I-IV) þar sem markmiðin 
voru fjórskipt. Í fyrsta lagi var leitast við að reikna hlutfall sjúklinga með 
lungnakrabbamein sem gengust undir skurðaðgerð hjá heilli þjóð. Í öðru lagi að 
meta skammtíma- og langtímaárangur þessara aðgerða með sérstakri áherslu á 
afdrif sjúklinga sem gengust undir blaðnám, en einnig á afdrif þeirra sem höfðu 
kirtilfrumukrabbamein eða voru aldraðir (≥75 ára). Í þriðja lagi var markmiðið að 
meta hvort alþjóðlega flokkun IASLC/ATS/ERS á kirtilfrumukrabbameinum frá 
árinu 2011 spái fyrir um lifun þessara sjúklinga. Í fjórða lagi að kanna hversu 
margir sjúklingar eldri en 75 ára gengust undir skurðagerð og af hverju sjúklingar 
sem taldir voru með skurðtækan sjúkdóm gengust ekki undir aðgerð.  
Sjúklingar voru fundnir í þremur aðskildum skráningarkerfum. Sjúklingar sem 
gengust undir aðgerð voru fundnir í rafrænni aðgerðarskrá Landspítala og 
gagnagrunni rannsóknastofu Landspítala í meinafræði. Upplýsingar um sjúklinga 
sem ekki gengust undir skurðaðgerð voru fengnar úr krabbameinsskrá 
Krabbameinsfélags Íslands. Sjúkraskrár og aðgerðarlýsingar voru skoðaðar og 
klínískar upplýsingar um sjúklinga skráðar rafrænt. Lifun var metin með aðferð 
Kaplan-Meier og forspárþættir lifunar metnir með fjölþáttagreiningu Cox. Allar 
rannsóknirnar fjórar voru afturskyggnar og lýðgrundaðar.  
Grein I tók til 397 sjúklinga sem gengust undir 404 skurðaðgerðir við 
lungnakrabbameini á Íslandi frá árinu 1994 til ársins 2008. Á öllu tímabilinu var 
hlutfall þeirra sem gengust undir skurðaðgerð 26,4% og 8,7% fengu alvarlega 
fylgikvilla í kjölfar aðgerðar. Dánartíðni innan 30 daga frá aðgerð var 1% og 5 ára 
heildarlifun reyndist 40,7%. Sjúklingar sem ekki gengust undir skurðaðgerð höfðu 
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4,8% fimm ára lifun og fyrir alla lungnakrabbameinssjúklinga í heildina var lifunin 
12,4%.   
Grein II tók til 489 sjúklinga sem gengust undir blaðnám við 
lungnakrabbameini á Íslandi á árunum 1991-2014. Dánartíðni innan 30 daga var 
0,6% og 4,7% fengu alvarlega fylgikvilla. Heildarlifun fimm árum frá aðgerð var 
49,2% og þriggja ára lifun jókst frá 48,3% á árunum 1991-1994 í 72,8% á 
árunum 2011-2014 (p = 0,0004). Svipuð aukning í lifun sást einnig fimm árum frá 
aðgerð en skemmri eftirlitstími á síðasta tímabilinu gerir samanburð á þriggja ára 
lifun áreiðanlegri.     
Grein III lýsti árangri aðgerða hjá 285 sjúklingum með kirtilfrumukrabbamein 
sem gengust undir lungnaskurðaðgerð á árunum 1991-2010 og undirflokkun 
þeirra samkvæmt IASLC/ATS/ERS flokkuninni frá árinu 2011. Algengasta 
vefjaundirgerðin reyndist vera þrúgufrumu (acinar) ríkjandi kirtilfrumukrabbamein 
(46%), þar á eftir þétt (solid) ríkjandi kirtilfrumukrabbamein með slímmyndun 
(23%) og hreisturlík (lepidic) ríkjandi kirtilfrumukrabbamein (20%). Fimm ára lifun 
var 45,3%. Ekki sást marktækur munur á lifun eftir undirgerðum 
kirtilfrumukrabbameins og IASLC/ATS/ERS flokkunin reyndist ekki vera 
sjálfstæður forspárþáttur lifunar í fjölþáttagreiningu líkt og sumar erlendar 
rannsóknir hafi sýnt.  
Í grein IV var fjallað um aldraða einstaklinga (≥ 75 ára) sem greindust með 
lungnakrabbamein af ekki smáfrumugerð. Hlutfall þeirra sem gengust undir 
skurðaðgerð og árangur aðgerða var borinn saman við yngri sjúklinga sem 
gengust undir skurðaðgerð. Skurðhlutfall hjá öldruðum reyndist 18% borið saman 
við 32% hjá þeim yngri (p < 0,001). Hvorki reyndist marktækur munur á 
fylgikvillum né 30 daga dánartíðni milli hópanna. Algengustu ástæður þess að 
sjúklingar voru ekki teknir í aðgerð þrátt fyrir skurðtækan sjúkdóm reyndust 
ófullnægjandi lungnastarfsemi (58%), hjartasjúkdómur (17%) og margþætt önnur 
heilsufarsvandamál (17%). Heildarlifun var betri fyrir yngri hópinn en þann eldri 
(40% sbr. 44%, p = 0,019) en ekki reyndist munur á krabbameinssértækri lifun 
(51% sbr. 50%, p = 0,8).  
Samantekið þá er hlutfall sjúklinga sem gangast undir skurðaðgerð vegna 
lungnakrabbameins hátt hér á landi. Skammtímaárangur þessara aðgerða er 
góður og tíðni alvarlegra fylgikvilla og 30 daga dánartíðni lág. Að frátöldum 
árangri eftir lungnabrottnám eru langtímalífshorfur sjúklinga svipaðar og í 
erlendum rannsóknum og lífshorfur fara batnandi.  
Lykilorð:  
Lungnakrabbamein, skurðhlutfall, kirtilfrumukrabbamein, blaðnám, lífshorfur, 
aldraðir. 
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Abstract 
Lung cancer is the third most common type of cancer and the prime cause of 
cancer-related deaths in Iceland. As surgical resection is the only well-defined 
and well-studied curative treatment, the aim is to offer surgery to as many 
patients as possible who have resectable disease. However, less than one-
quarter of the patients (most often non-small cell lung carcinoma, NSCLC) are 
diagnosed at the early stages and thus are candidates for surgery.   
The most common surgical procedure is lobectomy, but in some cases a 
sublobar resection (wedge or segment resection) is performed or 
pneumonectomy is required. The most common histological type of lung cancer 
is adenocarcinoma (AC), followed by squamous cell carcinoma (SCC) and large 
cell carcinoma (LCC). The short- and long-term outcomes of pulmonary 
resections for NSCLC have improved over the past years, and even if the total 5-
year survival of lung cancer patients is less than 20%, the survival of patients 
with resectable localized disease can be up to 80%.  
This thesis is based on four peer-reviewed papers (I‒IV) and the aim was to 
investigate four key issues: (1) to investigate the surgical resection rate for lung 
cancer surgery in a whole nation; (2) to determine short- and long-term outcomes 
of surgery, with special emphasis on patients who underwent lobectomy, had AC 
separately, or were elderly (≥ 75 years); (3) to determine whether the 
international IASLC/ATS/ERS adenocarcinoma classification system from 2011 
predicts survival in surgical patients with lung cancer in Iceland; and (4) to 
determine how many patients aged ≥ 75 years underwent pulmonary resection  
and to determine the reasons for the operation not being performed in patients 
with resectable disease.  
Three separate registries were used to identify cases. The histology database 
from the Department of Pathology at Landspitali University Hospital and the 
diagnosis and operation registry at Landspitali were used to identify patients who 
underwent surgery for NSCLC, and the Icelandic Cancer Registry was used to 
find patients who were not operated on. Clinical information was gathered from 
hospital charts and surgical records, and entered into a data sheet. Survival was 
analyzed using the Kaplan-Meier method and multivariate Cox analysis was 
used to evaluate possible independent prognostic factors of survival. All four 
studies were retrospective, population-based nationwide studies.  
In paper I, all 404 cases (397 patients) who underwent pulmonary resection 
for NSCLC in Iceland during 15 years (1994‒2008) were studied. The surgical 
resection rate was 26.4%, and 8.7% had major postoperative complications. The 
30-day mortality rate was 1% and the 5-year overall survival was 40.7%. Patients 
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who did not undergo surgical resection had a 5-year survival of 4.8%, as 
compared to 12.4% for all lung cancer patients combined.  
Paper II involved 489 consecutive patients who underwent lobectomy for 
NSCLC in Iceland from 1991 to 2014. The 30-day mortality was 0.6% and 4.7% 
had a major complication postoperatively. The 5-year overall survival was 49.2% 
and the 3-year overall survival improved from 48.3% in the period 1991‒1994 to 
72.8% in 2011‒2014 (p = 0.0004). Similar improvement was observed in 5-year 
survival, but 3-year survival was chosen for comparison due to shorter follow-up 
during the last 4-year period.   
Paper III described the outcome of 285 patients with resected primary AC of 
the lung in Iceland 1991‒2010, and their subclassification according to the 
IASLC/ATS/ERS adenocarcinoma classification from 2011. The most common 
AC subtype was acinar-predominant (46%), followed by solid-predominant with 
mucin production (23%) and lepidic-predominant (20%). At 5 years, the overall 
survival was 45.3% and no difference was found in survival between the 
histological subtypes. The histological subtype was not found to be an 
independent predictor of overall survival (p = 0.7), in contrast to several studies 
that have reported more favourable survival for certain subtypes of ACs.   
Paper IV was a retrospective study on the surgical resection rate and 
outcome in elderly patients (≥ 75 years old) who had a pulmonary resection for 
NSCLC in Iceland between 1991 and 2014. The elderly patients were compared 
with younger patients (< 75 years), with surgical resection rates being 18% and 
32%, respectively (p < 0.001). The most frequent reasons for not performing 
surgery were insufficient pulmonary function (58%), heart disease (17%), and 
multiple comorbidities (17%). No significant differences in rates of complications 
or 30-day mortality were observed between the older and the younger groups. 
Five-year overall survival was significantly different (40% and 44%) in the elderly 
and younger groups, respectively (p = 0.019) but cancer-specific survival was not 
significantly different (51% vs. 50%; p = 0.8).  
In summary, the surgical resection rate for non-small cell lung carcinoma and 
the short-term outcome was good, as reflected in the low rates of postoperative 
complications and 30-day operative mortality, Furthermore, with the exception of 
pneumonectomies, the long-term survival after surgical resection was similar to 
what other studies have shown―and is improving.  
 
Keywords:  
Lung cancer surgery, surgical resection rate, adenocarcinoma, lobectomy, 
survival, elderly. 
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1 Introduction 
Lung cancer, with its high mortality rate, is a considerable health problem in most 
parts of the world (Ferlay et al., 2013). As 90% of cases are related to smoking 
and are therefore preventable (Brawley et al., 2014; CDC, 2016), numerous 
public health projects are in progress in the western world in order to prevent 
smoking and lung cancer (Codern-Bove et al., 2014; Coleman et al., 2010; Loke 
& Mak, 2015). Currently, the only well-defined and thoroughly studied curative 
treatment for non-small cell lung cancer (NSCLC) is surgical resection, but 
surgery is only indicated in the early stages of the disease. For more advanced 
stages, chemo- and/or radiotherapy, immunotherapy or targeted treatment, are 
the treatments of choice, depending on the patient’s disease and condition 
(Novello et al., 2016). Many factors can be used to predict the prognosis and 
survival of the patients, but those who undergo surgical resection have a more 
favourable prognosis than those who are not treated with resection. However, in 
recent years numerous new treatments for NSCLC have been introduced, and 
the survival of lung cancer patients as a whole is improving (Goldstraw et al., 
2016). Even so, most patients in whom the disease has spread have a dismal 
prognosis (Siegel et al., 2016).  
1.1  Lung cancer 
1.1.1  Epidemiology  
In Iceland, as in the other Nordic countries and most other parts of the world, 
lung cancer is the third most common cancer diagnosed, with only breast cancer 
in women and prostate cancer in men being more common (Engholm et al., 
2014; Ferlay et al., 2013; Torre et al., 2015). Lung cancer is, however, the 
leading cause of cancer-related death, representing 26% of all cancer mortality 
(Figure 1) (Siegel et al., 2015). In Iceland, lung cancer mortality is higher than 
that for breast, prostate, and colon cancer combined (Krabbameinsskra, 2016).  
In western Europe, the incidence of lung cancer in men is around 42/100,000 
inhabitants per year and for women it is 20/100,000 inhabitants (Ferlay et al., 
2013). However, since 2011 in Iceland, more women than men have been 
diagnosed with lung cancer, the incidence being 33.6/100,000 in women and 
30.1/100,000 in men. Every year, around 160 individuals are diagnosed with lung 
cancer in Iceland (Krabbameinsskra, 2016), but with lower smoking rates, a 
declining age-standardized incidence has been noted―especially in men, as in 
most developed countries (Engholm et al., 2010; Kohler et al., 2015). In 
developing countries, however, the incidence of lung cancer is expected to rise 
due to increased cigarette consumption (Silvestri et al., 2009) 
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1.1.2  Smoking and other risk factors 
By far the most important and relevant risk factor in the development of lung 
cancer is cigarette smoking, which is believed to account for around 80‒90% of 
all deaths from lung cancer (CDC, 2016; Siegel et al., 2016). The association 
between smoking and lung cancer is strongest with small cell lung carcinoma 
(SCLC) and squamous cell carcinoma (SCC) histology―but somewhat lower for 
adenocarcinoma (AC), where it is still believed to explain 80‒85% of all cases 
(Miller & Franklin, 1997).  
The risk of lung cancer is dose-dependent, with every cigarette smoked 
having the potential to cause DNA damage (Warren & Cummings, 2013). The 
exposure to activated carcinogens from tobacco smoke results in the formation 
of DNA adducts which, if not managed by the cellular repair systems may persist 
in the cells, thus increasing the likelihood of mutations, leading to the disruption 
of cell growth, cell proliferation and cell survival (Warren & Cummings, 2013). 
Indeed, increased mutation frequencies are observed in lung cancers arising in 
smokers compared to never-smokers (Govindan et al., 2012). Pipe smoking 
does not seem to be safer than smoking cigarettes (Tverdal & Bjartveit, 2011).  
Figure 1:  Estimated new cancer cases and estimated cancer deaths in 
the United States in 2016. Adapted from Siegel et al. (2015). 
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Second-hand smoking has also been shown to be a risk factor for 
development of lung cancer, although it is not as strong a causative factor as 
direct smoking (IARC, 2004). Second-hand smoking is thought to affect children 
and adolescents more than adults, and studies have indicated that around 17% 
of the lung cancer incidence in individuals who have never smoked is linked to 
second-hand smoking (Janerich et al., 1990; Thun et al., 2008). Some of the 
other environmental factors that have been linked to lung cancer are asbestos, 
arsenic (IARC, 2012b), and radiation (IARC, 2012a).  
Many factors other than smoking are involved in the aetiology of lung cancer. 
The disease is more common in people with chronic obstructive pulmonary 
disease (COPD) (Skillrud et al., 1986) and in the relatives of lung cancer patients 
(Etzel et al., 2003). In a study from Iceland, the relative risk of being diagnosed 
with lung cancer was shown to be double if individuals had a relative with lung 
cancer, even if the relative was distantly related and the data were corrected for 
smoking (Jonsson et al., 2004). A meta-analysis published shortly afterwards 
confirmed these results (Matakidou et al., 2005). Similar reports have been 
published by other groups, such as the International Lung Cancer Consortium 
from 2012 (Cote et al.), which reported a 1.5-fold increase in risk due to family 
history.  
Numerous genome-wide association studies have identified common low-
penetrance genetic risk alleles that moderate effects on lung cancer risks (Musolf 
et al., 2017). Among others, regions on chromosomes 15q, 6p, and 5p have 
been found to be associated with a higher risk of lung cancer (Amos et al., 2008; 
Hung et al., 2008; Thorgeirsson et al., 2008; Wang et al., 2008). Several other 
rare genetic variants―such as those located in the EGFR and TP53 
genes―have been identified that appear to increase lung cancer risk in a small 
number of families (Bell et al., 2005; Lou et al., 2016; Zhuang et al., 2016).  
1.1.3  Presenting symptoms 
Around 90% of all lung cancer patients have symptoms at diagnosis, but 5‒10% 
of cases are detected incidentally (Spiro et al., 2007). However, in patients with 
resectable disease, the proportion of patients diagnosed incidentally is higher, or 
around 30% (Raz et al., 2007). The most common symptoms at diagnosis are 
shown in Table 1.  
Cough is the most common symptom, followed by dyspnea, chest pain, and 
haemoptysis. Chest pain is usually intermittent and ill-defined. Direct pleuritic 
pain can be caused by invasion of the tumour into the pleura. Haemoptysis is 
rarely severe or fresh, and usually consists of only blood coloration of the sputum 
(Spiro et al., 2007). 
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Table 1:  The most common symptoms and signs of lung cancer. Patients 
can have more than one symptom at the same time. Adapted from 
Spiro et al. (2007), Pass et al. (2012), and Sandström & Eklund 
(2015)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumour in the upper right lung and bulky metastasis in the right mediastinum 
can cause obstruction to the superior vena cava, which is called superior vena 
cava (SVC) syndrome. It can lead to oedema in the head, neck, and arms 
(Saadeen & Jazieh, 2008). If a tumour invades the stellate ganglion, Horner’s 
syndrome can be seen―which includes ptosis, relative pupillary miosis, and 
unilateral anhydrosis on the same side as the lung tumour (Martin, 2007). 
Tumours in the apices of the lungs are called Pancoast tumours, and can invade 
the brachial plexus and cause neuralgic pain in the patient’s arm and shoulder 
(Detterbeck, 1997) (Figure 2). Wheezing and stridor are usually caused by 
tumours in the main bronchus or trachea (Spiro et al., 2007). If the tumour 
involves the recurrens nerve, the patient can present with hoarseness.  
 
Symptoms Frequency % 
Cough 45‒75 
Weight loss 40‒65 
Dyspnea 35‒60 
Pain 20‒49 
Haemoptysis 15‒35 
Clubbing 0‒20 
Fever 0‒20 
Weakness 0‒10 
Superior vena cava obstruction 0‒4 
Dysphagia 0‒2 
Wheezing and stridor 0‒2 
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Figure 2:  Computed tomography image showing a Pancoast tumour in the 
superior lobe of the right lung. Image: Stefan Barath, Skånes 
Universitetssjukhus, Lund.  
Around one-third of patients are diagnosed because of symptoms that are 
caused by metastases, most commonly found in bones, liver, adrenal glands, 
brain, or spinal cord (Spiro et al., 2007). Pain is a common presenting symptom 
of lung cancer and often comes from bone metastasis.  Around 10% of patients 
are diagnosed with brain metastases at diagnosis, and can present with 
symptoms such as headache, seizure, paralysis, and/or personality changes 
(Spiro et al., 2007). 
Paraneoplastic symptoms are well known in lung cancer, occurring in around 
10‒20% of patients in various forms (Spiro et al., 2007; Sridhar et al., 1998).  
These are clinical systemic symptoms that are not caused by the growth of the 
tumour itself or a metastasis. Endocrine disorders are most common, including 
hypercalcaemia, syndrome of inappropriate antidiuretic hormone production 
(SIADH), and Cushing syndrome (Spiro et al., 2007). A prospective study on 
clubbing of fingers showed that it is present in around 30% of patients and is 
more common in women than in men, and also in patients with NSCLC rather 
than SCLC (Sridhar et al., 1998). The incidence of hypertrophic pulmonary 
osteoarthropathy is much lower, however, at around 1% (Ito et al., 2010; Izumi et 
al., 2010).  
1.1.4  Histology 
Around 95% of lung cancers fall into four main histological patterns (Figure 3); 
SCLC, SCC, AC, and large cell carcinoma (LCC). Together, SCC, AC, and LCC 
are called non-small cell lung carcinoma (NSCLC). In the past decades, an 
increase in the incidence of ACs has been seen, which is now the most frequent 
histological type and more often found in females (Dela Cruz et al., 2011). AC is 
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also the most frequent histological type in patients who are non-smokers (Dela 
Cruz et al., 2011). The incidence of SCC and SCLC, however, is decreasing. The 
frequency of smoking is declining, lowering the frequency of SCC and SCLC. 
Due to the changes in smoking patterns, especially the increased use of filtered 
cigarettes, there is a decrease of SCC but not AC (Ginsberg, 2005; Stellman et 
al., 1997).  
Each histological type of NSCLC has its own diagnostic criteria. In recent 
years, molecular markers and immunohistochemistry have been increasingly 
used in lung cancer diagnosis, and have clinical value regarding the choice of 
treatment (Travis et al., 2015). Earlier, such as in the 2004 WHO classification of 
AC, the primary diagnosis was based on H&E examination of the sample. 
According to the 2004 WHO classifications for lung tumours, to diagnose SCC, 
keratin must be seen inside or between cells and/or cell-to-cell bridges (Travis et 
al., 2004). In the 2015 WHO classification (Travis et al.), there have been some 
changes where immunohistochemistry is used to diagnose SCC and differentiate 
between keratinizing, non-keratinizing, and basaloid subtypes. According to the 
2011 IASLC/ATS/ERS classification, however, the use of immunohistochemical 
studies, (e.g. p63 staining), histochemical studies (e.g. mucin staining), and 
molecular studies may be used where and when they are available. Furthermore, 
in the 2015 WHO classification, LCCs that have pneumocyte marker expression 
(TTF1 and/or NapsinA) are classified as solid AC―even when mucin is absent. 
Diagnostic criteria for AC in the 2004 classification are intra-/intercellular mucus 
and/or gland formation. In 2011, a new classification system for ACs was 
introduced by the IASLC/ATS/ERS, which is explained further in the following 
section. In the classification from 2004, LCCs are classified as having big tumour 
cells without differentiation towards squamous or glandular epithelium (Travis et 
al., 2004). However, the 2015 classification (Travis et al., 2015) restricts the 
diagnosis of LCC to resection samples and uses immunohistochemistry to 
differentiate them regarding which category they belong to. SCLCs account for 
13‒20% of lung cancers and differ from NSCLCs in numerous ways both 
clinically, histologically and molecularly. They are of aggressive nature and have 
usually already metastasized at diagnosis (Simon & Turrisi, 2007).  The histology 
shows that cells in SCLC are twice the size of a lymphocyte and they do not form 
a distinct pattern. Only a few nucleoli can be seen, and the proliferation rate is 
high (Simon & Turrisi, 2007). 
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Figure 3:  The major histological types of lung cancer: a. Small cell lung 
carcinoma; b. Squamous cell carcinoma; c. Adenocarcinoma; and d. 
Large cell carcinoma. 
1.1.4.1 Adenocarcinoma subtyping 
AC is the most common histological subtype of lung cancer (Devesa et al., 2005; 
Forman et al., 2013) and has a widely divergent clinical, molecular, pathological, 
and radiological spectrum. A need for universally accepted criteria for AC 
subtypes has therefore been needed. In the WHO classification for tumours of 
the lung from 1999 and 2004, 94% of the ACs were classified in the “mixed 
subtype” category (Travis et al., 2004). Although histologically correct, this 
classification had limited clinical relevance and a multidisciplinary approach was 
needed. In 2011, the International Society for the Study of Lung Cancer (IASLC), 
the American Thoracic Society (ATS), and the European Respiratory Society 
(ERS) launched a new classification system for primary lung ACs (Travis et al., 
2013; Travis et al., 2011) with the aim to provide uniform terminology and 
diagnostic criteria for AC, and at the same time address advances in oncology, 
surgery, radiology, molecular biology, and pathology that could identify 
prognostic and predictive factors and therapeutic agents. This system 
categorizes ACs into four subgroups: pre-invasive, minimally invasive, invasive, 
a)  b)  
d)  c)  
Gudrun Nina Oskarsdottir 
8 
or variants of invasive adenocarcinoma (see Table 2). One of the major changes 
in the 2011 classification concerns the discontinuation of the term 
bronchioloalveolar adenocarcinoma (BAC). It was formerly used for a broad 
spectrum of tumours with similar histology but very different clinical presentation 
and survival rates. In the most recent classification, it has been categorized into 
different subtypes, i.e. AC in situ, minimally invasive AC, and invasive mucinous 
AC. 
1.1.5  Diagnosis 
If a patient presents with symptoms suggestive of lung cancer, chest radiography 
is often the first imaging method used (MacDonald & Hansell, 2003). On a chest 
radiograph, the size of the tumour can be evaluated in addition to atelectasis 
and/or pulmonary effusion (MacDonald & Hansell, 2003). However, invasion of 
mediastinal structures and lymph nodes is not easily visualized on a plain chest 
X-ray (MacDonald & Hansell, 2003). Thus, a computed tomography (CT) scan is 
often indicated (Figure 4), where the size of the tumour can be seen better along 
with the invasion to surrounding structures. Uncalcified tumours, diameter over 
10 mm, irregular edges, and sharp edges are all factors that strongly suggest 
malignancy (Ginsberg et al., 2007).  
Positron emission tomography (PET) scanning is used to better distinguish 
malignant tumours from benign tumours. The metabolism of cancer cells is 
higher than that of the surrounding cells, and with higher metabolism there is 
higher glucose consumption by the cell. Thus, 18F-fluorodeoxyglucose (FDG) 
can be administered intravenously, followed by a PET-scan to determine the 
FDG uptake of the tissue. The sensitivity and specificity of PET scanning are 90‒
100% and 65‒95%, respectively (Ginsberg et al., 2007). A PET scanner will be 
available in Iceland later this year (autumn 2017), but until now patients with 
NSCLC requiring PET-scan have been sent to Copenhagen for evaluation.  
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Table 2: The 2011 IASLC/ATS/ERS classification for primary lung 
adenocarcinoma. Adapted from Travis et al. (2011) 
 
Pre-invasive adenocarcinoma 
- Atypical adenomatous hyperplasia 
- Adenocarcinoma in situ 
o Mucinous 
o Non-mucinous 
o Mixed mucinous and non-mucinous 
Minimally invasive adenocarcinoma 
- Mucinous 
- Non-mucinous 
- Mixed mucinous and non-mucinous 
Invasive adenocarcinoma 
- Lepidic-predominant adenocarcinoma  
- Acinar-predominant adenocarcinoma 
- Papillary-predominant adenocarcinoma 
- Micropapillary-predominant adenocarcinoma 
- Solid-predominant adenocarcinoma with mucin production 
Variants of invasive adenocarcinoma 
- Invasive mucinous adenocarcinoma 
- Colloid 
- Enteric 
- Foetal 
o Low-grade 
o High-grade 
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Figure 4:  A computed tomography scan demonstrating tumour in the right 
upper lobe with irregular and sharp edges. Image: Tómas 
Guðbjartsson, Landspitali University Hospital.  
Bronchoscopy is used for both diagnosis and staging of lung cancer. In a 
bronchoscopy, a sample of the lesion can be taken for histology and/or cells can 
be taken for cytology with a brush sample or bronchoalveolar lavage. White-light 
bronchoscopy is the standard method, and has better sensitivity and specificity in 
large, central lesions (88%) than in small, peripheral ones (33%) (Schreiber & 
McCrory, 2003). Autofluorescent bronchoscopy in combination with white-light 
bronchoscopy increases the sensitivity and specificity of finding pre-malignant 
lesions (Sun et al., 2011).   
If the tumour is not reachable with regular bronchoscopy techniques, a CT-
navigated percutaneous/transtracheal puncture of the lesion may be necessary 
for histological confirmation of the disease (Laroche et al., 2000).  Although not 
yet available in Iceland, some centres have started to use electromagnetic 
navigation bronchoscopy (ENB) to obtain a sample from a peripheral lesion. 
Single-centre studies have shown the efficacy and safety of the use of ENB 
(Wang Memoli et al., 2012; Zhang et al., 2015), and a prospective study is in 
progress (Folch et al., 2016). 
Sputum cytology can be used in the diagnosis of lung cancer, but the 
specificity and sensitivity are not high. They are higher for central lesions than for 
peripheral ones (Schreiber & McCrory, 2003). 
1.1.6  Screening  
Lung cancer has many characteristics that suggest that screening for LC may be 
useful. It is the most lethal cancer for both women and men in the western world, 
it has a long pre-clinical phase, and there is a cure for the patients who are 
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diagnosed early (Warner et al., 2010). This is reflected in an overall 5-year 
survival rate for lung cancer patients in the 10‒17% range (Jemal et al., 2010; 
Siegel et al., 2016; Verdecchia et al., 2007), but the range is 65‒83% for patients 
with localized stage-1 disease (Goldstraw et al., 2016).  
Several methods could be used to screen for lung cancer. Chest X-ray (CXR), 
low-dose CT scanning (LDCT), biomolecular markers in sputum (Carozzi et al., 
2010), breath and blood (liquid biopsies) (Esposito et al., 2017; Hofman, 2017; 
Perez-Callejo et al., 2016; Perez-Ramirez et al., 2016), and fluorescence 
bronchoscopy (Kennedy et al., 2000) are methods that have been evaluated, 
with LDCT being the most widely used (Moyer, 2014; Patz et al., 2016). 
  The first lung cancer screening studies using conventional CXR were done 
in the 1970s, but the results from the first randomized study on the subject were 
published in 1986 and suggested that there was no benefit (Fontana et al.). 
In 1996, a study was published comparing CXR with LDCT, and LDCT was 
found to detect more cancers than CXR (Kaneko et al.). None of the studies 
published to date have shown any difference in overall survival, irrespective of 
whether they were performed on smokers or the general population (Frost et al., 
1984; Marcus et al., 2000; Oken et al., 2011). The first trial to show a difference 
in mortality in patients was the Lung Cancer Screening Trial (with 53,452 
participants) where the relative risk of lung cancer mortality was less, by 20.3% 
(Aberle et al., 2011). The results of this trial are promising, but more factors must 
be taken into account. The risks of LDCT scanning are important to consider, 
such as radiation exposure, increased patient costs, and possible emotional and 
physical morbidity associated with the follow-up or with overdiagnosis. In 2014, 
the US Preventive Services Task Force recommended annual screening using 
LDCT for adult patients aged 55‒80 years with a 30 pack-year smoking history, 
who currently smoke or have stopped in the past 15 years (Moyer, 2014; Patz et 
al., 2016).  
In Europe, many studies on the screening of lung cancer using LDCT are in 
progress, such as the NELSON lung cancer screening study in Belgium and the 
Netherlands (Ru Zhao et al., 2011), but also studies in Denmark and Germany 
(Becker et al., 2012; Pedersen et al., 2009). The Lung Cancer Screening Trial is 
by far the largest study―and is the only study so far to have shown a survival 
benefit from screening (Aberle et al., 2011). To validate the survival benefits, the 
European studies will be pooling their data, to get around 30,000 patients with 
long-term follow-up (Becker et al., 2012; Pedersen et al., 2009). So far, no 
screening has been implemented in Iceland, but a protocol for lung cancer 
screening in the Nordic countries is being developed.  
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1.1.7  Staging 
After the diagnosis of lung cancer, the stage of the disease must be determined, 
both for deciding the treatment and for prediction of survival.  
NSCLC is usually staged using the International Association for the Study of 
Lung Cancer (IASLC) tumour, node, metastasis (TNM) staging system (see 
Table 3). The tumour (T) stage is determined by the size, location, and invasion 
of the tumour. The node (N) stage is determined by the location and number of 
lymph nodes with tumour invasion. Finally, the metastasis (M) stage is 
determined by the presence of distant metastasis.  
CT scanning is the method of choice for effective evaluation of the T stage in 
a patient with suspected lung cancer (MacDonald & Hansell, 2003). The 
specificity and sensitivity for detecting invasive growth in mediastinum are 40‒
84% and 57‒94%, respectively (Munden et al., 2005). The use of whole-body 
PET is recommended for all patients without confirmed M1 disease. Whole-body 
PET provides additional evidence that the primary tumour is malignant, and 
identifies both possible lymph node metastases and distant metastases. The 
spread to mediastinal lymph nodes is of key importance in staging of NSCLC 
(Goldstraw et al., 2016). A numbering system has been developed to rank lymph 
nodes according to their prognostic significance (Figure 5) (Asamura et al., 
2015). 
Traditionally, lymph nodes under 1 cm in size on a CT-scan have been 
considered to be benign (De Leyn et al., 2007), but it has been shown that in up 
to 20% of cases, micro-metastasis is present in lymph nodes smaller than 1 cm. 
Furthermore, lymph nodes larger than 1 cm may be enlarged without being 
cancerous, due to nonspecific inflammation (De Leyn et al., 1997). A CT-scan or 
an MRI can be used to evaluate the size of mediastinal lymph nodes, but the N 
stage cannot be evaluated with precision. PET scanning adds information on 
whether the lymph nodes show abnormal metabolic activity. Pet scanning can 
therefore be used to evaluate both enlarged lymph nodes and smaller 
mediastinal lymph nodes. PET scanning has greater specificity and sensitivity 
(89‒92% and 70‒85%) than CT scanning (82% and 57%) (Toloza, Harpole, & 
McCrory, 2003). However, invasive methods using endobronchial 
ultrasound/endoscopic ultrasound (EBUS/EUS) or mediastinoscopy give a more 
accurate diagnosis of lymph node status and a better indication of whether 
metastases are present. 
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Table 3:  The 7
th 
edition of the TNM staging of non-small cell lung cancer. 
Adapted from Edge et al. (2010) 
T      Primary tumour  
T1:    Tumour with the highest diameter, surrounded by lung or visceral pleura, without 
growth into main bronchus or carina 
- T1a: ≤ 2 cm 
- T1b: 2‒3 cm 
T2:     Tumour 3‒7 cm, with one of the following:  
- T2a: 3‒5 cm 
- T2b: 5‒7 cm 
- Growth into main bronchus at least 2 cm distal to the carina 
- Growth into visceral pleura 
- Associated with atelectasis or obstructive pneumonitis that extends to      
the hilar region but does not involve the entire lung 
T3:     Tumour is  
- > 7 cm or  
- Of any size, which directly invades any of the following: parietal pleura, 
mediastinal pleura, chest wall, diaphragm, phrenic nerve, parietal 
pericardium, or tumour in the main bronchus less than 2 cm distal to the 
carina but without involvement of the carina 
- Associated atelectasis or obstructive pneumonitis of the entire lung or 
separate tumour nodule(s) in the same lobe 
T4:     Tumour of any size, which invades any of the following: mediastinum, heart, great   
vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina, 
or separate tumour nodules in a different ipsilateral lobe 
N         Lymph nodes 
N0:     No regional lymph node metastasis 
N1:    Metastasis in ipsilateral peribronchial and/or hilar lymph nodes and intrapulmonary 
nodes, including involvement by direct extension  
N2:      Metastasis in ipsilateral mediastinal and/or sub- or precarinal lymph nodes 
N3:  Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral, or 
contralateral scalene, or supraclavicular lymph node(s)  
M        Metastasis 
M0:     No distant metastasis 
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M1:     Distant metastasis  
- M1a: separate tumour nodule(s) in a contralateral lobe, tumour with 
pleural nodules, or malignant pleural (or pericardial) effusion 
- M1b: Distant metastasis in extrathoracic organs 
Anatomical stage/prognostic groups 
Stage IA T1a/b N0 M0 
Stage IB T2a N0 M0 
Stage IIA 
T1a/b, T2a 
T2b 
N1 
N0 
M0 
Stage IIB 
T2b 
T3 
N1 
N0 
M0 
Stage IIIA 
T1-2 
T3 
T4 
N2 
N1-2 
N0-1 
M0 
Stage IIIB 
T1-4 
T4 
N3 
N2 
M0 
Stage IV T1-4 N0-3 M1 
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Figure 5:  The lymph node zones in the mediastinum (Mountain-Dresler 
modification) (Rusch et al., 2009). Reused with permission from 
Elsevier and Copyright Clearance Center. 
Until recently, mediastinoscopy was considered to be the most accurate 
method for staging of mediastinal lymph nodes (Toloza, Harpole, Detterbeck, et 
al., 2003). Ipsilateral lymph nodes to the tumour (N2) in the upper mediastinum 
are sampled or resected, together with lymph nodes that drain the lung 
contralateral to the tumour (N3). Importantly, however, the lower lymph node 
zones are not accessible with mediastinoscopy―such as lymph nodes in 
position 9―but positions 4 and 7 still are readily accessible. More recent 
methods for mediastinal lymph node staging are transbronchial needle aspiration 
(TBNA) with EBUS, transthoracic needle aspiration (TTNA), and EUS-guided 
needle aspiration (EUS-NA). Several studies have shown that EBUS-TBNA in 
expert hands is superior to mediastinoscopy in terms of its diagnostic 
performance. It is therefore now recommended as the first-line procedure for 
mediastinal lymph node staging in international guidelines (Slavova-Azmanova et 
al., 2016; Um et al., 2015; Vansteenkiste et al., 2014).  
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Figure 6:  An EBUS bronchoscope, where an ultrasound probe is used along 
with bronchoscopy to visualize the airway wall and structures 
around it. Image: Stefan Barath, Skånes Universitetssjukhus, Lund.  
As listed here, there are many possible ways to stage the patient, but the 
selection of the appropriate diagnosis pathway is dependent on the degree of 
suspicion of metastatic disease, the patient’s comorbidities, and the availability 
and performance characteristics of procedural options (Toloza, Harpole, 
Detterbeck, et al., 2003). 
Last year, the new 8
th 
Edition of the TNM Classification for Lung Cancer was 
introduced by the IASLC (Goldstraw et al., 2016), and since January 1, 2017, it  
has become the official staging system for NSCLC. As this system is only being 
implemented this year, all analysis in this study was done according to the 7
th 
Edition. Changes in the 8
th
 Edition include a further classification of the T factor 
according to tumour size. There were no changes in the N factor, but the M 
factor was divided into three categories, with addition of a group for single distant 
metastasis in one organ (M2b). 
1.2  Lung cancer treatment 
1.2.1  Surgical treatment 
The most effective curative treatment for lung cancer is surgical resection, where 
the tumour is removed along with the lymph nodes around it. This is an option for 
NSCLC patients with early-stage disease, and in some cases locally advanced 
disease, but only occasionally metastatic disease (Novello et al., 2016). SCLC is 
seldom treated with surgical resection, but rather with chemotherapy and 
radiotherapy (Novello et al., 2016).   
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Figure 7:  Left panel: pulmonary resection for NSCLC at Landspitali University 
Hospital. Right panel: an anterolateral thoracotomy. Images: Tómas 
Guðbjartsson.  
1.2.1.1 The history of pulmonary resections for lung cancer 
The first reported surgical resection for lung cancer was a lobectomy performed 
in 1912 by Dr H. Morriston Davies (Davies, 1913). Unfortunately, the patient only 
survived for a few days. The first successful lobectomy for lung cancer was 
reported in 1932 by Dr Evarts Graham, who also performed the first 
pneumonectomy for lung cancer (Horn & Johnson, 2008). At this time, 
pneumonectomies became the standard surgical treatment for lung cancer. In 
1962, lobectomy became the more commonly perfomed procedure, after being 
shown to be at least as safe as a pneumonectomy. Since then, many studies 
have shown the benefit of lobectomy over other resections in most patients 
(Scott et al., 2007).  
In the past two decades, new technology has been developed for pulmonary 
resections, focusing on minimally invasive techniques. Video-assisted 
thoracoscopic surgery (VATS) (Figure 8) was first applied to lung cancer 
resections in 1992 (Sihoe & Shing, 2012) and is now used in many centres to 
perform lobectomies and sublobar resections. Furthermore, robot-assisted 
thoracic surgery using the da Vinci robot system (Intuitive Surgical, Sunnyvale, 
CA) is used in some centres in Europe and the United States, but its 
development is relatively slow due to the high costs and lack of benefit over 
VATS (B. J. Park et al., 2016; Swanson et al., 2014).  
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Figure 8:  Video-assisted thoracoscopic surgery (VATS) at Landspitali 
University Hospital. Image: Tómas Guðbjartsson.  
1.2.1.2 Preoperative assessment 
For a patient to be a candidate for surgery the tumour must be localized in the 
lung, i.e. it must be at TNM stage I or II. There are exceptions―for example, in 
some cases with ipsilateral lymph node metastases (stage IIIA), if the tumour 
grows invasively into some mediastinal organs (T4 disease), or if there is a 
solitary distant metastasis such as in the brain or adrenal gland in an otherwise 
healthy patient (Novello et al., 2016). These metastases can be removed in a 
separate surgery before removal of the primary tumour.  
Preoperatively, the patient has to undergo careful clinical evaluation to 
determine whether surgery is possible. Patients can be excluded from pulmonary 
resection because of any serious disease where the life expectancy is short, or if 
there are multiple comorbidities, especially reduced pulmonary function. Age 
alone should not be a contraindication (Bravo-Iniguez et al., 2014). If it is 
determined that the patient’s medical condition in general is safe for surgery, the 
pulmonary function tests are evaluated to see whether he/she can afford to lose 
part of the lung. The main determinants of lung function are FEV1 and DLCO 
(the diffusion capacity of the lung for carbon monoxide). If either is < 80%, 
exercise testing or split lung function is recommended (Vansteenkiste et al., 
2014) and used in selected cases. This, along with the CT-scan, PET-scan, and 
histology results, is taken to a multidisciplinary meeting and discussed before 
deciding on surgery (Novello et al., 2016).   
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1.2.1.3 The choice of surgical procedure 
In patients with early-stage lung cancer who are fit for surgical resection, 
lobectomy is usually the recommended surgical procedure (Scott et al., 2007; 
Vansteenkiste et al., 2014). In a lobectomy, one lobe of the lung is removed 
along with the lymph nodes around it. Sometimes two lobes on the right side 
have to be removed, which is named bilobectomy. Lobectomy is the preferred 
method over sublobar resection and pneumonectomy, due to its lower 
recurrence rate compared to sublobar resection, but also because of its lower 
mortality and morbidity compared to pneumonectomy (Holmes et al., 1995). In 
sublobar resections, part of the lobe is removed―either as a wedge or an 
anatomical segmentectomy. Pneumonectomy―the removal of a whole lung―is 
a more extensive intervention than lobectomy, with more complications and a 
higher mortality rate than for either lobectomy or sublobar resection (Suen et al., 
1999; Thorsteinsson et al., 2009).  
 Recently, however, the use of sublobar resection has been recommended for 
patients with small peripheral stage-I NSCLCs, instead of lobectomy, as 
comparable outcomes have been reported (Deng et al., 2016; Fiorelli et al., 
2016; Yang et al., 2016), 
In patients who are believed to tolerate a limited surgical intervention, a 
sublobar resection is recommended rather than any other intervention―e.g. 
radiotherapy (Scott et al., 2007; Vansteenkiste et al., 2014). Sublobar resections 
(wedge resection or segmentectomy) have a higher recurrence rate than 
lobectomy in general, which is thought to be because of small metastases in 
intrapulmonary lymph nodes (Holmes et al., 1995). Until proven otherwise, 
sublobar resection is believed to give better results than radiotherapy alone 
(Vansteenkiste et al., 2014).  
Of all the patients treated surgically, between 10% and 15% need to undergo 
a pneumonectomy, usually because of a centrally located tumour that involves 
more than one pulmonary lobe. Pneumonectomy is a considerably more 
extensive surgical procedure than lobectomy, the complication rate and 30-day 
mortality being at least twice as high as for lobectomy and sublobar resection 
(Suen et al., 1999; Thorsteinsson et al., 2009). In selected cases of centrally 
located upper lobe tumours, a sleeve lobectomy is recommended over 
pneumonectomy where complete resection can be achieved with either 
technique (Q. L. Ma et al., 2016).  
In selected cases, pulmonary resection can be an option for treatment of 
patients with locally advanced disease (Eberhardt et al., 2015). If the tumour has 
grown into the chest wall, diaphragm, or pericardium (stage T4N0-N1 disease), 
the American College of Chest Physicians (ACCP) recommends evaluation 
considering surgical treatment (Jett et al., 2007). The relevant organ is then 
removed along with the lung cancer, and the wound is covered in stretched 
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polytetrafluoroethylene (Gore-Tex®). Currently, however, surgical resection is 
usually not recommended where there is N2 involvement (stage IIIA), at least not 
for bulky metastatic disease (Eberhardt et al., 2015; Jett et al., 2007).  
Patients with Pancoast tumours most often receive neoadjuvant chemo- and 
radiotherapy preoperatively (Eberhardt et al., 2015). The same applies for 
patients with growth into the mediastinum; in some cases, they can receive 
neoadjuvant chemo-radiation treatment to shrink the tumour first (Eberhardt et 
al., 2015).  
1.2.1.4 The surgical procedure 
The first thoracotomies performed were done under general anaethesia with a 
posterolateral thoracotomy approach. This method provides good anatomical 
access for the surgeon to the lung, hilum, mediastinum, trachea, and 
oesophagus, but requires an incision through the entire latissimus dorsi muscle 
(Shields et al., 2009). Thus, the use of posterolateral thoracotomy is decreasing 
in favour of the use of anterolateral muscle-sparing techiques (Nosotti et al., 
2010) with minimal rib-spreading. These different thoracotomy approaches result 
in similar outcomes, but patients have a shorter in-hospital stay and use less 
pain medication with the muscle-sparing approach (Nosotti et al., 2010). In 
Iceland, the muscle-sparing approach has been used in the majority of 
lobectomies in the last 10 years, but before 2005 most operations were 
performed with a  posterolateral approach.  
The VATS technique has been used for almost 20 years for all types of 
surgery for lung cancer, and its use is on the increase. Several non-randomized 
studies have shown benefits with VATS, such as less scarring and a quicker 
recovery (Blasberg et al., 2016; Laursen et al., 2016), but superior survival has 
not been observed depending on the surgical technique used. Open thoracotomy 
and VATS can therefore both be utilized as appropriate to the expertise of the 
surgeon (Vansteenkiste et al., 2014). Until now, in Iceland, all lobectomies, 
pneumonectomies, and most lesser resections have been performed with an 
open thoracotomy―and VATS has mostly been used for selected lesser 
resections (Alexandersson et al., 2011).  
1.2.2  Radiation therapy 
Radiation therapy is extensively used in lung cancer, either with palliative intent 
for treatment of both regional and distant disease or for selected patients, with 
curative intent as SBRT for small peripheral tumours or in combination with 
chemotherapy for locally advanced (stage-III) disease (Nagata et al., 2015). 
Moreover, radiotherapy is occasionally used in the neoadjuvant (selected stage-
III) or adjuvant (not radically resected) setting.  
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Figure 9:  The linear accelerator Þór, used for radiotherapy of cancer patients 
at Landspitali University Hospital.  
For medically inoperable patients where the tumour is small and localized to the 
lung, stereotactic body radiotherapy (SBRT) is the recommended curative 
treatment (Vansteenkiste et al., 2014). The radiotherapy beams are then very 
accurately and precisely aimed at the tumour, with a high dose. The total dose 
given should be to a biological equivalent of ≥ 100 Gy, prescribed to the 
encompassing isodose (Vansteenkiste et al., 2014). The treatment is usually 
well-tolerated, even in old patients (> 80 years) and patients suffering from 
severe comorbidities (Takeda et al., 2013). There is growing evidence to suggest 
equivalent outcomes after SBRT and lobectomy (Chang et al., 2015; Nagata et 
al., 2015). However, to date these studies have often involved only small cohorts 
of patients with not always completely histologically confirmed cases (Shirvani et 
al., 2012; Takeda et al., 2013). Thus, larger randomized studies will be needed 
before SBRT can be used to replace lobectomy as the standard of care for early-
stage lung cancer (Vansteenkiste et al., 2014).  
Only occasionally, such as in patients with Pancoast tumours or with 
ipsilateral lymph node metastasis (stage IIIA), radiotherapy is given 
preoperatively with curative intent (Eberhardt et al., 2015). Otherwise, 
neoadjuvant radiotherapy has not been shown to increase survival in stage-IIIA 
or stage-IIIB patients (Sirzen et al., 2003). Its use should therefore be restricted 
to carefully chosen patients (Eberhardt et al., 2015; Sirzen et al., 2003).    
In completely resected early-stage NSCLC, adjuvant radiotherapy is not 
indicated (Vansteenkiste et al., 2014), as the rate of complications is increased. 
In contrast, if there is tumour growth in surgical margins, adjuvant radiotherapy 
should be considered after giving the patient adjuvant chemotherapy 
(Vansteenkiste et al., 2014).  
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For patients with NSCLC who are diagnosed at a locally advanced stage, 
where surgical resection is not indicated (Laroche et al., 1998), concomitant 
chemotherapy and radiotherapy is the treatment of choice (Peters et al., 2012). 
The traditional treatment involves 2 Gy once daily, five days a week, up to a total 
dose of 68‒70 Gy. The radiation field should include the tumour itself along with 
the lymph nodes that are involved (Emami et al., 2003). Radiation pneumonitis 
and oesophagitis are common early complications after radiotherapy to the lung 
(Pan et al., 2016; Tang et al., 2016). With concomitant chemo-radiotherapy, the 
frequency of these complications is higher, so only patients with a good 
performance status should be offered this treatment regimen (Fruh et al., 2013).   
In SCLC, radiation treatment to the area of the tumour is used concomitantly 
with chemotherapy whenever possible, and in addition, whole-brain radiation is 
used to prevent brain metastasis (Fruh et al., 2013).  
1.2.3  Chemotherapy 
Numerous studies have shown that NSCLC patients at stages II‒IIIA―and 
occasionally at stage IB―who undergo surgical resection benefit from receiving 
adjuvant chemotherapy (Novello et al., 2016). A platinum-based adjuvant 
chemotherapy with agents such as cisplatin/carboplatin is usually recommended 
(Burdett et al., 2015; Novello et al., 2016), with the overall survival increasing by 
5.4% (Pignon et al., 2008). Patients at stage I, however, do not benefit as much 
as patients at stages II and IIIA (Scott et al., 2007). Chemotherapy is not without 
complications, and many patients do experience nausea, stomatitis, malaise and 
fatigue. Bone marrow suppression, detected as neutropenia, thrombocytopenia 
and/or anemia, often leads to complications such as infections and bleedings 
(Burdett et al., 2015). Furthermore, drug-specific side effects may include e.g. 
nephrotoxicity, cardiotoxicity or ototoxicity from cisplatin and neuropathy or drug 
administration-induced phlebitis from vinorelbine (Fass-verksamheten, 2016).   
Patients with stage-III disease do benefit from concomitant chemo-
radiotherapy, as mentioned in the previous section. A platinum-based 
chemotherapy doublet is then recommended, administered as one cycle before 
and two cycles during the radiotherapy period. Giving these treatments 
modalities concomitantly has better anti-tumoural effect as compared to 
sequential administration, but also entails an increased risk of toxicity (Eberhardt 
et al., 2015).  
Recommended 1
st 
line palliative therapy for advanced NSCLC is a combined 
therapy of a platinum-based drug such as cisplatin/carboplatin along with a third-
generation agent such as pacletaxel, pemetrexed, docetaxel, gemcitabin or 
vinorelbine. As the purpose is to reduce symptoms and increase the patient’s 
quality of life, many factors have to be considered when choosing which 
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treatment to give, such as the patient’s complaints, symptoms, and performance 
status (Novello et al., 2016).  
Chemotherapy undeniably benefits patients with SCLC. Four cycles of a 
cisplatin and etoposide, carboplatin and etoposide or anthracycline-based 
combination should be offered to all patients, even though the disease is rarely 
curable―unless the patient has mild disease and gets both radiotherapy and 
chemotherapy (Fruh et al., 2013).   
1.2.4  Targeted therapy 
For the past two decades, molecular biology has been in focus for the treatment 
of lung cancer. Since tumorigenic mutations in the epidermal growth factor 
receptor (EGFR) gene were discovered, specific targeted therapies have been 
intensively studied (Hirsch et al., 2006; Salomon et al., 1995). Targeted therapies 
are now used routinely as first-line treatments, mostly for patients with two 
molecular subsets of NSCLC. The best-defined is an activation mutation in the 
EGFR gene that codes for a tyrosine kinase receptor involved in gene 
transcription, cell proliferation, and cell survival (Salomon et al., 1995). In 
NSCLC, the EGFR can be deregulated by over-expression, mutations, and gene 
amplification (Hirsch et al., 2006). Tyrosine kinase inhibitors (TKIs), erlotinib, 
afatinib, or gefinitib can be used to target EGFR-mutated tumours as a first-line 
treatment, and these patients have a significantly better prognosis than those 
without any EGFR mutation (D'Angelo et al., 2012). Other targetable molecular 
subsets of lung cancer are those with fusion genes (translocations) involving the 
anaplastic lymphoma kinase (ALK) or ROS1 genes (Novello et al., 2016), which 
regulate cell proliferation (Soda et al., 2007). These translocations are present in 
about 5% of NSCLCs and can lead to uncontrolled proliferation of cancer cells 
(Morris et al., 1994). Today, tumours with ALK or ROS1 fusions are treated with 
TKI agents such as crizotinib (Novello et al., 2016), but this drug was first 
accepted for the treatment of lung cancer in 2011 (Mendez et al., 2011). Other 
genes involved in lung tumorigenesis such as MET, HER2, BRAF, and RET, also 
have targeted therapy options, although their clinical use is not yet 
recommended routinely (Novello et al., 2016).  
1.2.5  Immune therapy 
Patients with NSCLC where EGFR, ALK or ROS1 alterations are not present, 
may benefit from immune therapy (Langer et al., 2016; Novello et al., 2016; Reck 
et al., 2016). Nivolumab and pembrolizumab have shown overall survival benefits 
when compared to docetaxel (Novello et al., 2016), the most benefit being seen 
in those who express programmed death-ligand 1 (PD-L1) (Herbst et al., 2016). 
PD-1 is a transmembrane protein that has a special role in suppressing the 
immune system, such as in pregnancy and autoimmune disease (Tripathi & 
Guleria, 2015). PD-L1 is a ligand for this receptor, and is expressed on 
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macrophages and dendritic cells (Okazaki & Honjo, 2007; Tripathi & Guleria, 
2015). Immune checkpoint inhibitors such as nivolumab and pembrolizumab 
target this pathway by blocking PD-1, thereby activating the host’s own immune 
system to attack the tumour cells (Novello et al., 2016).  
1.3 Survival and prognostic factors 
The overall (all-cause) 5-year survival of lung cancer patients is only in the 10‒
18% range in Iceland, which is similar to the situation in most other western 
countries (Krabbameinsskra, 2016; Siegel et al., 2015, 2016). The most well-
known prognostic factor for survival is the TNM staging (Goldstraw et al., 2016; 
Spira & Ettinger, 2004) (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Overall survival by pathological stage according to the seventh 
edition of the TNM staging system by the IASLC Staging and 
Prognostic Factors Committee. MST, mean survival time (Goldstraw 
et al., 2016). Reused with permission from Elsevier and Copyright 
Clearance Center. 
Other prognostic factors include histological type (i.e. squamous cell carcinoma 
vs. adenocarcinoma), age, history of weight loss (Pater & Loeb, 1982; Stanley, 
1980), and some gene mutations (i.e. EGFR, K-ras, p53) (de Melo et al., 2015; 
Hames et al., 2016; Horio et al., 1993; Kern et al., 1994; Kerr et al., 2014; Slebos 
et al., 1990).  
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1.3.1  Survival of patients with adenocarcinoma 
The survival of patients with pulmonary AC is better than for other histological 
types. Despite the recent advances in diagnostic techniques and treatments for 
primary lung AC, the survival rate is still only in the 30‒40% range (Huang et al., 
2013; Kauffmann et al., 2013; Q. Ma et al., 2012; Xu et al., 2011). Most studies 
on the new classification of AC have shown the classification to be an 
independent prognostic factor for survival (Huang et al., 2013; Russell et al., 
2011; Warth et al., 2012). The 5-year disease-free survival for AC in situ and 
minimally invasive AC has been 100% (Behera et al., 2016; Russell et al., 2011; 
Warth et al., 2012; Yoshizawa et al., 2011). The more benign subtypes of AC are 
classified as lepidic-predominant (LPA) and acinar-predominant (APA). LPA has 
an overall 5-year survival of 55.6‒100% and that for APA is 43‒68% (Mansuet-
Lupo et al., 2014; Russell et al., 2011; Warth et al., 2012; Westaway et al., 2013; 
Yoshizawa et al., 2011). Papillary and solid-predominant subtypes have 
intermediate outcome, with a 5-year overall survival of between 71% and 74.7% 
and between 43.3% and 70%, respectively (Gu et al., 2013; Russell et al., 2011; 
Yoshizawa et al., 2011). Micropapillary and mucinous subtypes of AC are usually 
categorized as having a poor outcome, with an overall 5-year survival of 0‒67% 
and 51‒88% (Gu et al., 2013; Russell et al., 2011; Travis et al., 2015; Yoshizawa 
et al., 2011).  
1.3.2  Survival in the elderly 
Numerous studies have suggested that age alone should not be a 
contraindication for pulmonary resection, with favourable reported short- and 
long-term survival that is comparable to that in younger patients (Bravo Iniguez 
et al., 2016; Liu et al., 2013; Rivera, Dahan, et al., 2011; Rivera, Falcoz, et al., 
2011). Even so, a careful individual preoperative assessment is needed. Most 
studies have shown the 30-day mortality rates in the elderly to be higher than in 
younger patients (Liu et al., 2013; Rivera, Falcoz, et al., 2011), whereas others 
have shown similar results between age groups (Bravo Iniguez et al., 2016; Fan 
et al., 2007). Some studies have shown favourable surgical outcome and survival 
in the elderly (Dillman et al., 2009; Palma et al., 2010), but not all of them (Fan et 
al., 2007). 
The surgical resection rates (SSRs) are lower in the elderly than in younger 
patients (Bravo Iniguez et al., 2016; Dillman et al., 2009; Palma et al., 2010). 
Furthermore, it has been suggested that sublobar resection and less invasive 
surgery are preferable in a selected patient group with early-stage disease 
(Vansteenkiste et al., 2014), so a new randomized controlled trial is in progress 
and the results are pending (Yang et al., 2016).  
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1.3.3  Survival following lobectomy 
The overall survival of patients who undergo lobectomy for NSCLC has improved 
during the past decades, with more recent studies showing a 5-year survival in 
the 65‒82% range (Deng et al., 2016; Nilssen et al., 2016; Paul et al., 2014). The 
survival of patients with NSCLC is highly dependent on the TNM stage. A 
recently published meta-analysis of patients with stage-I disease showed a 77% 
pooled 3-year survival for NSCLC patients undergoing a lobectomy (Deng et al., 
2016). In other studies, the 3-year survival has been reported to be 27‒51% for 
stage IIIA (Dickhoff et al., 2016), but up to 96% for stage IA (Okada et al., 2014).  
The prognostic factors are the same for lobectomies as for pneumonectomies 
and sublobar resections; with TNM staging being the most important prognostic 
factor.  
1.4 Lung cancer in the elderly  
The probability of being diagnosed with NSCLC increases considerably with age, 
with half of the patients being diagnosed at more than 70 years of age (Gajra et 
al., 2016; Siegel et al., 2016). With an ageing population, the number of patients 
who are diagnosed and treated for NSCLC is expected to increase.  
Many older patients with metastatic disease do not receive chemotherapy 
(Davidoff et al., 2010; Lang et al., 2009), and the surgical resection rate is lower 
in patients over 70 years of age (Damhuis & Schutte, 1996; van der Drift et al., 
2012). The treatment regimen chosen for each patient, regardless of the patient‘s 
age, must be chosen carefully with an independent assessment of performance 
status, comorbidities, and other factors (Novello et al., 2016). Comprehensive 
geriatric assessment (CGA) is a tool based on a multidisciplinary and global 
approach to elderly patients with cancer and can help to adapt cancer 
management to the fitness or frailty of each patient (Extermann & Hurria, 2007; 
Novello et al., 2016). 
It is questionable whether palliative chemotherapy prolongs life in the elderly 
and whether it improves the quality of life. The prospective ELVIS trial (The 
Elderly Lung Cancer Vinorelbine Italian Study) compared single-agent 
chemotherapy to best supportive care in elderly patients with metastatic NSCLC. 
It showed a significant increase in both survival and quality of life, but the 
recruitment to the study very slowl and had to be terminated early (The Elderly 
Lung Cancer Vinorelbine Italian Study Group, 1999). In the retrospective analysis 
by Ansari et al., comparable survival of elderly and younger patients with a good 
performance status was found, which indicates that chemotherapy also improved 
survival in elderly patients (Ansari et al., 2011).  
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Adjuvant chemotherapy has not been studied prospectively in elderly patients 
(Poudel et al., 2016). A retrospective analysis done on patients in the LACE 
study (Pignon et al., 2008) did not show any difference in hazard ratio of death 
and rates of severe toxicity between elderly and younger patients. International 
guidelines have recommended the use of doublet chemotherapy for those 
eligible (PS 0‒2 and adequate organ function), and the use of carboplatin 
instead of cisplatin in 70- to 89-year-old patients (Novello et al., 2016). Due to the 
need for more studies on adjuvant therapy in the elderly, the use of adjuvant 
therapy in patients over 80 years of age is usually undertaken with extra caution 
(Gajra et al., 2016).  
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2 Aims 
The general aim of this thesis was to study the outcome and survival in different 
subgroups of patients who have undergone surgical resections for NSCLC in 
Iceland.  
The specific aims of each paper are listed below:  
I. To investigate the surgical resection rate for lung cancer in a whole 
nation and to determine surgical outcomes in patients who 
underwent different types of pulmonary resection for NSCLC in 
Iceland with curative intent.  
II. To determine the short- and long-term outcome and survival in 
patients who underwent a lobectomy for NSCLC in Iceland during 
the 24-year study period, focusing on 30-day and long-term survival.  
III. To determine whether the IASLC/ATS/ERS subclassification of 
adenocarcinoma, published in 2011, affected survival and to 
investigate whether the subtypes in Iceland were different to those in 
other western countries.  
IV. To investigate the outcomes of pulmonary resections for NSCLC in 
elderly patients (≥75 years old), to compare them to those in younger 
patients, and to assess surgical resection rates, operability, and 
reasons for excluding elderly from surgery.  
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3 Materials and methods 
All four papers in this thesis were epidemiological cohort studies that focused on 
pulmonary resections for NSCLC in Iceland. The operations were all performed 
at Landspitali University Hospital in Reykjavik, which is the only centre in Iceland 
where cardiothoracic surgery is performed. It serves the whole population of 
330,000 individuals (December 2016). For all four of the studies, we used a 
database at the Department of Cardiothoracic Surgery at Landspitali. This 
database includes all patients who have been operated for NSCLC in Iceland 
from January 1, 1991 to the present time, but the four studies included patients 
operated until December 31, 2014. Cases were also identified and cross-
checked using a central, computerized database at the Department of Pathology, 
Landspitali University Hospital, which has details of all lung histology specimens 
in Iceland. To further minimize the risk of missing cases, the diagnosis and 
operation registries at Landspitali University Hospital were checked for patients 
operated on for lung cancer.  
Demographic information and clinical data were collected and registered from 
hospital charts and surgical reports using a standardized data sheet. Baseline 
characteristics, age, gender, and comorbidities were registered along with data 
on presenting symptoms, type of operation, tumour size, stage and histology, 
complications, and survival (for details, see section 3.2). Patients were staged 
using the seventh
 
edition of the TNM staging system (Edge et al., 2010) (see 
section 1.1.7 for more details).  
All patients were followed regarding survival using the Icelandic national 
population registry, Statistics Iceland (www.statice.is). This register has 
information on the personal identification numbers of all citizens of Iceland. All 
deaths must be reported to this registry, and causes of deaths are registered in 
the Icelandic Cause of Death Register. 
The Icelandic National Bioethics Committee and the Icelandic Data Protection 
Authority granted all the approval that was necessary for the studies.  
3.1 Study populations 
Table 4 gives an overview of the study populations in the four papers. All four 
studies were nationwide cohort studies, but involved different subgroups of 
patients who had surgical resection for NSCLC with curative intent in Iceland. 
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Table 4:  Overview of papers I‒IV  
 
 Paper I Paper II Paper III 
Paper IV 
Elderly/ 
younger 
Subgroup All cases Lobectomies 
Adenocarcinoma 
histology 
Age ≥ 75 
years 
Study period 1994‒2008 1991‒2014 1991‒2010 1991‒2014 
Number of cases 
operated on 
404 493 285 140/550 
Mean age, years 
(range) 
66  
(37‒89) 
67  
(35‒89) 
67  
(37‒89) 
80/65  
(75‒89/ 
35‒74) 
Proportion of 
males 
52% 46% 43% 59%/45% 
3.1.1  Study I 
This study included 404 consecutive patients who underwent pulmonary 
resection at Landspitali for NSCLC between January 1, 1994 and December 31, 
2008. All types of resections were included, and the cases were divided and 
analyzed in three 5-year periods. To calculate the surgical resection rate, 
information on all histologically confirmed diagnoses of NSCLC (1530 patients) 
was gathered from the Icelandic Cancer Registry, a registry that covers all 
cancers diagnosed at all healthcare facilities in Iceland since 1955. Patients who 
were diagnosed post-mortem were not included in the analysis, and this also 
applied to patients without a histologically proven diagnosis (n = 133) and 
patients with small cell carcinoma (n = 306), pulmonary carcinoids, sarcoma, or 
carcinoma in situ. Date of death was registered or the patients were identified as 
living on July 10, 2010. Mean follow-up time was 49 months (range 0‒194).  
3.1.2  Study II 
From January 1, 1991 until December 31,
 
2014, 493 lobectomies were 
performed for NSCLC at Landspitali, corresponding to 75.5% of all curative-intent 
pulmonary resections for NSCLC during the study period. Eleven patients 
(11/493, 2.2%) had lobectomy together with a lesser resection performed 
simultaneously, and four patients (4/493, 0.8%) underwent a bilobectomy. 
Patients operated with exploration-only thoracotomy, exploratory video-assisted 
thoracoscopic surgery (VATS), a palliative procedure, or resection for purposes 
of biopsy only were excluded. Patients were also excluded if pathological 
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samples showed adenoid cystic carcinoma, mucoepidermoid carcinoma, 
pulmonary carcinoid, sarcoma, carcinoma in situ (CIS) or fibrosis only. Date of 
death was registered or the patients were identified as living on September 1, 
2016. Mean follow-up time was 42 months (range 1‒279).  
3.1.3  Study III  
Study III included all patients who had primary AC of the lung and underwent 
pulmonary resection with curative intent in Iceland between January 1, 1991 and 
December 31, 2010. Patients with adenosquamous carcinoma were excluded. 
Patients who had exploratory, palliative, or lesser resection for biopsy purposes 
only were excluded. Nine other patients were excluded because of lost 
histological slides. This left 285 patients for further analysis. Date of death was 
registered or the patients were identified as living on January 31, 2015. To 
calculate the five-year survival of the patients according to histological subtypes, 
only the subtypes containing more than 20 patients were included in the survival 
analysis. Mean follow-up time was 45 months (range 1‒254).  
3.1.4 Study IV 
Data from the Icelandic Cancer Registry were used to identify 859 elderly 
patients (≥ 75 years old) who were diagnosed with NSCLC between 1991 and 
2014. There were missing data for 77 patients (lost to follow-up, patient charts 
not found, or diagnosis made post-mortem) and these patients were excluded 
from further analysis. This left 782 patients for further analysis, 140 of whom 
underwent pulmonary resection. A flow chart of the study population in study IV 
is given in Figure 11. The hospital charts of all 782 patients were reviewed and 
different variables were registered for each patient, as explained in detail in 
section 3.2. A proportion of these patients had stage-I or -II disease and were not 
operated on. To investigate why, the reason for exclusion from surgery was also 
registered.  
The 140 elderly patients (≥ 75 years old) with NSCLC who underwent surgical 
resection were compared to 550 surgical patients younger than 75 years. These 
patients were all included in the surgical database mentioned in section 3. Date 
of death was registered or the patients were identified as living on December 31, 
2014. Mean follow-up time was 5 years (range 0‒23).  
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Figure 11: Flow chart of the study population in study IV. Patients were 
classified as elderly if they were ≥ 75 years of age. NCSLC, non-
small cell lung cancer.  
3.2 Clinical variables  
The following variables, divided into pre-, peri-, and postoperative variables, were 
registered in the surgical database:  
Preoperative: age, gender, indication for surgery, incidental diagnosis, 
presenting symptoms, history of smoking (current or former), and any 
comorbidities of significance such as COPD, arrhythmias, or ischaemic heart 
disease―but also if neoadjuvant chemo- or radiotherapy was administered. 
Results from preoperative pulmonary function tests, including FEV1 and FVC, 
were also registered.  
All elderly patients 
with NSCLC in  
1991-2014 
n = 859 
Study population: 
Elderly with NSCLC in 
1991-2014  
n = 782 
Elderly who underwent 
pulmonary resection for 
NSCLC  
n = 140 
Elderly who did not undergo 
pulmonary resection  
 n = 642  
Stage I-II 
n = 103 
Stage III and IV 
n = 471 
Incomplete staging  
n = 68 
Excluded:  
Lost to follow-up, 
missing patient chart or 
diagnosis made post-
mortem 
n = 77 
Patients < 75 years who 
underwent pulmonary 
resection for NSCLC in 
1991-2014 
n = 550 
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Perioperative: operation time (skin to skin), ASA score, whether 
mediastinoscopy had been performed just before the pulmonary resection (same 
anaesthesia), and whether major intraoperative bleeding had occurred.  
Postoperative: major and minor complications, administration of adjuvant 
chemo- or radiotherapy, length of hospital stay (LOS), pathology of the tumour 
(including tumour size, tumour type, and nodal involvement), staging, whether 
recurrent NSCLC had been diagnosed (long-term), and survival of all the 
patients―both overall (all-cause) survival and cancer-specific survival.  
In study III, a senior pathologist― one of the co-authors (J.B.)―reviewed all 
the histological slides for patients who had AC histology. The AC subtype was 
registered according to the 2011 IASLC/ATS/ERS adenocarcinoma classification 
system (Travis et al., 2011) as described in section 3.3, and the size of the 
tumour was re-evaluated and registered. 
In study IV, for the patients who did not undergo surgery, clinical data were 
collected from patient records from healthcare centres all over the country, using 
a standardized data sheet with the following variables: age at diagnosis, gender, 
date at diagnosis, and date of death. The method used for diagnosis (i.e. 
clinically/chest X-ray/pathological diagnosis of a metastasis) was registered 
along with the cTNM stage (clinical tumour, node, metastasis). If the patients had 
stage-I or -II disease, the reasons for exclusion from surgery were also 
registered.  
3.3 Definitions of variables 
Current smokers were defined as patients who had smoked within five years of 
surgery and never-smokers were defined as patients who had smoked less than 
100 cigarettes in their lifetime.  
Minor complications were defined as: air leakage for more than 7 days, 
pneumonia, intraoperative bleeding of more than 1 litre, new-onset atrial 
fibrillation/flutter, wound infection, and recurrent laryngeal nerve paralysis. Major 
complications were defined as reoperation for bleeding, postoperative heart 
failure, acute respiratory distress syndrome (ARDS), myocardial infarction (MI), 
empyema, stroke, and bronchopleural fistula (BPF). Operative mortality was 
defined as death occurring within 30 days of surgery.  
3.4 Histopathological classification (paper III) 
An experienced pathologist and one of the authors (J.B), who was blinded 
regarding the clinical outcome of the patients, reviewed the slides and subtyped 
the tumours. The size, tumour count, and subtype were registered. 
Gudrun Nina Oskarsdottir 
36 
Haematoxylin- and eosin-stained slides from each case were reviewed and 
staining for mucin (PAS with and without diastase, alcian blue) was done if 
indicated. No immunohistological staining was performed for the purposes of this 
study. The predominant pattern was defined as the morphological pattern 
occupying the greatest area of tumour.  
The primary adenocarcinomas of the lung were divided into four categories 
using the 2011 IASLC/ATS/ERS classification, as shown in Table 2.  
The majority of cases were invasive, a group which is subclassified into five 
predominant patterns: lepidic-predominant (LPA), acinar-predominant (APA), 
papillary-predominant (PPA), micropapillary-predominant (MPA), and solid-
predominant (SPA) with mucin production. If the tumour was not invasive, it fitted 
into the other three groups―pre-invasive AC, minimally invasive AC, or variant of 
invasive AC. 
The histology of acinar-predominant AC included round- to oval-shaped 
glands with a central luminal space surrounded by tumour cells, along with 
distruction of alveolar architecture or myofibroblastic stroma.  
AC in situ (AIS), minimally invasive AC (MIA), and LPA all have a lepidic 
pattern with different amounts of invasion. Lepidic pattern consists of a blend of 
type-II pneumocytes or Clara cells growing along the surface of alveolar cells. If 
no invasion was detected in the sample, AIS was diagnosed. If the invasion was 
less than 5 mm, the sample was categorized as MIA. If the invasion into visceral 
pleura or lymphovascular space was ≥ 5 mm or there were signs of necrosis, it 
was diagnosed as LPA.  
Papillary pattern (PPA) consists of complex branching papillae with cuboidal 
to columnar cells growing along a fibrovascular core. The pattern was considered 
micropapillary (MPA) when the tumour cells grew in papillary tufts without a 
fibrovascular core, often at the tumour edge.  
If there was a sheet of cells without a recognizable pattern that was not 
compatible with LPA, APA, PPA, or MPA, the diagnosis was solid-predominant 
AC with mucin production.  
Invasive mucinous AC (IMA), formerly mucinous BAC, was diagnosed when 
the growth was lepidic of columnar or goblet cells with abundant intracellular 
mucin admixed with other invasive AC pattern. 
Colloid AC was diagnosed when there were macroscopically or 
microscopically visible cystic features. There are abundant pools of extracellular 
matrix with mucin-secreting tumour cells. The foetal AC subtype has a pattern of 
glycogen-rich, non-ciliated cells resembling foetal lung tubules.  
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3.5 The Icelandic healthcare system and the treatment of lung 
cancer patients 
During the study period (1991‒2014), the population of Iceland increased from 
255,866 to 325,671 (Hagstofa, 2016). Iceland‘s major tertiary care hospital is 
situated in the capital, Reykjavik, and it is the only hospital in Iceland that 
performes cardiothoracic surgery. All patients being considered for pulmonary 
resection for NSCLC are discussed by a multidisciplinary tumour board including 
thoracic surgeons, pulmonologists, oncologists, radiologists, and pathologists. 
The preoperative work-up differs between patients, but during the study period it 
usually included a chest radiograph, a CT-scan of the chest, upper abdomen, 
and head, bone scintigraphy, and pulmonary function tests. PET-scan was not 
available in Iceland during the study period. Since 2013, patients who have 
needed a PET-scan have been sent to Rigshospitalet, Copenhagen, but PET-
scan will be available at Landspitali from the autumn of 2017. Tumour samples 
were obtained through bronchoscopy or transthoracic CT-guided needle biopsy. 
Mediastinoscopy was perfomed in selected cases, and endobronchial or 
endoscopic ultrasound (EBUS/EUS) was only used towards the end of the study 
period.  
All patients were discussed at a multidisciplinary meeting after diagnostic 
work-up. If the patient had early-stage disease and was fit enough for surgery, 
the surgeon decided whether to perform pneumonectomy, lobectomy, or 
sublobar resection. All the patients had an epidural placed for postoperative 
analgesia, and general anaesthesia with double-lumen endotracheal tube for 
lung isolation. The surgical procedures were performed by nine different 
surgeons using standardized surgical techniques, and in the last decade, mostly 
by one of them. During the first half of the study period, posterolateral 
thoracotomy was the preferred method, but during the last 10-year period, the 
anterolateral thoracotomy approach was most often used. VATS was only used 
in selected wedge resections or segmentectomies.  
3.6 Follow-up 
At Landspitali, the in-hospital stay is usually 5‒10 days following pulmonary 
resection, if the resection has been uneventful and there have been no 
significant acute complications. One month after discharge, the patient is seen at 
the outpatient clinic by the surgical team. Further follow-up is in the hands of the 
referring pulmonologist, who follows the patients every 3‒4 months after the 
surgery for two years, usually with a CXR or CT-scan before the visit. The 
frequency of check-ups then shifts to every 6 months for the following 3 years. If 
the cancer recurs, all treatment goes through Landspitali, so there was no loss to 
follow-up in the patients included in the surgical database.  
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In study IV, we studied patients who did not have surgical resection, and the 
loss to follow-up in that study group was 77 out of 859 patients (8.9%). Follow-up 
time was calculated as the median time for all patients, from surgical resection to 
either death or censoring.  
3.7 Statistical methods 
For continuous variables, unless otherwise specified, the mean/median ± the 
standard deviation is given. Student’s t-test was used to compare continuous 
variables between two groups and ANOVA was used if there were more than two 
groups. The Kolmogorov-Smirnov test was used to check for the normal 
distribution of data. For categorical variables, the number of patients along with 
the percentage of the total patients is given. The Chi-square test was used to 
compare categorical variables and Fisher’s exact test or Chi-square test with 
Yates’ correction was used if expected values were equal to or less than five in 
studies I and IV, and if equal to or less than 10 in study II. This was necessary 
because the Chi-square test is not considered suitable for a low number of 
observations in one sample unless the sample size is large (Daniel & Cross, 
2013). In all the statistical analyses, a two-sided p-value of < 0.05 was 
considered significant.  
3.7.1  Surgical resection rate 
The surgical resection rate was calculated by dividing the number of patients 
who had pulmonary resection by the total number of patients who had 
histologically confirmed NSCLC in the same period according to the Icelandic 
Cancer Registry. The denominator consisted of NSCLC patients where all 
patients with small cell cancer, carcinoids, carcinoma in situ, and sarcomas were 
excluded. Patients with post-mortem diagnosis were also excluded.  
3.7.2  Survival analysis 
Survival analysis is a method for comparing the risk of an event (usually death) 
between groups in a time-dependent manner. All the studies presented in this 
thesis included survival analysis of a subgroup of lung cancer patients. Overall 
survival (OS) and cancer-specific survival (CSS) were calculated using the 
Kaplan-Meier method. The Kaplan-Meier method is the method most commonly 
used for survival analysis, and has been since it was published in 1958 (Kaplan 
& Meier, 1958). It is a time-to-event analysis that gives a graphical estimation of 
survival in one or more groups, in many small intervals. The figure depicts a 
series of declining or rising horizontal steps representing the events and crosses 
representing censored events.  
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The log-rank test―a non-parametric test that evaluates the estimates of the 
hazard functions of the groups―was used to compare survival. It estimates the 
difference in survival between groups, but does not permit other variables to be 
taken into account. In our studies, the Wilcoxon rank-sum test was tried 
experimentally in study IV, to see whether it would differ from the log-rank test. 
The Wilcoxon test, a test that emphasizes the first part of the survival curve, is 
mostly used when censored observations are not present, and it was therefore 
less relevant than the log-rank test in our studies.  
The Cox proportional hazard model was used to evaluate prognostic factors 
of survival in studies II and III. A univariate analysis was performed on all factors 
that were thought to be possible prognostic factors of survival. Significant or 
nearly significant (p < 0.1) factors in the univariate analysis and factors thought 
to contribute to survival were put into the multivariate model. A subset of 
variables was selected for inclusion in the final model by a stepwise selection 
procedure using bidirectional elimination―where different variables were fitted in 
the model by first adding each one at a time and then eliminating them one at a 
time.  
The final multivariate hazard model for overall survival in study II was 
corrected for age, the time period divided into six four-year periods, stage (TNM), 
histological type, ischaemic heart disease preoperatively, COPD, postoperative 
congestive heart failure (CHF), major complication, and free tumour margins. In 
study III, the final model included gender, age, stage, adenocarcinoma subtype 
(subgroups with more than 20 patients), size of the tumour, incidental detection, 
dyspnea, major complication, IHD preoperatively, ARDS as a complication, 
postoperative pneumonia, and ASA score.  
The hazard ratio (HR) is obtained from the Cox proportional hazard model for 
variables that fulfill the proportional hazard assumption. Global goodness-of-fit 
test was done to check for assumption of proportionality and for graphic plotting 
of variables. Stratification was used as required. The results are presented as 
HR with 95% confidence interval (CI). The HR is considered to be significant 
when the CI does not include the value 1. A value of < 1 is considered to be 
protective while a value of > 1 is considered to increase the risk of death. The 
statistical significance is found by evaluating both the CI and the p-value.  
3.7.3  Statistical programs 
Microsoft Excel (Microsoft Corp. Redmond, WA, USA) was used for discriptive 
statistics, and we used R version 2.10.1 or 3.1.3 with the help of R studio 
(Boston, MA, USA) version 0.98.1103 for survival calculations and construction 
of graphics.  
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4 Results 
4.1 Paper I 
Between 1994 and 2008, there were 1,530 histologically confirmed cases of 
NSCLC in Iceland, of which 404 cases (397 patients) were operated on with 
curative intent. The surgical resection rate (SRR) for the whole period was 
therefore 26.4%, and did not significantly change during the study period (Figure 
12). The surgical procedures consisted of 73.5% lobectomies (n = 297), 14.9%  
pneumonectomies (n = 60), and 11.6% sublobar resections (n = 47).  
 
Figure 12:  Surgical resection rate (SSR) for NSCLC in Iceland from 1994 to 
2008. The difference in SRR between the periods was not 
statistically significant. 
The mean age of the patients was 66 years. Most patients were current or 
previous smokers (96.5%), and 30.5% of them had an FEV1 less than 75% of 
the predicted value in preoperative pulmonary function tests. A higher proportion 
of patients who underwent sublobar resections had COPD or coronary artery 
disease than patients who underwent lobectomy or pneumonectomy.  
The majority of patients (57.4%) had AC histology (Table 5). One-third 
(31.7%) of the patients had SCC, and the rest had LCC or other NSCLC 
histological subtypes, including adenosquamous histology. Most patients (87%) 
were at stages I, II, or IIIA, but 13.9% were at more advanced stages (stages IIIB 
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Gudrun Nina Oskarsdottir 
42 
or IV) diagnosed perioperatively or postoperatively. The stage distribution did not 
change significantly between the time periods.  
 
Table 5:  The histology, staging, and resection type for the 404 resections 
performed for NSCLC in Iceland from 1994 to 2008 
 
 
 
 
 
 
 
 
 
 
 
 
Almost 9% of the patients were diagnosed with at least one major 
complication, including reoperation for bleeding or empyema. The rate was 
significantly higher in patients who underwent pneumonectomy (18.3%) than in 
patients who underwent lobectomy (7.1%) or a sublobar resection (6.4%). The 
rates of other complications are given in Table 6. Four patients died within 30 
days of operation, and the 30-day (operative) mortality was therefore 1.0%. 
Total 5-year survival was 40.7% for the whole group and increased from 
34.8% in the first period to 43.8% in the last period (log-rank test, p = 0.039). 
Patients who underwent pneumonectomy had a significantly less favourable 5-
year survival of 22%, compared to 44.6% for lobectomy and 40.7% for sublobar 
resection (p = 0.006).  
Overall 5-year survival in all the patients who were diagnosed with NSCLC in 
the study period was 12.4%, but it was only 4.8% in the patients who did not 
undergo surgical resection (n = 1,126).  
 
  
 n (= 404) % 
Histology 
- Adenocarcinoma 
- Squamous cell 
- Large cell 
- Other 
 
232 
128 
23 
20 
 
57.4 
31.7 
5.7 
5.0 
pTNM stage 
- I 
- II 
- IIIA 
- IIIB 
- IV 
 
224 
94 
30 
35 
21 
 
55.4 
23.3 
7.4 
8.7 
5.2 
Resection type   
- Lobectomy 
- Pneumonectomy 
- Sublobar resection 
297 
60 
47 
73.5 
14.9 
11.6 
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Table 6:  Complications, both major and minor, in patients who underwent 
pulmonary resection with curative intent for NSCLC in Iceland 
between 1994 and 2008  
 
Lobectomy Pneumonectomy 
Lesser 
resection 
All 
procedures 
n            % n              % n               % n           % 
All major complications 21 7.1 11 18.3 3 6.4 35 8.7 
-ARDS 6 2.0 3 5.0 0 0 9 2.2 
-Reoperation for 
bleeding 
6 2.0 3 5.0 0 0 9 2.2 
-Reoperation for 
empyema or BPF 
3 1.0 4 6.7 0 0 7 1.7 
-Heart failure 6 2.0 0 0 1 2.1 7 1.7 
-Myocardial infarction 4 1.3 1 1.7 1 2.1 6 1.5 
-Empyema 3 1.0 3 5.0 0 0 6 1.5 
-Bronchopleural fistula 1 0.3 1 1.7 0 0 2 0.5 
-Stroke 0 0 0 0 1 2.1 1 0.2 
All minor complications 105 35.4 30 50.0 16 34.0 151 37.4 
-Intraoperative bleeding 24 8.1 20 33.3 0 0 44 10.9 
-Atrial fibrillation/flutter 18 6.1 15 25.0 1 2.1 34 8.4 
-Recurrent laryngeal 
nerve paralysis 
5 1.7 2 3.3 0 0 7 1.7 
-Air leakage > 7 days 63 21.2 1 1.7 6 12.8 70 17.3 
-Pneumonia 16 5.4 3 5.0 7 14.9 26 6.4 
-Wound infection 5 1.7 1 1.7 2 4.3 8 2.0 
ARDS, adult respiratory distress syndrome; BPF, bronchopleural fistula. 
4.2 Paper II  
Between 1991 and 2014, 493 lobectomies (in 489 patients) were performed for 
NSCLC with curative intent in Iceland and the mean age of the patients was 67 ± 
9.5 years (Table 7). A higher proportion of women had smoked within five years 
of surgery (p = 0.0007) and a higher proportion of women had AC histology (p = 
0.0004). A higher proportion of men had ischaemic heart disease diagnosed 
before the pulmonary resection (p < 0.0001). The mean age of the patients 
Gudrun Nina Oskarsdottir 
44 
increased significantly over the time periods, from 63 years in 1991‒1994 to 68 
years in 2011‒2014 (p = 0.009).  
 
Table 7:  Demographics of 493 cases operated with lobectomy for NSCLC in 
Iceland, 1991‒2014 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; FEV1, forced expiratory 
volume in 1 second 
 
Table 8 shows the postoperative stage distribution of the 493 cases. Most 
patients had stage-I disease (55.4%), 30% of whom were at stage IA. Almost 
one-third of the patients (29.6%) had stage-II disease, and 15% (74 patients) had 
disease at stage IIIA. Most of the patients with stage-III disease were diagnosed 
perioperatively or postoperatively. The proportion of patients at stage IA rose 
from the first period to the last period (25.9% vs. 39.4%; p = 0.03).  
Demographics n (%) 
Descriptive factors 
- Women (ref men) 
- Age (years) 
 
265 (53.8) 
67 (range: 35‒89) 
Risk factors, comorbidity 
- Smoking history 
- Current smoker (within 5 years) 
- COPD 
- IHD 
- Arrhythmias 
- FEV1 < 75% 
 
Period  
 - 1991‒1994 
 - 1995‒1998 
 - 1999‒2002 
 - 2003‒2006 
 - 2007‒2010 
 - 2011‒2014 
 
 
468 (94.9) 
327 (66.3) 
128 (26.0) 
121 (24.5) 
66 (13.4) 
138 (28.0) 
 
 
58 (11.8) 
59 (12.0) 
67 (13.6) 
88 (17.8) 
94 (19.1) 
127 (25.8) 
 
Results 
45 
The 30-day, hospital, and 90-day mortality was 0.6% (3 patients), 1.2% (6 
patients), and 1.4% (7 patients), respectively. The overall 5-year survival in all 
the patients was 49.2% over the whole 24-year study period. Overall 5-year 
survival in patients at stage I was 64.2%. Three-year OS increased significantly 
from the first period (1991‒1994) to the last period (2011‒2014), from 48.3% to 
72.8% (log-rank, p = 0.0004).  
 
Table 8:  The postoperative TNM stage distribution of 493 cases that had a 
lobectomy for NSCLC in Iceland in the 24-year period 1991‒2014. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multivariate analysis on different factors that might predict survival (Figure 13) 
showed that time period (HR = 0.88, 95% CI 0.82‒0.94; p = 0.0003) was a 
significant prognostic factor for survival, as were free surgical margins (HR = 
0.44, 95% CI 0.3‒0.65; p < 0.0001). Advanced age (HR = 1.03, 95% CI 1.02‒
1.04; p < 0.001) and stage (HR = 1.4, 95% CI 1.25‒1.46; p < 0.0001) were 
independent predictors of worse survival.   
 Stage 
I II IIIA Total 
1991-1994 26 (44.8) 20 (34.4) 12 (20.7) 58 (100) 
1995-1998 34 (57.6) 18 (30.5) 7 (11.9) 59 (100) 
1999-2002 30 (44.8) 26 (38.8) 11 (16.4) 67 (100) 
2003-2006 52 (59.1) 24 (27.2) 12 (13.6) 88 (100) 
2007-2010 51 (54.2) 24 (25.6) 19 (20.2) 94 (100) 
2011-2014 80 (63.0) 34 (26.8) 13 (10.2) 127 (100) 
Total 273 (55.4) 146 (29.6) 74 (15.0) 493 (100) 
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Figure 13: Forest plots showing the results of multivariate analysis of 
preoperative factors (a) and postoperative factors (b) for 493 
patients who underwent lobectomy for NSCLC in Iceland in the 
period 1991‒2014. Lines that cross the dotted line are not 
significant prognostic factors of overall survival.  
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4.3 Paper III 
During the study period between 1991 and 2010, 285 patients out of 473 patients 
who underwent surgical resection for NSCLC had AC histology, and 56.8% of 
them were women. Table 9 shows the patient demographics (with minor 
corrections made to Table 1 of paper 3). The patients were 67 years old on 
average and 95.1% were current or previous smokers. Most patients had 
lobectomy (79%, 224 patients), 12% (37) had a lesser resection, and 24 patients 
(9%) had a pneumonectomy.  
 
Table 9:  Demographics of the 285 patients who had a pulmonary resection 
with curative intent for primary lung adenocarcinoma in the years 
1991‒2010. The numbers of patients are given, with percentages in 
parentheses.   
Demographics 
Pneumonectomy 
n = 24 
Lobectomy 
n = 224 
Lesser 
resection 
n = 37 
Total 
n = 285 
Age, mean 65 66 68 67 
Female 14 (4.9) 129 (45.2) 19 (6.7) 162 (56.8) 
Smoking history 
 - Never-smoker 
 - Current smoker 
22 (7.7) 
2 (0.7) 
15 (5.2) 
212 (74.4) 
11 (3.9) 
153 (53.7) 
36 (12.6) 
1 (0.4) 
23 (8.1) 
271 (95.1) 
14 (4.9) 
191 (67.0) 
 Comorbidities 
- COPD 
- IHD 
- Arrythmias 
 
4 (1.4) 
3 (1.0) 
1 (0.4) 
 
57 (20.0) 
55 (19.2) 
33 (11.6) 
 
13 (4.6) 
17 (6.0) 
7 (2.5) 
 
74 (26.0) 
75 (26.3) 
41 (14.3) 
COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease. 
 
Histological subtyping is shown in Table 10. Almost all―273 (95.8%) of the 
cases―were invasive ACs, where only nine patients (3.2%) had variants of 
invasive AC and three patients (1%) had pre-invasive AC. The most common 
histological subtype was acinar-predominant AC, comprising almost half of the 
cases (46%). Solid-predominant AC with mucin production was diagnosed in 
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23% and lepidic-predominant in 20%. No cases of atypical adenomatous 
hyperplasia (AAH) or enteric-predominant (EPA) AC were identified.  
The majority of patients had early-stage disease, with 57.8% being stage-I 
and 31.5% of those being stage-IA. Two of the patients with pre-invasive AC 
were at stage IA but the third was at stage IIIA. 
 
Table 10:  Adenocarcinoma subtyping according to the pTNM stage of all 
patients who were diagnosed with adenocarcinoma in Iceland, 
1991‒2010, and had a surgical resection. The numbers of patients 
are given, with percentages in parentheses.   
Predominant 
subtype  
Stage  
 I                   II                    IIIA 
 
Total 
Pre-invasive 
- AIS 
2 (0.7) 
1 (0.4) 
0 (0) 
0 (0) 
1 (0.4) 
0 (0) 
3 (1.0) 
1 (0.4) 
- MIA 1 (0.4) 0 (0) 1 (0.4) 2 (0.7) 
Invasive 
- Lepidic 
150 (52.6) 
39 (14.7) 
81 (28.4) 
11 (3.9) 
42 (14.7) 
5 (1.8) 
273 (95.8) 
55 (20.0) 
- Acinar 67 (23.5) 38 (13.4) 24 (8.4) 129 (46.0) 
- Micropapillary 0 (0) 1 (0.4) 2 (0.7) 3 (1.0) 
- Papillary 12 (4.2) 5 (1.8) 4 (1.4) 21 (7.0) 
- Solid 32 (11.2) 26 (9.2) 7 (2.5) 65 (23.0) 
Variant of invasive 
- Mucinous 
7 (2.5) 
5 (1.8) 
1 (0.4) 
1 (0.4) 
1(0.4) 
1 (0.4) 
9 (3.2) 
7 (2.5) 
- Colloid 1 (0.4) 0 (0) 0 (0) 1 (0.4) 
- Foetal 1 (0.4) 0 (0) 0 (0) 1 (0.4) 
Total 159 (57.8) 82 (28.8) 44 (15.4) 285 (100) 
AIS, adenocarcinoma in situ. MIA, minimally invasive adenocarcinoma. pTNM, postoperative tumour, node, 
metastasis. 
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The five-year overall survival for all surgically resected pulmonary ACs during 
the whole study period was 45.3%. Patients with stage-I disease had a 5-year 
survival of 61.5%, as compared to 14% for patients with stage-IIIA disease (log-
rank test, p < 0.001) (Figure 14). The difference in survival between the different 
subtypes of AC was not statistically significant, as can be seen from Figure 15 
(log-rank test, p = 0.32). The 5-year survival for LPA was 55%, and it was 38% 
for APA, 52% for SPA, and 38% for PPA.  
The overall survival in patients with SCC (n = 156) and LCC (n = 32) was 
35% and 28%, respectively (log-rank test, p = 0.02). When the survival was 
corrected for stage, the difference in survival was no longer significant (p = 0.98).  
Univariate analysis showed that gender, advanced TNM stage, increased 
tumour size, dyspnea at diagnosis, suffering a major postoperative complication, 
or having ischaemic heart disease was significantly associated with worse OS. In 
multivariate analysis, only advanced age (HR = 1.03, 95% CI 1.02‒1.05; p < 
0.0001) and TNM stage (stage IIIA: HR = 3.98, 95% CI 2.37‒5.98; p < 0.001) 
were independent prognostic factors of OS.   
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Figure 14: Overall survival in 285 patients with surgically resected  
adenocarcinoma of the lung in the period 1991‒2010, according to 
stage (log-rank test, p < 0.001).  
 
 
 
 
 
Results 
51 
Figure 15:  Overall survival of the adenocarcinoma subtypes that had more than 
20 patients. The difference was not significant (log-rank, p = 0.32).  
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4.4 Paper IV 
In the years 1991 to 2014, a total of 2,556 patients were diagnosed with lung 
cancer in Iceland, 859 of whom were elderly (≥ 75 years old). However, 77 of 
these patients had to be excluded because of missing data, leaving 782 elderly 
patients (32%, 782/2,479) for further analysis.  
AC was the most common histological type (48%) in all the elderly patients, 
and its proportion rose significantly during the last two 6-year periods. Some 471 
patients (62%) were at stage III or IV, 29% were at stage I or II, and the clinical 
stage could not be determined in 9% (68 patients). The proportion of elderly 
patients diagnosed with stage-IA disease increased during the last study period 
(p < 0.001), and at the same time the proportion of patients at stage IIB 
decreased (p = 0.035).  
 
Table 11:  The stage distribution of all elderly patients (≥ 75 years old) with 
NSCLC who were diagnosed at early stages (I and II) in Iceland 
during the period 1991‒2014. The numbers of patients are given, 
with percentages in parentheses.   
TNM stage 1991‒1996 1997‒2002 2003‒2008 2009‒2014 Total 
IA 10 (31) 6 (17) 13 (18) 38 (45) 68 (30) 
IB 10 (31) 13 (36) 24 (32) 26 (31) 73 (32) 
IIA  8 (22) 8 (22) 17 (22) 12 (14) 44 (19) 
IIB 5 (16) 9 (25) 21 (28) 9 (11) 44 (19) 
NSCLC, non-small cell lung carcinoma. 
The overall surgical resection rate was 18% (140/782) for all the elderly 
patients, and this did not change significantly during the study period.  
The mean age in the elderly group was 80 years, as opposed to 65 years for 
the younger group. During the study period, the proportion of elderly patients 
diagnosed with NSCLC increased steadily from 29% in the first study period to 
37% in the last (p = 0.006).  
A total of 103 patients were diagnosed at stage IA, IB, IIA, or IIB, but did not 
have surgical resection. Another 68 patients did not finish staging work-up. 
Usually further work-up was not considered necessary in these cases, since it 
was known beforehand that they would not be offered surgery for various 
reasons (shown in Table 12). The most common reason for not operating on 
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elderly patients diagnosed at stages IA to IIIB was insufficient lung function 
(58%), followed by heart disease (17%), multiple comorbidities (17%), patient 
refusal of treatment (16%), and poor performance status (13%). There were 
other, less common reasons as well.   
 
Table 12:  The reasons that were given for not performing pulmonary resection 
on 103 elderly patients with stage-IA to stage-IIB NSCLC in Iceland, 
1991‒2014.  
Reason  
IA‒IIB 
(n = 103) 
n (%) 
Incomplete staging 
(n = 68) 
n (%) 
Insufficient lung function 60 (58) 32 (47) 
Heart disease 17 (17) 11 (16) 
Multiple comorbidities  17 (17) 9 (13) 
Patient denied operation or further 
treatment 
16 (16) 8 (12) 
Frailty and poor performance score 13 (13) 14 (21) 
Unresectable tumour location 4 (4) 6 (9) 
Patient died of other causes before 
complete work-up/treatment 
4 (4) 2 (3) 
Other life-threating or terminal 
disease 
4 (4) 3 (4) 
Dementia 3 (3) 6 (9) 
Reason for not operating could not 
be determined 
3 (3) 3 (4) 
 
When comparing preoperative patient demographics and risk factors, there 
were more men in the elderly group (p = 0.006), a higher proportion of patients 
had coronary heart disease (p < 0.001), and a higher proportion had a history of 
arrythmias (p < 0.001). The elderly group also had a lower FEV1 (p < 0.001), 
were more likely to have been diagnosed incidentally (p < 0.001), and were more 
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likely to have had a sublobar resection (p < 0.001). The younger patients were 
more likely to have undergone a pneumonectomy (p < 0.001) and to have been 
given adjuvant chemotherapy (p < 0.001).  
There was no significant difference in 30-day mortality, median length of stay, 
or rate of postoperative complications between younger patients and elderly 
patients. There was, however, a significant difference in overall survival (44% vs. 
40% at five years; p = 0.02) between the groups, but not in cancer-specific 
survival (50% vs. 51% at five years; p = 0.8). 
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5 Discussion 
In this thesis, the epidemiology, diagnosis, treatment, and prognosis of different 
subgroups of NSCLC patients has been investigated. The patients in all studies 
represent a whole nation, and the main focus was on short- and long-term 
outcomes after pulmonary resection in subgroups of patients.  
5.1 Long-term overall and cancer-specific survival 
The overall 5-year survival for the patients was 40.7% in study I (all types of 
pulmonary resections), 49.2% in study II (only lobectomies), 45.3% in study III 
(only AC histology), 40% for elderly patients (all types of resections) in study IV 
and 44% for younger patients (all types of resection) in study IV. These survival 
figures only vary with a range of 10% (40‒50%), showing the small variation in 
survival between the different studies and subgroups analyzed. As expected, the 
most favourable survival was seen in patients who underwent a lobectomy and in 
patients with AC histology. We analyzed these prognostic factors further by 
correcting for other factors in the multivariate survival model, such as TNM 
staging (Goldstraw et al., 2016). Not surprisingly, the TNM staging system was 
the most significant prognostic factor in all of the studies presented.  
Overall survival of NSCLC patients improved with time following pulmonary 
resection in Iceland. In study I, the 5-year survival rose from 34.8% to 43.8% 
from the first 5-year period to the last, and in study II the overall 3-year survival 
for lobectomies increased from 48.3% in 1991‒1994 to 72.8% in 2011‒2014. 
The cancer-specific survival also increased during the 24-year study period; 
underscoring the fact that most NSCLC patients die from their disease and not 
for other reasons. The reason for the increased survival with time was probably 
multifactorial. In study I, the stage distribution did not change significantly 
between periods from 1994 to 2008, but in studies II and IV―which had longer 
study periods (24 years)―more patients were diagnosed with stage-IA disease 
in the later time periods, without any change in the ratio of incidentally diagnosed 
tumours. The increased proportion in stage-IA patients was probably one of the 
main influential factors in increased survival. Calendar year, however, still 
remained an independent prognostic factor for survival after correction for stage, 
age, and other factors in the multivariate analysis (Table 3 of paper II). Thus, the 
improved survival appears to be influenced by factors other than stage and 
incidental diagnosis. The rise in the proportion of ACs, as demonstrated in study 
IV, does not explain this development either, as the time period (calendar year of 
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diagnosis) also remained a prognostic factor when the histological type was 
corrected for in the multivariate survival analysis. Improved imaging techniques 
and improved staging, with increased use of mediastinoscopies and EBUS, have 
most likely also contributed to the improvement in survival.  
As expected, the survival of patients who underwent pneumonectomy was 
inferior to that for the other types of less extensive operations. The results of 
study I, however, show that the 5-year survival of patients after pneumonectomy 
(22%) was disproportionally low in this study compared to other studies, where 
rates are usually between 27% and 40% (Alexiou et al., 2001; Okada et al., 
2000). The reason for this is open to debate, but understaging due to low rates of 
mediastinoscopies performed during the first half of the study may have played a 
role. Proper staging is of special importance in patients with tumours that require 
pneumonectomy, as they are often large and centrally located and have often 
spread to the lymph node, underscoring the importance of staging work-up.  
Importantly, multivariate analysis was performed in studies II and III to assess 
independent predictive factors of OS. Both studies showed that advanced age 
and TNM stage were strong independent predictive factors for survival. The 
histological AC subtype according to the 2011 IASLC/ATS/ERS classification, 
however, did not turn out to be an independent predictor of OS in study III 
(multivariate analysis, p = 0.7). This was somewhat surprising, as numerous 
other studies have found the very same classification to predict survival of 
NSCLC patients (Russell et al., 2011; Warth et al., 2012; Yoshizawa et al., 
2013). Still, the study is limited by the fact that it only included 285 patients in the 
multivariate analysis, which limited the statistical power. In a study by Westaway 
et al. that included 152 patients, the classification was also shown to have limited 
prognostic significance in advanced resected pulmonary AC (Westaway et al., 
2013), which is similar to our findings (study III). We therefore concluded that 
more studies might be needed on the possible prognostic relevance of the AC 
subtype classification.   
When comparing different histological types of NSCLC in study III, there was 
no difference between survival in patients with SCC, AC, or LCC after correction 
for stage; however, AC was a prognostic factor for survival in univariate analysis. 
This might suggest that ACs are more often detected at early stages.  
A statistically significant difference was observed in OS of the young and 
elderly patients in study IV (log-rank test, p = 0.019), but not in CSS. 
Interestingly, when the Wilcoxon test was used to compare OS of the groups, no 
statistically significant difference was observed (p = 0.109). Wilcoxon test 
emphasizes the early events of the survival curve. This may indicate that the OS 
is initially similar, but due to chronological age and long follow-up time, the 
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survival curve for the elderly drops after a few years. Other studies have shown 
similar results (Cerfolio & Bryant, 2006; Fan et al., 2007; Qiang et al., 2015; 
Schneider et al., 2008). However, study IV was the first study to report these 
findings for surgically treated NSCLC patients representing a whole nation.  
5.2 Complications and 30-day mortality 
The rates of major and minor complications following pulmonary resection in 
studies I, II, and IV are relatively low compared to other reports (Andalib et al., 
2013; Irie et al., 2016; Myrdal et al., 2001; Thomas et al., 2014; Yano et al., 
1997). Still, however, one must bear in mind that comparison to other studies 
may be difficult because of the different criteria used. 
The major complication rate was 8.7% for all patients who underwent 
pulmonary resection for NSCLC (paper I). For comparison, Myrdal et al. (2001) 
reported a rate of 8.8% for surgically treated NSCLC patients in Sweden and the 
rate was 9.5% in a study by Nathan et al. (2016) performed on patients in the 
Surveillance, Epidemiology, and End Results (SEER) database. Other studies 
with wider definitions of major complications have reported rates of 12‒36% 
(Laursen et al., 2016; Maeda et al., 2016; Nojiri et al., 2016; Oor et al., 2016).  
Patients who undergo lobectomy usually have fewer complications than 
patients after pneumonectomy or sublobar resection (Myrdal et al., 2001; Suen et 
al., 1999; Thorsteinsson et al., 2009). The lobectomy patients (study II) had a 
major complication rate of 4.7% and a total complication rate of 21.1%. This is 
lower than reported by Myrdal et al. in Sweden (2001), where it was 5.7% for 
lobectomies. Other studies have shown total operative complication rates in the 
9‒57% range following lobectomy (Cai et al., 2013; Kent et al., 2014).  
The postoperative complications in patients over 75 years old (paper IV) were 
not significantly different from those in younger patients (major: 11% and 13%, 
respectively; p = 0.57; minor: 36% and 29%, respectively; p = 0.12). Actually, 
heart failure was the only complication that was more common in the elderly (4 
vs. 1%; p = 0.012). Still, it must be kept in mind that there is a risk for type-II error 
with such low rates of complications, and relatively small subgroups to compare.  
The 30-day operative mortality in studies I (1%), II (0.6%), and IV (> 75 years, 
2.0%; < 75 years, 1.0%; p = 0.387) was low compared to other studies 
(Abdelsattar et al., 2016; Bablekos et al., 2016; Irie et al., 2016; Myrdal et al., 
2001; Nathan et al., 2016; Pfannschmidt et al., 2007; Schattenberg et al., 2007; 
Strand et al., 2012). Most studies have had the same definition of operative 
mortality as we had, and have shown an average operative mortality rate of 1.5‒
3.8% (Abdelsattar et al., 2016; Bablekos et al., 2016; Irie et al., 2016; Myrdal et 
al., 2001; Nathan et al., 2016; Pfannschmidt et al., 2007; Schattenberg et al., 
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2007; Strand et al., 2012). However rates up to 11% have been reported for 
pneumonectomy patients operated for stage-III disease (Bablekos et al., 2016; 
Saha et al., 2014). In the study by Myrdal et al., the 30-day mortality was 0.6% 
following lobectomy (Myrdal et al., 2001), which is exactly the same rate as 
reported in study II.  
The reasons for the low complication rates and 30-day mortality rates are 
debatable. The four studies presented here were all nationwide and population-
based, and the patients were treated at a single centre. One possible 
explanation might be regional differences, with good teamwork in the surgical 
and anaesthesiology teams. Another explanation could be the early use of 
multidisciplinary discussion of every patient.  
5.3 Histology  
In all four studies, the histological diagnosis was based on the WHO 2004 or 
earlier classification of lung tumours (Travis et al., 2004) and the 2011 
IASLC/ERS/ATS classification for pulmonary AC (Travis et al., 2011).  The most 
common histological subtype was acinar-predominant AC and, as pointed out 
earlier (see section 5.1), the new histological subclassification did not turn out to 
be a prognostic factor for survival of AC patients.  
The distribution of histological subtypes of ACs was similar to those in studies 
from Europe and Australia (Mansuet-Lupo et al., 2014; Russell et al., 2011), with 
the majority of cases being invasive and around half of them being acinar-
predominant AC. Studies on Asian patients, however, usually report more cases 
of non-invasive AC (Nakagiri et al., 2014; Yanagawa et al., 2014).  
There was no significant difference in survival between the histological AC 
subgroups. However, a trend showing worse survival in the acinar-predominant 
subgroup was observed (38%), which has also been reported previously in 
numerous other studies (43‒68%) (Russell et al., 2011; Warth et al., 2012; 
Westaway et al., 2013). Thus, our findings could indicate that the acinar-
predominant subgroup should be grouped with poor prognosis subtypes, such as 
micropapillary-predominant AC. Furthermore, our findings also indicate that this 
large subgroup, acinar-predominant AC, is a heterogenous group that requires 
further subclassification based on nuclear features or architecture. 
In September 2015, the WHO launched a new classification of lung tumours  
with significant genetic, clinical, and radiological advances (Travis et al., 2015). 
The new classification meant substantial differences for lung cancer histology, 
but not for the 2011 IASLC/ERS/ATS subclassification of lung AC. In the 2015 
classification, the term “predominant” is no longer listed in the names for the 
major AC subtypes, but they should still be classified according to the 
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predominant subtype. This is of relevance here, especially for study III, where 
patients with AC according to earlier WHO classifications were included (Travis 
et al., 2004), as some of the tumours that were defined as LCC in the former 
classification are now categorized as ACs based on immunohistochemistry. In 
particular, in the new 2015 classification, tumours that were formerly called LCCs 
but express TTF1 and/or Napsin A are categorized as solid ACs even if mucin is 
absent (Travis et al., 2015).  
5.4 Surgical resection rate  
The surgical resection rate (SRR) in our nationwide, population-based study on 
all resected lung cancer patients over a 15-year period (paper I) was 26.4% and 
did not change significantly between the years 1994 and 2008. Furthermore, in 
study IV, the SRR in elderly patients (≥ 75 years old) was lower than in the 
younger patients (18% vs. 32%; p < 0.001).   
Other European studies have shown SRRs to be in the 11‒24% range (de 
Cos et al., 2008; Imperatori et al., 2016; Makitaro et al., 2002; Myrdal et al., 
2009; Strand et al., 2012). Our rate of 26.4% therefore appears to be higher than 
in most other studies. When comparing studies, one must take into account 
possible differences in the definition of SRR, which are not even always specified 
in the different studies (Strand, 2012). Some studies have included patients with 
SCLC; others have included patients with the diagnosis on the death certificate 
only. The reason for the high SRR in our study is not clear. One explanation may 
be that there are only a limited number of doctors in Iceland who perform lung 
cancer surgery, and the operations are all performed at a single institution where 
all patients diagnosed with NSCLC are discussed at a multidisciplinary meeting 
and the treatment decided. Another possible explanation might be regional 
variation, whereby some centres have better outcome than others―as shown in 
studies from Denmark (Rasmussen, 2016), Spain (de Cos et al., 2008), and 
Norway (Strand et al., 2012).  
The SRR for elderly patients was 18% in paper IV, which is in line with other 
studies (Mery et al., 2005; Shirvani et al., 2012). A lower proportion of elderly 
patients underwent pneumonectomy and a higher proportion underwent sublobar 
resections than younger patients. The elderly patients had favourable surgical 
outcomes with low rates of major complications, low 30-day mortality, and 
favourable survival. The only exception was heart failure, which was more 
common in the elderly group (4% vs. 1%; p = 0.012). The low SRR, few 
pneumonectomies, and a high number of sublobar resections in the elderly might 
reflect an appropriate selection of patients for surgery. However, it might also 
suggest that more elderly patients could tolerate surgery―and more often 
lobectomy than sublobar resection.   
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Previous studies have shown lower complication rates and mortality with 
sublobar resections and less invasive surgery (Alexandersson et al., 2011; 
Dell'Amore et al., 2015; Qiang et al., 2015). A recent randomized controlled trial 
comparing sublobar resection and lobectomy is ongoing, but the results are not 
yet published (Yang et al., 2016). It could be argued that SRR in elderly patients 
could be increased by offering less invasive surgery or sublobar resections, 
thereby reducing the number of patients who are denied surgery due to 
insufficient lung function, heart disease, or multiple comorbidities.   
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6 Conclusions 
Lung cancer is the leading cause of cancer-related death in the western world. 
Despite the great advances in surgical techniques, and also radiation therapy 
and chemotherapy, the survival in lung cancer is still considered to be poor. In 
the epidemiological studies presented in this thesis, we have reported short- and 
long-term outcomes in patients undergoing surgical resection for lung cancer in a  
nationwide population-based cohort.  
The surgical resection rate was high for NSCLC patients in Iceland in the 
period 1994‒2008. Short-term outcome was good, with a low rate of major 
complications and an operative mortality of only 1%. Furthermore, five-year 
survival improved significantly over the study period.  
The short-term outcome of lobectomy for NSCLC in Iceland in the period 
1991‒2014 was excellent, as reflected by the low 30-day mortality and low rate 
of complications. Long-term outcome was acceptable but, importantly, the 
survival improved significantly over the study period.  
The AC subtype according to the 2011 IASLC/ATS/ERS classification was not 
an independent prognostic factor for survival in our study of 285 patients in the 
period 1991‒2010. Pre-invasive and minimally invasive adenocarcinomas were 
rare.  
Elderly patients with resectable NSCLC were frequently excluded from 
surgery due to comorbid conditions. They may represent a selected group, but 
they have a favourable 30-day mortality and favourable long-term survival. This 
indicates that more patients with NSCLC who are elderly could be operated on.    
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7 Strengths and limitations  
All the data in studies I‒IV were based on a nationwide patient cohort with all the 
patients operated on at a single cardiothoracic centre over a time period of up to 
24 years. The patient cohort was well-defined, both clinically and geographically, 
and a further strength was the fact that all the patients were operated on at a 
single cardiothoracic centre, reducing the risk of institutional or selection bias. All 
patients were most likely included, as two registries were double-checked in 
order to minimize the risk of omitting patients. A further strength was that none of 
the patients were lost to follow-up in the surgical database, with only very few 
elderly patents being lost to follow-up in the non-surgical group in study IV. 
Importantly, the experienced senior pulmonary pathologist who reviewed the 
histology samples in study III was blinded regarding the clinical outcome of 
patients, thereby reducing the risk of response bias.  
The main limitation of all the four studies included in this thesis was their 
retrospective design. By recording data retrospectively, factors such as 
documentation of symptoms and complications are not as reliable as when the 
studies are prospective. Staging also improved during the study period, with 
more aggressive and routine use of preoperative mediastinoscopy and other 
staging methods from 2005 onward. PET-scan has not been available in Iceland, 
but since 2013 patients have been sent to Copenhagen, Denmark, for staging 
with PET-scan. Surgical treatment did not change much during the study period 
that covered 24 years, but in the latter half of the study period adjuvant 
chemotherapy was offered to most patients at stages II and IIIA. The lack of 
detailed information on adjuvant therapy in the survival analysis could therefore 
be considered to be a limitation.  
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8 Future work 
Fortunately, the field of research on lung cancer is expanding rapidly with a vast 
number of studies being published every year. In this thesis, four studies are 
presented that have been added to the literature during the past 5 years. This 
work has led to ideas for many more studies in the field of lung cancer in Iceland.  
The role of adjuvant chemotherapy should be looked into further, but many 
patients with localized disease at surgery later develop recurrent NSCLCs that 
were in many cases distant metastases. Although adjuvant chemotherapy has 
been shown to improve survival in stages II and III, its effect has been 
limited―with only around 5% survival benefit (Novello et al., 2016; Pignon et al., 
2008). Future studies should look further into the benefit of this therapy in 
different subgroups of NSCLC patients, to find out which patients benefit more 
than others (Burdett et al., 2015; Ganti et al., 2015; T. S. Park et al., 2014). The 
lung cancer study group in Iceland has already started to collect more detailed 
information on the adjuvant chemotherapy offered to patients at stages II and III, 
and has added this information to the surgical database. This has been done in 
order to determine whether adjuvant therapy has contributed significantly to the 
observed improvement in survival of NSCLC patients in Iceland (study II) or 
whether other factors are involved.  
Another interesting field for future studies is to take advantage of the almost 
complete histological samples of the patients in the surgical database. These are 
kept in a biobank at the Department of Pathology at Landspitali University 
Hospital and represent all cases of NSCLC diagnosed in a whole and well 
geographically defined population. Further characterization of these tumours at 
the DNA and RNA level using rapidly evolving molecular techniques (Lira et al., 
2014) could lead to a better understanding of lung cancer subgroups in our 
material, with future implications for improved diagnostics, refined prognostics, 
and personalized therapy.   
It could also be of interest to construct a prospective database of all lung 
cancer patients diagnosed in Iceland, to better understand the epidemiology and 
outcome of different modes of treatment, including pulmonary resections. This 
cooperation could involve deCODE Genetics, a genetic company located in 
Reykjavik, which has already contributed with important studies on family history 
and genetics of Icelandic lung cancer patients. This cooperation would involve 
extensive collaboration between pulmonologists, oncologists, and thoracic 
surgeons together with specialists in genetic research, statisticians, and software 
technicians. Such a registry would be a platform for publication of high-quality 
studies that not only focus on the short- and long-term outcomes following 
surgery, but also on the quality of life of the patient.   
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ORIGINAL ARTICLE
Background: The proportion of patients with non–small-cell lung 
cancer (NSCLC) who undergo surgery with curative intent is one 
measure of effectiveness in treating lung cancer. To the best of our 
knowledge, surgical resection rate (SRR) for a whole nation has 
never been reported before. We studied the SRR and surgical out-
come of NSCLC patients in Iceland during a recent 15-year period.
Methods: This was a retrospective study of all pulmonary resections 
performed with curative intent for NSCLC in Iceland from 1994 
to 2008. Information was retrieved from medical records and from 
the Icelandic Cancer Registry. Patient demographics, postoperative 
tumor, node, metastasis stage, overall survival, and complication 
rates were compared over three 5-year periods.
Results: Of 1530 confirmed cases of NSCLC, 404 were resected, 
giving an SRR of 26.4%, which did not change significantly during 
the study period. Minor and major complication rates were 37.4% 
and 8.7%, respectively. Operative mortality rates were 0.7% for 
lobectomy, 3.3% for pneumonectomy, and 0% for lesser resection. 
Five-year survival after all procedures was 40.7% and improved from 
the first to the last 5-year period (34.8% versus 43.8%, p = 0.04). 
Five-year survival for stages I and II together was 46.8%, with no 
significant change in stage distribution between periods. Five-year 
survival after pneumonectomy was 22.0%, which was significantly 
lower than for lobectomy (44.6%) and lesser resection (40.7%) (p < 
0.005). Unoperated patients had a 5-year survival of 4.8%, as com-
pared to 12.4% for all the NSCLC patients together.
Conclusion: Compared with most other published studies, the SRR 
of NSCLC in Iceland is high. Short-term outcome is good, with a low 
rate of major complications and an operative mortality of only 1.0%. 
Five-year survival improved significantly over the study period.
Key Words: NSCLC, Resection rate, Outcome, Complications, Survival.
(J Thorac Oncol. 2012;7: 1164–1169)
Lung cancer is the leading cause of cancer-related deaths in the western world.1 In Iceland, the mortality from lung can-
cer is similar to that of breast, prostate, and colon cancer com-
bined, and non–small-cell lung cancer (NSCLC) accounts for 
about 85% of lung cancer cases.2 Although surgical resection 
is still the only well-defined curative treatment for NSCLC, 
it is only possible for the one third of patients diagnosed with 
stage I or stage II disease and for selected cases of stage IIIA 
disease.3,4,5
Surgical resection rate (SRR) is one measure of effec-
tiveness in treating NSCLC, for example, in a particular geo-
graphic location. SRR has varied considerably, often ranging 
from 15% to 25% in European studies,6–9 and it was 29% in a 
study including more than 700 hospitals in the United States.5 
However, smaller single-institution studies from the United 
States have found SRRs of up to 37%,10 and there have been 
studies from Europe that show SRRs as low as 10%.6,11–13 None 
of the previously published studies have found an SRR for a 
whole nation. The same applies to outcome analysis of sur-
gical treatment of NSCLC. Numerous authors have reported 
short-term complications and long-term survival for lobec-
tomies, pneumonectomies, and lesser resections separately, 
with only a few of the studies analyzing all the different pro-
cedures together. In these studies, the combined rate of major 
complications has been around or over 10%,14–16 and operative 
mortality has ranged from 1.5% to 7%.5,8,14,17–19 For pneumo-
nectomies, the figures were often double these values.14–16
The aim of this study was to investigate the SRR for 
the whole nation of Iceland using centralized databases in the 
country. Another aim was to determine surgical outcomes for 
the different lung procedures that were performed with cura-
tive intent in NSCLC patients in Iceland as a whole.
MATERIALS AND METHODS
This was a retrospective study of all patients in Iceland 
who underwent pulmonary resection with curative intent 
for NSCLC from January 1, 1994 to December 31, 2008. 
Exploratory-only thoracotomies, palliative procedures, and 
lesser resections for biopsy purposes were excluded.
A central, computerized histology database from the 
Department of Pathology of Landspitali University Hospital, 
containing details of all lung histology specimens in Iceland 
was used to identify cases. To minimize the risk of cases being 
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missed, we also reviewed the diagnosis and operation registry 
at Landspitali University Hospital, the only center performing 
cardiothoracic surgery in Iceland.
We obtained information on all cases with a histo-
logically confirmed diagnosis of primary NSCLC from the 
Icelandic Cancer Registry.2 This registry covers all cancer 
cases diagnosed at hospitals and other healthcare facilities 
in Iceland since 1955. SRR was calculated by dividing the 
number of all pulmonary resections with curative intent for 
NSCLC by the number of all histologically confirmed cases 
of NSCLC within the same period. One hundred and thirty-
three patients (6.6% of all patients with a lung cancer diag-
nosis) did not have a histologically confirmed diagnosis, and 
306 patients had small-cell carcinoma. These two groups were 
excluded from the NSCLC group that made up the denomina-
tor for the calculation of SRR. We also excluded patients with 
carcinoid tumors (n = 38), sarcomas, and carcinoma in situ.
Baseline demographic information and clinical data 
were collected from hospital charts and surgical reports using 
a standardized data sheet. Age, comorbidities, and presenting 
symptoms were collected along with data regarding the type 
of operation, tumor, postoperative tumor, node, metastasis 
(TNM) stage, complications, and survival.
Patients being considered for pulmonary resection had 
been reviewed by a multidisciplinary tumor board including 
thoracic surgeons, pulmonologists, oncologists, radiologists, 
and pathologists. The preoperative workup varied between 
patients, but usually included a chest radiograph, a computed 
tomography (CT) scan of the chest, upper abdomen and head, 
and also bone scintigraphy and spirometry. Preoperative biop-
sies were obtained through bronchoscopy or transthoracic 
CT-guided needle biopsy. Mediastinoscopy was performed pre-
operatively in a proportion of the cases, but positron emission 
tomography (PET) scan has never been available in Iceland.
Patients were staged postoperatively (pathological stage, 
pTNM) using both the 6th and the 7th edition of the TNM 
staging system,20 but data is primarily reported for the 6th ver-
sion. Preoperative clinical staging (cTNM) was not performed 
uniformly and is not reported in this study.
All surgical procedures were performed in general 
anesthesia with double lumen intubation and thoracic epidu-
ral anesthesia. The operations were performed by six surgeons 
using standardized techniques with intraoperative lymph-
adenectomy of enlarged hilar or ipsilateral mediastinal lymph 
nodes, but during the last 5-year period these lymph nodes 
were routinely removed or sampled. A posterolateral thora-
cotomy was most often performed, but during the last 5-year 
period an anterolateral approach was used.
Major complications were defined as reoperation for 
bleeding, heart failure, acute respiratory distress syndrome, 
myocardial infarction, empyema, stroke, and bronchopleu-
ral fistula. Minor complications were defined as air leakage 
for more than 7 days, pneumonia, intraoperative bleeding of 
more than 1 liter, atrial fibrillation/flutter, wound infection, 
and recurrent laryngeal nerve paralysis. Operative mortality 
was defined as death occurring within 30 days of surgery. To 
assess trends, the 15-year study period was divided into three 
5-year periods.
Statistics
Microsoft Excel was used for descriptive statistics, 
and R version 2.10.1 for survival calculations. Student’s t 
test, Fisher’s exact test, and the χ2 test were used to compare 
groups, and differences were considered to be statistically sig-
nificant when the p value was less than 0.05. Overall survival 
(OS) was analyzed by the Kaplan-Meier method, and the log-
rank test was used to compare survival between groups. All 
patients were followed up with respect to survival by using 
data from the Icelandic National Population Registry.21 In this 
way, patients could be assigned a date of death or were identi-
fied as living on July 10, 2010. Mean follow-up time was 49 
months (range, 0–194 months).
The study was approved by the Icelandic National Bioethics 
Committee and the Data Protection Authority. As individual 
patients were not identified, individual consent was waived.
RESULTS
There were 1530 histologically confirmed cases of 
NSCLC during the 15-year period, of which 404 underwent 
surgery (397 patients). The SRR was 26.4% and did not 
change significantly between the three 5-year periods (28.2%, 
24.3%, and 26.8%, respectively; Table 1). The surgical proce-
dures consisted of 297 lobectomies (73.5%), 60 pneumonec-
tomies (14.9%), and 47 lesser resections (11.6%).
The mean age of patients who underwent surgery was 
65.9 years; those in the pneumonectomy group were 6 years 
younger on average than those in the lesser resection group 
(Table 2). Over 95% of the patients were current or previous 
smokers, and many of them had reduced pulmonary function. 
A history of coronary artery disease and chronic obstructive 
TABLE 1.  Evaluation of Trends From 1994 to 2008 for 
Patients in Iceland Who Underwent Surgical Resection 
With Curative Intent for NSCLC, Divided into Three 5-Year 
Periods
1994–1998 
(n = 124)
1999–2003 
(n = 119)
2004–2008 
(n = 161)
All Periods 
(n = 404)
Male sex 66 (53.2) 60 (50.4) 85 (52.8) 211 (52.2)
Mean age 64.4 65.4 67.1 65.8
Age > 69 years 46 (37.1) 48 (40.3) 74 (46.0) 168 (41.6)
Surgical resection 
rate (SRR), %
28.2 24.3 26.8 26.4
Adenocarcinoma 
histology
67 (54.0) 64 (53.8) 103 (64.0) 234 (57.4)
Incidental 
diagnosis
40 (32.8) 38 (31.9) 61 (37.9) 139 (34.6)
Mediastinoscopy 
performed
11 (8.9) 21 (17.6) 25 (15.5) 57 (14.1)
Stage I or II 
disease
98 (79.0) 94 (79.0) 126 (7.83) 318 (78.7)
Pneumonectomies 16 (12.9) 18 (15.1) 26 (16.1) 60 (14.9)
5-year survival, % 34.8 40.6 43.8a 40.7
The numbers of patients are given with percentages in parentheses, except for age, 
surgical resection rate, and survival, where mean and percentage are given.
aStatistically significant difference between groups (p < 0.05).
NSCLC, non–small-cell lung cancer.
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pulmonary disease was significantly more common in patients 
who underwent lesser resection than in patients who underwent 
pneumonectomy or lobectomy. A forced expiratory volume of 
less than 75% of the predicted value in 1 second was also iden-
tified in more patients who underwent lesser resection (42.6% 
versus 28.9% for the other patients, p = 0.06; Table 2).
Adenocarcinoma was the most common histological 
type of lung cancer (57.4%), whereas squamous-cell histol-
ogy accounted for 31.7% (Table 3). Squamous-cell carcinoma 
was more frequent in those who underwent pneumonectomy 
than in the other patients. As shown in Table 3, almost 87% 
of the patients had stage I, stage II, or stage IIIA disease, 
but 13.9% had stage IIIB or IV disease in postoperative 
staging. The proportion of stage I cases was highest in the 
patients who underwent lesser resection (78.7%). In Table 
4 the stage distribution using the 7th edition of the TNM 
system is also given. The stage distribution did not change 
significantly between periods (Table 1). A mediastinoscopy 
was performed preoperatively in 20 of the pneumonectomies 
(33.3%), in 36 of the lobectomies (12.1%), and in one of the 
lesser resections (2.1%).
Almost 9% of the patients had major complications, 
of which reoperation for bleeding (n = 9), reoperation for 
empyema and/or bronchopleural fistula (n = 7), heart failure 
(n = 7), and myocardial infarction (n = 6) were the most com-
mon (Table 5). The rate of major complications was signifi-
cantly higher for the patients who underwent pneumonectomy 
(18.3%) than for those who underwent lobectomy (7.1%) and 
lesser resection (6.4%) (p = 0.01; Table 5).
Two patients died within 30 days of lobectomy and two 
others died after pneumonectomy, but there was no operative 
mortality after lesser resection. Operative mortality for the 
whole group was therefore 1.0%.
Five-year OS for the whole group was 40.7%. It was 
significantly higher for the last 5-year period than for the 
first (43.8% versus 34.8%; log-rank test, p = 0.039) (Table 1). 
Figure 1 shows OS for the different procedures. Survival at 5 
years was 44.6% after lobectomy, 40.7% after lesser resection, 
TABLE 2.  Patient Demographics and Comorbidities in Patients in Iceland, Who Underwent Surgical Resection With 
Curative Intent for NSCLC, 1994 to 2008
Lobectomy 
(n = 297)
Pneumonectomy 
(n = 60)
Lesser Resections 
(n = 47)
All Procedures 
(n = 404)
Male sex 148 (49.9) 42 (70.0) 21 (44.7) 211 (52.2)
Age, years (range) 65.9 (37–89) 62.7 (45–83) 69.1 (43–84) 65.8 (37–89)
History of smoking 285 (96.0) 59 (98.3) 46 (97.9) 390 (96.5)
COPD 73 (24.7) 14 (23.3) 19 (40.4)a 106 (26.3)
FEV1 < 75% predicted 83 (27.9) 20 (33.3) 20 (42.6) 123 (30.5)
Coronary artery disease 72 (24.2) 12 (20.0) 26 (55.3)a 110 (27.2)
ASA score, mean 2.6 2.6 2.6 2.6
The numbers of patients are given with percentages in parentheses, except for age and ASA score where means are given.
a Statistically significant difference between groups (p < 0.05).
NSCLC, non–small-cell lung cancer; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; ASA, American Society of Anesthesiologists.
TABLE 3.  Tumor Histology, Disease Stage (pTNM), and Other Pathological Data for Patients in Iceland, Who Underwent 
Surgical Resections (Lobectomy, Pneumonectomy, and Lesser Resections) with Curative Intent for NSCLC, 1994 to 2008
Lobectomy 
(n = 297)
Pneumonectomy 
(n = 60)
Lesser Resections 
(n = 47)
All Procedures 
(n = 404)
Tumor histology
 Adenocarcinoma 179 (60.2) 22 (36.7)a 31 (66.0) 138 (57.4)
 Squamous-cell 85 (28.6) 32 (53.3)a 11 (23.4) 128 (31.7)
 Large-cell 19 (6.4) 3 (5.0) 1 (2.1) 23 (5.7)
 Other (including adenosquamous) 13 (4.3) 3 (5.0) 4 (8.5) 20 (5.0)
Disease stage (pTNM)
 I 179 (60.2) 8 (13.3)a 37 (78.7) 224 (55.4)
 II 59 (19.9) 27 (45.0)a 8 (17.0) 94 (23.3)
 IIIA 19 (6.4) 9 (15) 2 (4.3) 30 (7.4)
 IIIB 22 (7.4) 13 (21.7) 0 35 (8.7)
 IV 18 (6.1) 3 (5.0) 0 21 (5.2)
Mean size of tumor, mm (range) 39 (4–190) 57 (20–150) 23 (8–50) 40 (4–190)
Positive surgical margins 27 (9.1) 7 (11.7) 9 (18.8) 43 (10.6)
The numbers of patients are given with percentages in parentheses, except for tumor size where means with range are given.
a Statistically significant difference between groups (p < 0.05).
TNM, tumor, node, metastasis; NSCLC, non–small-cell lung cancer.
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and significantly lower (22.0%) after pneumonectomy (p = 
0.006). The NSCLC patients who did not undergo surgery 
had a much less favorable survival: only 4.8% after 5 years. 
Survival for all NSCLC patients together was 12.4% at 5 
years, but 46.8% for stages I and II together for the operated 
patients. Survival for the different stages is shown in Table 4 
and Figure 2.
DISCUSSION
Our results show that the SRR for NSCLC in Iceland (at 
26.4%) is higher than in other European studies, where SRR 
has usually been reported to be in the 15% to 25% range.6–9 
To the best of our knowledge, this is the first report of SRR 
for a whole nation. Short-term outcome for all procedures was 
excellent, with low rates of major complications and an opera-
tive mortality of only 1.0%; other studies have found figures 
between 1.5% and 7%.5,8,14,17–19
The rate of major complications was 8.7%, which is low 
compared to other studies. However, comparisons between 
studies can be difficult because of the different criteria used. 
In the study by Myrdal et al.14 the rate of major complications 
was 8.8%, and it was 12.4% in the study by Yano et al.15 In 
another study, the major complication rate was 13%, but the 
authors’ definition of major complications was wider than that 
in the present study.16
Five-year survival in this study was 40.7% for the 
whole study period and it improved from 34.8% during the 
first 5-year period to 43.8% for the last 5-year period (p = 
0.04). Survival figures from other studies have ranged from 
30% to 60% at 5 years,10,22–24 and from around 50% to 60% 
for patients with stage I and II disease, which are somewhat 
higher than observed for stage I and II patients in our study, 
or 47%.20
Few studies evaluating surgical outcomes of NSCLC 
have included all three types of operations. In this study, sur-
vival after lesser resection was similar to that after lobectomy, 
even though a higher proportion of patients in the lesser resec-
tion group had underlying cardiopulmonary disease. There 
was, however, a higher proportion of patients with stage I 
disease in the lesser-resection group. The low complication 
rate and low mortality rate in the lesser-resection group raises 
the question of whether some of these patients could have 
TABLE 4.  Overall 5-Year Survival According to Both the 6th 
and 7th Edition of the TNM Staging System for Patients in 
Iceland With NSCLC Who Underwent Surgical Resection With 
Curative Intent, 1994 to 2008
TNM 
Stage
6th 
Edition (n) 
Survival at 
5 Years (%)
7th 
Edition (n) 
Survival at 
5 Years (%)
I 224 55.3 194 58.1
II 94 26.6 128 29.4
IIIA 30 19.9 61 22.1
IIIB 35 23.8 3 NAa
IV 21 7.1 18 5.4
I + II 318 46.8 322 46.7
III + IV 86 18.4 82 17.8
a Only three patients, calculations therefore not available.
NA, not available.
TABLE 5.  Minor and Major Complications in Patients in Iceland Who Underwent Different Lung Operations With 
Curative Intent for NSCLC, 1994 to 2008
Lobectomy 
(n = 297)
Pneumonectomy 
(n = 60)
Lesser Resections 
(n = 47)
All Procedures 
(n = 404)
Minor complications 105 (35.4) 30 (50.0) 16 (34.0) 151 (37.4)
Intraoperative bleeding 
> 1 l
24 (8.1) 20 (33.3)a 0 (0) 44 (10.9)
Atrial fibrillation/flutter 18 (6.1) 15 (25.0)a 1 (2.1) 34 (8.4)
Recurrent laryngeal 
nerve paralysis
5 (1.7) 2 (3.3) 0 (0) 7 (1.7)
Air leakage for > 7 days 63 (21.2) 1 (1.7) 6 (12.8) 70 (17.3)
Pneumonia 16 (5.4) 3 (5.0) 7 (14.9)a 26 (6.4)
Wound infection 5 (1.7) 1 (1.7) 2 (4.3) 8 (2.0)
Major complications 21 (7.1) 11 (18.3)a 3 (6.4) 35 (8.7)
ARDS 6 (2.0) 3 (5.0) 0 9 (2.2)
Reoperation for 
bleeding
6 (2.0) 3 (5.0) 0 9 (2.2)
Reoperation for 
empyema and/or BPF
3 (1.0) 4 (6.7) 0 7 (1.7)
Heart failure 6 (2.0) 0 1 (2.1) 7 (1.7)
Myocardial infarction 4 (1.3) 1 (1.7) 1 (2.1) 6 (1.5)
Empyema 3 (1.0) 3 (5.0) 0 6 (1.5)
Bronchopleural fistula 1 (0.3) 1 (1.7) 0 2 (0.5)
Stroke 0 0 1 (2.1) 1 (0.2)
A patient could have more than one complication. The numbers of patients are given with percentages in parentheses.
a Statistically significant difference between groups (p < 0.05).
NSCLC, non–small-cell lung cancer; ARDS, acute respiratory distress syndrome; BPF, bronchopleural fistula.
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tolerated a lobectomy. Alternatively, this could also be an 
argument for greater use of lesser resections in patients with 
small tumors. This question is being actively studied, as there 
is growing evidence that lesser resections are a reasonable 
approach for small peripheral tumors (of < 2 cm) and also for 
small ground-glass opacity lesions detected by CT imaging.25
As expected, survival after pneumonectomy was signifi-
cantly lower than after lobectomy and lesser resection. Our 
result of 22% 5-year survival after pneumonectomy seems 
disproportionately low when compared to the results of other 
studies that have shown rates from 27% to 40%.26–29 The reason 
for the low survival after pneumonectomy is open to debate, 
but understaging because of a low rate of mediastinoscopies 
may have had a role. Tumors requiring pneumonectomy are 
often large and centrally located, and spread more often to the 
mediastinal lymph nodes, making mediastinoscopy even more 
important in the workup of these patients.30 The use of PET 
scans, which was not available for this patient population, is 
also known to improve preoperative staging and to prevent 
unnecessary surgery.
As shown in Table 1, it is unlikely that stage distri-
bution explains improved survival, as it did not change sig-
nificantly during the study period. A number of advances 
have been made in the preoperative evaluation and staging 
of patients with NSCLC in recent years. Improvements in 
imaging techniques and increased use of mediastinoscopy 
may have resulted in more patients being excluded from 
surgical resection because of advanced disease. This could 
have contributed to the fact that survival improved during 
the last 5-year period of this study. Improvements in surgi-
cal techniques, with increases in the number of cases oper-
ated on per surgeon, are also known to play a role.24 Finally, 
more frequent use of adjuvant chemotherapy for stage II dis-
ease during the last period might also have contributed to 
improved survival.31
This is a retrospective study with the potential bias that 
it can introduce, problems like lack of a complete preopera-
tive stage and documentation of complications. Furthermore, 
PET scan was not available in Iceland for staging, and medi-
astinoscopy was used routinely for mediastinal staging dur-
ing the last 5 years of the study. The strength of this study is 
that our cohort consisted of patients from a whole popula-
tion, all of whom were operated on in a single center. The 
results were therefore less likely to be affected by tertiary 
referral.
We have reported resection rate, rates of complications, 
and survival rates for all patients who underwent surgery with 
curative intent for NSCLC in the Icelandic population during 
a 15-year period. In our opinion, these data should be reported 
together in context to help evaluate the outcome of surgical 
care for patients with NSCLC. Furthermore, we have reported 
survival of patients with NSCLC who were not operated on, 
which is important for comparison.
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ORIGINAL ARTICLE
Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and
long-term survival
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S. Jonssonc,d, M. Planckb and T. Gudbjartssona,d
aDepartments of Cardiothoracic Surgery, Landspitali University Hospital, Reykjavik, Iceland; bDepartment of Pulmonology, Skåne University
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ABSTRACT
Introduction: Lobectomy is the standard curative treatment for non-small cell carcinoma (NSCLC) of
the lung. Most studies on lobectomy have focused on short-term outcome and 30-day mortality. The
aim of this study was to determine both short-term and long-term surgical outcome in all patients
who underwent lobectomy for NSCLC in Iceland over a 24-year period.
Material and methods: The study involved 489 consecutive patients with NSCLC who underwent lob-
ectomy with curative intent in Iceland, 1991–2014. Patient demographics, pTNM stage, rate of peri-
operative complications, and 30-day mortality were registered. Overall survival was analyzed with the
Kaplan–Meier method. The Cox proportional hazards model was used to evaluate factors that were
prognostic of overall mortality. To study trends in survival, the study period was divided into six 4-year
periods. The median follow-up time was 42 months and no patients were lost to follow-up.
Results: The average age of the patients was 67 years and 53.8% were female. The pTNM disease
stage was IA in 148 patients (30.0%), IB in 125 patients (25.4%), IIA in 96 patients (19.5%), and IIB in 50
patients (10.1%), but 74 (15.0%) were found to be stage IIIA, most often diagnosed perioperatively. The
total rate of major complications was 4.7%. Thirty-day mortality was 0.6% (three patients). One- and 5-
year overall survival was 85.0% and 49.2%, respectively, with 3-year survival improving from 48.3% to
72.8% between the periods 1991–1994 and 2011–2014 (p¼ .0004). Advanced TNM stage and age were
independent negative prognostic factors for all-cause mortality, and later calendar year and free surgi-
cal margins were independent predictors of improved survival.
Conclusions: The short-term outcome of lobectomy for NSCLC in this population-based study was
excellent, as reflected in the low 30-day mortality and low rate of major complications. The long-term
survival was acceptable and the overall 3-year survival had improved significantly during the study
period.
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Introduction
Lung cancer (LC) is the leading cause of cancer-related
deaths in the western world, including Iceland [1,2], account-
ing for around 26% of cancer-related deaths globally [1]. In
Europe and North America, non-small cell lung carcinoma
(NSCLC) accounts for around 80% of LC [3], where surgical
resection is the only well-defined and well-studied curative
treatment [4]. Pulmonary resection is indicated for patients
with localized or regional disease, which currently applies to
almost one-third of all patients diagnosed with NSCLC in
Iceland [2]. Five-year survival for resected patients is reported
to range from 40% to 70%, depending mostly on the TNM
stage at diagnosis [5,6], as compared to less than 5% for
non-resected patients with metastasized disease [6]. Thus,
resection should be offered to all patients where surgery is
indicated; that is, for patients at stages I and II [4] and in
selected patients who are diagnosed at stage IIIA [7].
Lobectomy is considered the gold standard of treatment
for NSCLC [4], as numerous studies have shown that
lobectomy has better outcome than sublobar resections with
regard to both recurrence of cancer and long-term survival
[8,9]. Until recently, segmentectomy and wedge resection
have been used when pulmonary function or other comor-
bidities pose a high operative risk. However, the use of seg-
mentectomy has recently been recommended for small
peripheral stage I NSCLCs instead of lobectomy [10,11], as
outcomes are comparable to those after lobectomy. On the
other hand, pneumonectomy is still reserved for more exten-
sive disease, as the surgical morbidity and mortality are
higher than for lobectomy or sublobar resections [7].
Most studies on pulmonary resections for NSCLC – and
especially lobectomy – have focused more on short-term out-
come than on long-term survival [12,13]. These studies have
usually been based on single tertiary-care centers, with the
risk of selection bias. With lobectomy being the most com-
mon surgical procedure for NSCLC and regarded as the gold
standard for curative treatment of NSCLC, this is a subgroup
that is important to focus on and report their outcome.
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We performed a whole-nation study in Iceland, taking advan-
tage of centralized population-based registries on the diag-
nosis and treatment of NSCLC, with complete long-term
survival data. The main aim was to investigate both short-
term and long-term outcome in NSCLC patients who under-
went lobectomy in Iceland over a 24-year period, concentrat-
ing especially on 30-day and long-term survival.
Material and methods
This was a retrospective study of all patients who underwent
lobectomy for primary NSCLC with curative intent in Iceland
from January 1, 1991 until December 31, 2014. We excluded
patients who underwent exploratory thoracotomy, explora-
tory video-assisted thoracoscopic surgery (VATS), pulmonary
metastasectomy, palliative procedure, or resection for biopsy
only. This also applied to patients with advanced disease
who underwent resection without curative intent. Patients
were also excluded when the postoperative pathological
diagnosis showed only carcinoma in situ or one of the follow-
ing: adenoid cystic carcinoma, mucoepidermoid carcinoma,
carcinoid, or sarcoma. Finally, 17 patients who were at stage
IV, including those with solitary metastasis to the brain or
one adrenal gland at diagnosis, were excluded.
Cases were identified from a centralized database covering
all the surgical specimens of LC (in Iceland) at the Department
of Pathology, Landspitali University Hospital in Reykjavik. Cases
identified were cross-matched with two other independent
databases: a diagnosis registry and an operation registry at
Landspitali University Hospital. This was done to minimize the
risk of missing cases that were operated for NSCLC.
During the study period, 2556 patients were diagnosed
with NSCLC in Iceland. Of them, 653 cases were surgical candi-
dates, evaluated to tolerate a pulmonary resection. In 493
cases (75.5%), a lobectomy was performed. This included 11
patients (2.2%) who underwent lobectomy and an ipsilateral
sublobar resection during the same operation and four
patients (0.8%) who had a bilobectomy. The other surgical
resections for NSCLC were 83 sublobar resections (wedge or
segment resections; 12.7%) and 77 pneumonectomies (11.8%).
Medical records and surgical reports were reviewed and
variables were registered using a standard data sheet. For
each patient, over 80 different variables were collected.
These included the following: age, gender, smoking habits,
comorbidity (e.g., chronic obstructive pulmonary disease
(COPD), ischemic heart disease (IHD), and arrhythmias), pul-
monary function test results (forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC), and FEV1/FVC), details of
the operation, length of stay in the intensive care unit (ICU),
in-hospital stay in days, pTNM stage, postoperative complica-
tions, and American Society of Anesthesiology (ASA) score,
and also date and cause of death in patients who died dur-
ing the follow-up period.
Preoperatively, a multidisciplinary tumor board including
thoracic surgeons, pulmonologists, oncologists, radiologists,
and pathologists reviewed the cases. The preoperative work-
up varied between patients but usually included a chest
radiograph (CXR) and computed tomography (CT) of the
chest, abdomen, and head in addition to bone scintigraphy
and pulmonary function tests. Positron emission tomography
(PET) scan was not available in Iceland during the study
period, but it was done in selected cases at Rigshospitalet,
Copenhagen, Denmark. Tumor biopsies were obtained
through bronchoscopy or transthoracic CT-guided needle
biopsy. Mediastinoscopy was done routinely since 2005 and
endoscopic bronchial ultrasound (EBUS) with transbronchial
needle aspiration biopsies was performed in a proportion of
cases since 2013. The seventh edition of the TNM staging
system was used to stage patients postoperatively (pTNM).
Detailed clinical TNM (cTNM) staging was not adequately reg-
istered for all patients, so only pathological staging (pTNM) is
presented in this study.
Landspitali University Hospital is the only hospital in
Iceland in which cardiothoracic surgery is performed, and
this study was therefore done on a nationwide basis. All the
surgical procedures were performed by nine surgeons, one
of whom performed the vast majority of them in the last
decade. All the patients had epidural placed for postopera-
tive analgesia and general anesthesia with double lumen
endotracheal tube for lung isolation. Posterolateral thoracot-
omy was the method used during more than half of the
study period, but during the last 10 years, an anterolateral
approach was the preferred method. During the study
period, video-assisted thoracoscopic surgery (VATS) was not
used for lobectomies but it was used for selected wedge
resections and segmentectomies. The lobectomies were
standardized with intraoperative lymphadenectomy of
enlarged hilar or ipsilateral mediastinal lymph nodes, and
from 2005 with routine ipsilateral mediastinal lymphadenec-
tomy according to the ESTS guidelines [14,15].
Ex-smokers were defined as patients who had stopped
smoking more than 5 years before surgery, and never-smok-
ers were defined as patients who had smoked less than 100
cigarettes in their lifetime. Surgical complications were div-
ided into major and minor complications. Major complica-
tions were defined as: bronchopleural fistula (BPF),
myocardial infarction (MI), adult respiratory distress syndrome
(ARDS), reoperation for postoperative bleeding, congestive
heart failure (CHF), and empyema with or without reopera-
tion. Minor complications were defined as: new-onset atrial
fibrillation, postoperative pneumonia, recurrent nerve paraly-
sis, wound infection, air leakage over 7 days, and intraopera-
tive bleeding of >1 L (without reoperation). Operative
mortality was defined as death within 30 days of surgery, but
hospital mortality and 90-day mortality were also registered.
Patients were assigned a date of death or identified as living
on September 1, 2016, using data from the Icelandic National
Population Registry. Median follow-up time was 42 months
(mean 62.6 months, range: 1–279).
To investigate trends in survival, the 24-year study period
was divided up into six 4-year periods.
Statistics
Microsoft Excel 2010 was used for descriptive statistics and R
version 3.1.3 (Wien, Austria) was used for survival analysis.
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Student’s t-test and ANOVA were used to compare continu-
ous variables between groups of two or more, following use
of the Kolmogorov–Smirnov test (KS test) for assessment of
normality of the data. Chi-square test was used to compare
categorical variables and Fisher’s exact test was used if the
values had an expected frequency of 10 or less. Differences
were considered to be significant when the p value was less
than 0.05. The Kaplan–Meier method was used to calculate
overall survival (OS) and log-rank test was used to compare
survival between groups. In order to identify factors that were
prognostic of long-term survival, the Cox proportional-hazards
model was used. Factors that had a p value of less than 0.1 in
univariate analysis were used in the preliminary model along
with factors that have been shown to be significant in other
studies. A subset of variables was chosen for inclusion in the
final model, using a stepwise selection procedure. To check
our assumption of proportionality, a global goodness-of-fit
test was done together with graphic plotting of variables.
The study was approved by the Icelandic National
Bioethics Committee (reference number: 98-060-CM) and the
Data Protection Authority (reference number: 2001011025SJ/
eb). As individual patients were not identified, the need for
individual consent was waived.
Results
Patient demographics and cardiovascular risk factors are
shown in Table 1. Of the 493 lobectomies for NSCLC, 265
(53.8%) were performed on female patients. The mean age
was 67 ± 9.5 years, and similar for both genders (p¼ .81).
More women had smoked within 5 years of surgery
(p¼ .0007), but more men had a history of ischemic heart
disease (p< .0001). More women had adenocarcinoma hist-
ology: 74.3% as compared to 59.6% in men (p¼ .0004). On
the other hand, no statistically significant gender differences
were found for history of COPD, arrhythmias, preoperative
FEV1< 75%, or ASA score. Altogether, 184 patients (37.3%)
were diagnosed incidentally, most often due to diseases or
symptoms unrelated to NSCLC that had resulted in a chest X-
ray or CT-scan. In the other 309 cases, the patients had
symptoms of LC, and cough (36.3%), dyspnea (23.1%), chest
pain (17.2%), pneumonia (17.4%), and/or weight loss (15.8%)
were the most common symptoms. Other symptoms such as
fever (11.4%) and hemoptysis (7.3%) were less common.
The mean operative time was 136min (range: 30–395min)
and median hospital stay was 9 days (range: 2–144 days).
The most common histological types were adenocarcinoma
(65.3%) and squamous cell carcinoma (25.8%), but large-cell
and adenosquamous carcinomas were less common (5.9%
and 3.0%, respectively). In 460 of the cases (93.3%), the
patients had cancer-free surgical margins; the remaining 33
patients had microscopic disease at the resection margins
(positive margins). The mean size of the tumors was
3.6 ± 2.3 cm, ranging from 0.2 to 19.5 cm.
Postoperative TNM staging is shown in Table 2. More than
half of the patients had stage I disease (55.6%), most of
them being stage IA (30.0% of the whole study population).
Patients at stage II were 29.6%, with 19.5% being at stage IIA
and 10.1% at stage IIB. A further 74 patients (15.0%) had sur-
gically resectable locally advanced disease (stage IIIA), most
of it being diagnosed perioperatively – with microscopic N2
ipsilateral mediastinal lymph node involvement or T4 tumor
with local invasion to the mediastinum. Table 2 shows that
the proportion of patients diagnosed at stage IA increased
from 25.9% in 1991–1994 to 39.4% in 2011–2014 (p¼ .03).
No significant changes between time periods were found for
other stages (IB, IIA, IIB, and IIIA). Furthermore, the mean age
of patients did increase during the study period, from 63.2
years in 1991–1994 to 67.6 years in 2011–2014 (p¼ .009),
and the 30-day mortality did not change significantly
between the 4-year time periods (p¼ .23).
Both minor and major complications are listed in Table 1,
but some patients had several major and/or minor complica-
tions. In 104 cases (21.1%), the patient suffered one or more
complications, with 23 patients (4.7%) having at least one
major complication and 81 patients (16.4%) having at least
one minor complication. The most common complication
Table 1. Patient demographics, risk factors, comorbidities, complications,
tumor factors, and staging for 493 cases that underwent a lobectomy for
NSCLC in Iceland, 1991–2014. The table also shows univariate association of
the patient demographics and comorbidities with long-term survival.
n (%) HR 95% CI p value
Descriptive factors
Women (ref men) 265 (53.8) 0.72 0.57–0.89 .003
Age (years) 67 (range: 35–89) 1.03 1.02–1.05 <.0001
Risk factors, comorbidity
Smoking history 468 (94.9) 1.38 0.77–2.45 .28
Current smoker (within 5 years) 327 (66.3) 1.08 0.85–1.37 .53
COPD 128 (26.0) 0.89 0.69–1.15 .36
IHD 121 (24.5) 1.47 1.15–1.88 .002
Arrhythmias 66 (13.4) 1.36 1.0–1.85 .05
FEV1< 75% 138 (28.0) 1.17 0.91–1.48 .22
Period
1991–1994 58 (11.8) ref ref ref
1995–1998 59 (12.0) 0.74 0.50–1.08 .11
1999–2002 67 (13.6) 0.90 0.62–1.32 .58
2003–2006 88 (17.8) 0.70 0.48–1.00 .05
2007–2010 94 (19.1) 0.69 0.47–1.01 .05
2011–2014 127 (25.8) 0.45 0.29–0.69 .0002
Major complications 23 (4.7) 1.69 1.07–2.66 .02
BPF 2 (0.4) 6.75 1.67–27.36 .01
MI 4 (0.8) 1.53 0.50–4.94 .43
ARDS 9 (1.8) 1.38 0.68–2.78 .37
CHF 10 (2.0) 2.18 1.16–4.10 .01
Empyema 6 (1.2) 2.40 0.99–5.81 .05
Reoperation for bleeding 10 (2.0) 1.34 0.66–2.71 .41
Minor complications 81 (16.4) 1.25 0.93–1.67 .14
AF 37 (7.5) 1.26 0.84–1.91 .26
Pneumonia 40 (8.1) 1.58 1.08–2.31 .02
RNP 8 (1.6) 1.72 0.85–3.28 .13
Wound infection 7 (1.4) 0.63 0.20–1.95 .42
Air leakage for >7 days 85 (17.2) 1.14 0.86–1.50 .37
Intraoperative bleeding >1 L 35 (7.1) 1.27 0.85–1.90 .24
Tumor factors
Diameter of tumor (mean, cm) 3.6 (0.2–19.5) 1.12 1.08–1.17 <.0001
Squamous cell carcinoma 127 (25.8) 1.28 1.01–1.63 .04
Adenocarcinoma 322 (65.3) 0.68 0.54–0.85 .0006
Free surgical margins 460 (93.3) 0.33 0.23–0.50 <.0001
Stage
IA 148 (30.0) ref ref ref
IB 125 (25.6) 1.44 1.04–2.00 .03
IIA 96 (19.5) 2.64 1.90–3.67 <0.0001
IIB 50 (10.1) 2.53 1.70–3.78 <0.0001
IIIA 74 (15.0) 3.62 2.56–5.14 <0.0001
COPD: chronic obstructive pulmonary disease; IHD: ischemic heart disease;
FEV1: forced expiratory volume in 1 s; BPF: bronchopleural fistula; MI: myocar-
dial infarction; ARDS: adult respiratory distress syndrome; CHF: congestive
heart failure; AF: atrial fibrillation; RNP: recurrent nerve paralysis.The p values in bold show significance.
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was persistent chest tube air leakage for more than 7 days
(17.2%), followed by pneumonia (8.1%) and intraoperative
bleeding exceeding 1 L (7.1%).
The 30-day mortality was 0.6% (three patients), hospital
mortality was 1.2% (six patients), and 90-day mortality was
1.4% (seven patients). Two of the three patients who did not
survive for 30 days died on postoperative day 11 – one from
pneumonia, sepsis, and hypotension and the other from car-
diogenic shock related to myocardial infarction. The third
patient had respiratory failure due to pneumonia that
required a tracheostomy and ventilator therapy, but eventu-
ally died on postoperative day 23. Patients who died in hos-
pital after postoperative day 30 usually died of respiratory
failure, but they all had compromised pulmonary function
preoperatively.
OS for all patients is plotted in Figure 1, with the
Kaplan–Meier graph showing 85.0%, 60.9%, and 49.2% of the
patients being alive at 1, 3, and 5 years postoperatively.
Figure 2 shows the OS in different 4-year time periods. CSS is
shown in Figure 3 and was estimated to be 85.9%, 63.8%,
and 54.6% at 1, 3, and 5 years, respectively. Both OS and CSS
improved significantly during the study period, with 3-year
OS increasing from 48.3% in 1991–1994 to 72.8% in
2011–2014 (log-rank test, p¼ .0004). The 3-year CSS was
48.3% in 1991–1994 and 76.6% in 2011–2014 (log-rank test,
p< .001). The 5-year OS was 64.2% for stage I, 35.1% for
stage II, and 20.4% for stage IIIA.
Table 1 shows a univariate analysis of the predictors for
OS. The predictors of increased mortality were advanced age
(HR¼ 1.03 per year, 95% CI: 1.02–1.05; p¼ .001), ischemic
heart disease (HR¼ 1.47, 95% CI: 1.15–1.88; p¼ .002), any
major complications (HR¼ 1.69, 95% CI: 1.07–2.66; p¼ .02),
postoperative congestive heart failure (HR¼ 2.18, 95% CI:
1.16–4.1; p¼ .01), postoperative pneumonia (HR¼ 1.58, 95%
CI: 1.08–2.31; p¼ .02), squamous cell histology (HR¼ 1.28,
95% CI: 1.01–1.63; p¼ .04), and advanced stage (HR¼ 3.62 for
stage IIIA compared to stage IA, 95% CI: 2.56–5.14; p< .0001),
which was by far the strongest prognostic factor. Protective
factors regarding mortality were female gender (HR¼ 0.72,
95% CI: 0.57–0.89; p¼ .003), free surgical margins (HR¼ 0.33,
95% CI: 0.23–0.5; p< .0001), and later calendar year of treat-
ment (HR for the period 2011–2014 was 0.45, 95% CI:
0.49–0.69; p< .0001).
Independent negative factors regarding survival were
advanced age (HR¼ 1.03, 95% CI: 1.02–1.04; p< .0001) and
advanced stage (HR¼ 1.4, 95% CI: 1.25–1.46; p< .0001). After
correction for stage and other significant factors in the multi-
variate model (see Table 3), later calendar year turned out to
be a significant protective factor regarding mortality, with an
HR of 0.88 per year (95% CI: 0.82–0.94; p¼ .0003).
Furthermore, a cancer-free surgical margin was also found to
be an independent factor prognostic of lower mortality
Table 2. Stage distribution of 493 cases operated with lobectomy for NSCLC
in Iceland over 24 years, divided into 4-year periods, expressed as n (% per
period).
Stage
IA IB IIA IIB IIIA Total
Period
1991–1994 15 (25.9) 11 (18.9) 17(29.3) 3 (5.2) 12(20.7) 58 (100)
1995–1998 19 (32.2) 15 (25.4) 10 (17.0) 8 (13.6) 7 (11.9) 59 (100)
1999–2002 13 (19.4) 17 (25.4) 15 (22.4) 11 (16.4) 11 (16.4) 67 (100)
2003–2006 19 (21.5) 33 (37.5) 15 (17.0) 9 (10.2) 12 (13.6) 88 (100)
2007–2010 32 (34.0) 19 (20.2) 15 (16.0) 9 (9.6) 19 (20.2) 94 (100)
2011–2014 50 (39.3) 30 (23.6) 24 (18.9) 10 (7.9) 13 (10.2) 127 (100)
Total 148 (30.0) 125 (25.4) 96 (19.5) 50 (10.1) 74 (15.0) 493 (100)
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Figure 1. Overall survival of all patients who underwent lobectomy for NSCLC
with curative intent in Iceland, 1991–2014. The broken line represents the 95%
confidence interval and crosses indicate censored cases.
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Figure 2. Overall survival of patients who had a lobectomy with curative intent
for NSCLC in Iceland in different 4-year time periods. The difference was signifi-
cant (log-rank test, p¼ .003).
0.0
0.2
0.4
0.6
0.8
1.0
20 1 3 4 5
Years
Ca
nc
er
 S
pe
cif
ic 
Su
rv
iva
l
1991−1994
1995−1998
1999−2002
2003−2006
2007−2010
2011−2014
58 45 38 28 25 22
59 46 40 36 32 29
67 52 44 32 30 26
88 77 65 54 49 45
94 82 69 59 52 45
127 117 96 62 29 6
1991−1994
1995−1998
1999−2002
2003−2006
2007−2010
2011−2014
Figure 3. Comparison of cancer-specific survival in patients operated with lob-
ectomy for NSCLC in Iceland in different 4-year time periods. The difference was
significant (log-rank test, p< .001).
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(HR¼ 0.44, 95% CI: 0.30–0.65; p< .0001). The patients who
did not have free surgical margins usually received adjuvant
chemotherapy, and were not reoperated or did not receive
adjuvant radiation.
Discussion
In this whole-nation study, we investigated both short-term
and long-term outcome after lobectomy for NSCLC over a
24-year period in a well-defined cohort of Icelandic patients.
The 30-day mortality was very low – only 0.6% – with almost
every second patient (49.2%) surviving for at least 5 years.
Furthermore, the 3-year OS improved significantly with time:
from 48.3% in 1991–1994 to 72.8% in 2011–2014 (p¼ .0004).
The explanation for the significant increase in OS seen
during the last 4-year period is probably multifactorial.
However, one of the main influential factors may have been
the increased ratio of patients with stage IA disease, which
rose from 25.9% to 39.4% between the periods 1991–1994
and 2011–2014 (p¼ .03). The reason for this increase in early-
stage NSCLC is unclear, but in Iceland, no screening for lung
cancer has been implemented and our analysis did not show
that the proportion of tumors that were diagnosed inciden-
tally had increased significantly during the study period
(p¼ .47). The increase in early-stage NSCLC is more likely
explained by improved imaging techniques and more thor-
ough postoperative follow-up, as well as increased public
awareness. When we corrected for stage and higher age in
the multivariate analysis, later calendar year was found to be
an independent factor of increased survival. The improved
outcome therefore appears to be influenced by factors other
than stage and incidental diagnosis. Thirty-day mortality, a
surrogate marker for surgical technique, perioperative care,
and postoperative complications, remained very low during
the 24-year study period (p¼ .23) and does not therefore
explain improved survival. The minor and major complication
rate stayed constant during the study period (p¼ .70 and
p¼ .46, respectively). The fact that nine surgeons performed
the surgical procedures and one of them performed the vast
majority in the last decade could have had an effect on
short-term outcomes, such as complications and length of
stay. Other possible factors, such as improved diagnostic
work-up with increased use of CT scans may have contrib-
uted as well as more thorough preoperative staging with
mediastinoscopies performed routinely since 2005. This,
along with increased use of adjuvant chemotherapy, may
also have contributed. Our findings are in line with a recent
Norwegian study where similar findings regarding survival to
those in the present study were reported for NSCLC patients
[16]. Unfortunately, we did not have detailed information on
the use of adjuvant chemotherapy in our patients, but it has
been offered to most stage II and IIIA patients since 2003.
Thus, the direct effect of adjuvant chemotherapy could not
be analyzed.
The factors that were prognostic of mortality in the pre-
sent study were advanced pTNM stage (HR¼ 3.62 for stage
IIIA vs. stage IA, 95% CI: 2.56–5.14; p< .0001), positive surgi-
cal margins, advanced age, and calendar year of treatment
(time period). TNM stage, advanced age, and positive surgical
margins have all been reported previously to be negative
prognostic factors in other studies [5,6,17]. To our know-
ledge, however, only very few studies have reported
improved survival according to calendar year. The most
important is the study by Morgant et al. [18], which found
better survival in lobectomy patients from 2005 to 2012 in
France, and a Norwegian study by Nilssen et al. [16], which
found a gain in 5-year survival from 47% in the period
1997–2003 to 62.6% in 2004–2011, in all resected NSCLC
patients. Furthermore, in recent unpublished studies (pre-
sented as abstracts) based on the SEER (Surveillance,
Epidemiology, and End Results) database, improved survival
was reported for patients with stage-II adenocarcinoma and
squamous cell carcinoma from 1988 until 2013 [19,20].
Other factors reported to be prognostic of increased mor-
tality in the literature are a history of weight loss and posi-
tive tumor markers (i.e., KRAS, EGFR, etc.) [17]. In our
retrospective study, weight loss was not a prognostic factor
regarding survival and tumor markers were not routinely
measured until the later part of the study.
The fact that OS for the whole patient cohort was found
to be around 50% at 5 years underscores the fact that many
of the patients who undergo lobectomy – even patients with
localized stage I disease – later die from spread of NSCLC, a
recurrent disease, or other smoking-related diseases such as
ischemic heart disease or COPD. In comparable studies, the
OS at 5 years usually lies between 40% and 70% [9,21]. The
OS found in the present study is therefore in line with other
reports. In the study by Morgant et al. [18], which included
all pulmonary resections for NSCLC in France operated
between 2005 and 2012, the 3-year survival for lobectomy
patients was 82%, as compared to 71% in the present study.
However, the French study also included non-malignant car-
cinoid tumors (with typical histology) and other benign
tumors in 10% of cases, where the prognosis is very favor-
able [22] compared to other histological types of NSCLC –
Table 3. Cox multivariate analysis for all patients who underwent lobectomy
for NSCLC in Iceland, 1991–2014.
HR 95% CI p value
Age 1.03 1.02–1.05 <.001
Period (ref: 1991–1994)
1995–1998 0.86 0.58–1.28 .46
1999–2002 0.90 0.62–1.32 .60
2003–2006 0.71 0.49–1.04 .08
2007–2010 0.60 0.41–0.89 .01
2011–2014 0.50 0.33–0.78 .002
1991–2014 0.88 0.83–0.94 <.001
Stage (ref stage: IA)
IB 1.30 0.93–1.81 .13
IIA 2.51 1.80–3.51 <.001
IIB 2.43 1.62–3.65 <.001
IIIA 3.49 2.44–4.99 <.001
Histology (ref: Squamous cell carcinoma)
Adenocarcinoma 0.91 0.70–1.17 .45
Large cell carcinoma 1.45 0.91–2.31 .12
Adenosquamous 1.63 0.86–3.07 .13
IHD 1.28 0.99–1.66 .06
COPD 0.89 0.69–1.17 .41
Postoperative CHF 1.24 0.51–3.02 .63
Major complications 1.21 0.64–2.30 .55
Free tumor margins 0.48 0.32–0.73 <.001
IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease;
CHF: congestive heart failure.The p values in bold show significance.
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which all the patients in the present study were diagnosed
with.
In the present study, 15% of the patients had stage IIIA
disease that was usually detected postoperatively after the
finding of positive ipsilateral microscopic mediastinal lymph
node sampled at surgery, or a T4 tumor that had invaded
the mediastinum. In a more recent study – by Dickhoff et al.
[13] – the 4-year survival following lobectomy ranged from
27% to 51% in the period 2010–2013. This wide difference in
survival was based on different induction therapies, and is in
line with our 4-year survival of 27.2% over the whole period,
which had improved to 41% in the period 2011–2014. During
the last period, adjuvant chemotherapy was offered to all
patients at stage IIIA, as recommended by the European
Society for Medical Oncology (ESMO) guidelines [7]. The 3-
year survival for stages II and IIIA together was 49% in the
present study, as compared to 56.6% in a newly published
study by Park et al. [23], where all the patients received
induction therapy. In our study, very few of the patients had
induction therapy.
Compared to other reports, the overall rate of complica-
tions was relatively low in the present study (21.1%), with
the complications usually being classified as minor (16.4%).
Furthermore, the overall rate of major complications was
only 4.7%, which also contributed to the very low 30-day
mortality (only 0.6%; three patients). For comparison, other
studies have reported an overall rate of complications in the
19.1–58.2% range, [24–26] and the 30-day mortality has most
often been between 1% and 2.5%. However, 30-day mortality
up to 4.1% has also been reported in the literature
[24,26,27]. In the study by Irie et al., a lower 30-day mortality
than ours was reported (0.5%), and there was an overall com-
plication rate of 19.1% [24]. However, that study only
involved 188 patients who were operated at a single center
over a 7-year period, with all of them being at cTNM stage I
and being operated with VATS technique. The present study,
however, covered 24 years with patients at stages I–IIIA, with
all of them operated with open thoracotomy.
The most common complication in the present study was
prolonged air leakage (17% of cases) – with a range of
9.6–24% in other comparable studies [24,28]. This difference
could possibly be explained by different definitions of pro-
longed air leakage or different management of chest tubes
between centers. Other postoperative complications in the
present study were also in line with previous reports, such as
pneumonia, new-onset atrial fibrillation, and perioperative
myocardial infarction [24,29].
The major limitation of our study is its retrospective
design, with the drawbacks that this can entail, such as the
lack of information on symptoms, the lack of information on
clinical staging, and the lack of documentation on complica-
tions. During the study period, PET scan was not available in
Iceland and mediastinoscopy was only routinely used for
staging of mediastinal lymph nodes during the later half of
the study period. The main strength of the study, however, is
the fact that the patient cohort consisted of patients repre-
senting a whole population, with all the patients being oper-
ated at a single center, reducing the risk of selection bias
and institutional bias. Our single-center nationwide approach
therefore eliminated referral bias and made identification of
risk profiles more reliable.
Conclusions
According to this population-based study, the short-term out-
come of lobectomy for NSCLC is excellent in Iceland, as
reflected by a low rate of complications and a 30-day mortal-
ity of only 0.6%. Long-term overall survival, with every
second patient surviving 5 or more years after surgery, was
acceptable and comparable to that in other studies.
Importantly, the survival improved over the 24-year study
period. The explanation for this gain in survival is not obvi-
ous, but it is most likely explained by the combination of
improvements in staging, postoperative care, surgical tech-
nique, and adjuvant chemotherapy for stage II/IIIA patients.
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Oskarsdottir GN, Bjornsson J, Jonsson S, Isaksson HJ, Gudbjartsson T. Primary adenocarcinoma of the lung –
histological subtypes and outcome after surgery, using the IASLC/ATS/ERS classiﬁcation of lung
adenocarcinoma. APMIS 2016; 124: 384–392.
Adenocarcinoma is the most common histological type of lung carcinoma. Recently the histologic classiﬁcation of ade-
nocarcinomas in the lung was modiﬁed to better reﬂect biologic properties and prognosis. We reviewed the histology of
all primary lung adenocarcinomas operated on in Iceland during a 20-year period and assessed the impact of histology
on survival. This nationwide study included 285 patients (mean age 67 years, 57% female), who underwent resection in
Iceland from 1991 to 2010. Tumors were reclassiﬁed according to the current IASLC/ATS/ERS classiﬁcation system.
Overall survival was estimated by the Kaplan–Meier method and Cox regression analysis used to evaluate prognostic
factors of overall mortality. Acinar predominant adenocarcinoma was the most common histological subtype (46%)
followed by solid-predominant (SPA) with mucin production comprised (23%). Non-invasive carcinomas were rare. A
diﬀerence in survival between the histological adenocarcinoma subtypes was not seen (p = 0.32) and multivariate analy-
sis showed that advanced stage and age predicted worse outcome, but histologic subtyping of adenocarcinoma did not.
In this nation-wide study there was not a statistical diﬀerence in survival according to adenocarcinoma subtypes and
the histological subtype did not predict mortality. Preinvasive and minimally invasive adenocarcinomas were rare.
Key words: Lung adenocarcinoma; histology; classiﬁcation; adenocarcinoma subtypes.
Tomas Gudbjartsson, Department of Cardiothoracic Surgery, Landspitali University Hospital, Reykjavik, Iceland.
e-mail: tomasgud@landspitali.is
Lung cancer is the leading cause of cancer-related
deaths in the western world (1). Non-small cell lung
carcinoma (NSCLC) accounts for 85% of all lung
cancer where adenocarcinoma (AC) is the most
common histology (2, 3). The strongest prognostic
factors of survival for patients with NSCLC are the
TNM stage (4), advanced age, history of weight
loss (5), ethnicity (6), and some genetic mutations
(i.e., EGFR, K-RAS, p53) (7–10).The three major
NSCLC histological types; squamous cell carci-
noma (SCC), AC, and large cell carcinoma (LCC)
have also been shown to inﬂuence survival in some
studies (11, 12), but not in all (13, 14). Bronchi-
oloalveolar adenocarcinoma (BAC) that was
described as a subtype of AC, has been thought to
have a better prognosis than non-BAC adenocarci-
nomas (15).
A new IASLC/ATS/ERS classiﬁcation for pri-
mary lung adenocarcinoma was published recently
(16). The aim was to provide uniform terminology
and diagnostic criteria for AC and at the same time
address advances in oncology, surgery, radiology,
molecular biology, and pathology that could iden-
tify prognostic and predictive factors and therapeu-
tic agents. The discontinuation of the term BAC is
one of the major changes in the new classiﬁcation.
Previously BAC tumors were regarded as a
heterogenous group of tumors with a relatively sim-
ilar histology; some having favorable survival rates,
whereas others had worse outcomes (17). In theReceived 22 November 2015. Accepted 5 January 2016
384
APMIS 124: 384–392 © 2016 APMIS. Published by John Wiley & Sons Ltd.
DOI 10.1111/apm.12522
new classiﬁcation patients with BAC are divided
into four main categories. Three of them were also
present in the earlier classiﬁcation but there are two
new subtypes, lepidic and micropapillary.
In this study we have reviewed all cases of AC
operated on in Iceland during 20 years using the
new AC classiﬁcation with special focus on the
inﬂuence of histological subtype on survival. The
cohort represents a relatively homogenous and
well-deﬁned Northern European population.
MATERIALS AND METHODS
Patient demographics
This nationwide study included all patients who under-
went surgical resection with curative intent for primary
lung adenocarcinoma in Iceland between January 1, 1991
and December 31, 2010. Patients with adenosquamous
carcinoma were excluded and grouped with squamous cell
carcinomas. Also excluded were patients who had explora-
tory, palliative, or lesser resections for biopsy purposes. A
total of 294 cases met the criteria, but data were missing
in nine cases (lost histological slides) and these cases were
therefore excluded.
Cases were identiﬁed from a centralized database that
contains details of all lung cancer specimens from the
Department of Pathology at Landspitali University Hospi-
tal in Reykjavik. To minimize the likelihood of missing
cases, we also reviewed the diagnosis and operation reg-
istry at Landspitali University Hospital, the only center
performing cardiothoracic surgery in Iceland.
Baseline demographic information and clinical data
were collected from surgical charts and hospital records
and entered on a standardized data sheet in Microsoft
Excel. In excess of 80 diﬀerent variables were entered,
including age; comorbidities; symptoms at diagnosis; post-
operative complications; tumor, node, metastasis (TNM)
stage; and survival. Patients were staged postoperatively
(pTNM) using the 7th edition of the TNM staging system
(18). Information on clinical TNM stage (cTNM) had not
been uniformly entered and is therefore not presented in
this study.
All patients were followed up with respect to survival
by using data from the Icelandic National Population
Registry (19). Patients were assigned a date of death or
were identiﬁed as living on January 31, 2015. Mean fol-
low-up time was 45 months (range: 1–254). Five-year sur-
vival was calculated for the subtypes with more than 20
patients, lepidic, acinar, solid with mucin, invasive muci-
nous, and papillary.
Histology
Original pathology reports were reviewed and the location,
size of tumor, and number of tumors recorded. Hema-
toxylin and eosin stained slides from all cases were
reviewed and subtyped by one of the authors (J.B.), who
was blinded to the patients’ clinical outcome. The 2011
IASLC/ATS/ERS adenocarcinoma classiﬁcation system
(16, 20) was used for subtyping. Stains for mucin (PAS
with and without diastase, alcian blue) were obtained if
indicated. No immunohistological staining was performed
for this study. The predominant pattern was deﬁned as the
morphologic pattern occupying the greatest area of tumor.
According to the new classiﬁcation there are four cate-
gories of AC; preinvasive AC, minimally invasive AC,
invasive AC, and variants of invasive AC (Fig. 1). The
preinvasive category is further subclassiﬁed into atypical
adenomatous hyperplasia (AAH) or AC in situ (AIS). The
invasive category has ﬁve subclassiﬁcations – lepidic-pre-
dominant AC (LPA), acinar-predominant AC (APA),
papillary-predominant AC (PPA), micropapillary-predo-
minant AC (MPA), and solid-predominant with mucin
production (SPA).
The lepidic pattern is included in three subtypes of AC;
AIS, MIA, and LPA. This pattern consists of a blend of
type II pneumocytes or Clara cells growing along the sur-
face of alveolar walls. If the only histological pattern in the
sample was lepidic and no invasion was seen, it was classi-
ﬁed as AIS. If there was less than 5 mm of invasion, the
sample was classiﬁed as minimally invasive AC (MIA). If
there were signs of necrosis or ≥5 mm of invasion into vis-
ceral pleura or lymphovascular space it was deﬁned as LPA.
The acinar-predominant AC (APA) was diagnosed in
tumors where there were round- to oval-shaped glands
with a central luminal space surrounded by tumor cells.
When the alveolar architecture was lost or myoﬁbroblastic
stroma was present, it was diagnosed as APA (16).
Papillary-predominant AC (PPA) was diagnosed where
there was papillary growth of cuboidal to columnar cells
growing along a ﬁbrovascular core. When the tumor cells
grew in papillary tufts without ﬁbrovascular cores, we
diagnosed micropapillary-predominant AC (MPA) in line
with the new classiﬁcation (16).
Solid-predominant AC with mucin production was
diagnosed when the tumor cells grew in a sheet without a
recognizable pattern of lepidic, acinar, papillary, or
micropapillary AC growth.
The diagnosis of invasive-mucinous AC (IMA) was set
if there was lepidic growth of columnar or goblet cells
with abundant intracellular mucin admixed with other
invasive AC pattern. The amount of the invasion
(>5 mm), the size (>3 mm), and the lack of a circum-
scribed border separated them from AIS or MIA.
Colloid AC was diagnosed when gross cystic features
were seen. There was a predominant pattern of abundant
pools of extracellular matrix with mucin-secreting tumor
cells.
Fetal AC has cells that resemble fetal lung tubules (16).
The glandular elements have tubules that are composed of
non-ciliated, glycogen-rich cells. These features were used
to identify fetal adenocarcinomas in our study.
Statistics
Microsoft Excel was used for descriptive statistics and
RStudio, Boston, MA, USA version 0.98.1103 for survival
analysis. Chi square test and student’s t test were used to
compare groups and diﬀerences were considered to be sig-
niﬁcant when the p-value was less than 0.05. Survival was
calculated using the Kaplan–Meier method and log-rank
test was used to compare survival between groups. Uni-
variate and multivariate analysis were done using Cox
regression analysis to assess the histologic subtype as a
prognostic factor for survival. The following variables
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were used in the univariate analysis: Histological subtype,
size, type of surgery, sex, age, incidental ﬁnding or not,
types of symptoms at diagnosis (cough, productive cough,
dyspnea, pneumonia, hemoptysis, chest pain, fever,
anorexia), major complication, minor complications, and
group TNM stage (I–IV). The variables that were found
to be signiﬁcant or near signiﬁcant (p < 0.1) in the uni-
variate analysis were included in the multivariate analysis
to identify prognostic factors of survival. The tumor size
and age were included as continuous variables. The hazard
ratio of size was interpreted per cm increase and age inter-
preted per year.
The Icelandic National Scientiﬁc Ethics Committee and
the Data Protection Authority approved the study. As
individuals were not identiﬁed, individual consent was
waived.
RESULTS
Patient demographics are described in Table 1. Of
the 285 patients with adenocarcinoma, 162 (57%)
were female and 123 (43%) male. The average age
was 67  9 years (range; 37–89). Women were
4 years younger than men at the time of surgery
(p = 0.02), less often had ischemic heart disease
(p = 0.001), and more of them still smoked at the
time of surgery (p = 0.006) (Table 1). Most of the
patients were current smokers (67%) and only 5%
had never smoked. The mean size of the tumors
was 2.8  2.1 cm (range; 0.2–19).
Lobectomy or bilobectomy was performed in 224
patients (79%), 37 (12%) had a wedge resection or
segmentectomy, and pneumonectomy was per-
formed in 24 cases (9%) (Table 1).
Histology
Histological subtyping is shown in Table 2, based
on thorough review of all the histological slides.
Almost half, or 46% of the cases, were acinar-pre-
dominant AC (APA), which was the most common
subtype. Second came solid-predominant with
mucin (SPA) production in 23% of cases, followed
Fig. 1. IASLC/ATS/ERS classiﬁcation of lung adenocarcinoma in resection specimens.
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by lepidic-predominant (LPA, 20%), and papillary-
predominant (PPA) subtypes in 7% of patients.
There were seven (2%) invasive-mucinous ACs
(IMA), two (0.7%) micropapillary-predominant
ACs (MPA), two (1%) minimally invasive ACs
(MIA), and 1 AC in situ (AIS). No cases of atypical
adenomatous hyperplasia (AAH) or enteric-predo-
minant (EPA) AC were identiﬁed.
Staging
The pathological TNM stage is shown in Table 2.
The only patient with AIS was diagnosed as stage
IA. One patient with MIA was stage IA and the
other stage IIIA. LPA, APA, and SPA were most
often in early stages, but some patients were in
higher stages.
Survival of diﬀerent adenocarcinoma subtypes
Figure 2 shows overall survival (OS) for all stages
and all histological AC subtypes together, being
84.9% at 1 year and 45.3% at 5 years.
Figure 3 shows OS for the diﬀerent TNM-stages
of patients with AC; with 5-year survival in stage
IA being 63%; stage IB 58%; stage IIA 26%;
stage IIB 29% and IIIA 14% (log-rank test,
p < 0.001).
Figure 4 shows OS for the diﬀerent histological AC
subtypes, but only subtypes with more than 20 patients
are shown. The 5-year survival was 55% for LPA,
38% for APA, 52% for SPA, 38% for PPA. There
was no statistical diﬀerence in survival between the dif-
ferent subtypes of ACs (Fig. 4, log-rank test p = 0.32).
If subtypes with similar survival are grouped together
(LPA and SPA vs APA and PPA), a trend toward dif-
ference in survival was seen between the groups (log-
rank test p = 0.08).
The one case of AIS was 2.2 cm in maximum
diameter. The patient was operated on in 2007 and
is currently (November 2015) in good health with
no evidence of recurrent disease 8 years later. One
patient had non-mucinous MIA. The primary
tumor had a 2.1-cm maximum diameter and the
patient was disease free for 10 years, when she died
from metastatic breast cancer. The other patient
Table 1. Patient demographics on the 285 patients with primary lung adenocarcinoma resected in Iceland 1991–2010. N
(%)
Patient demographics Total Male (N = 123) Female (N = 162)
Age (years)
Range 37–89 42–85 37–89
Mean 67 69 65
Smoking history 271 (95.1) 123 (43.1) 148 (51.9)
Never smoker 14 (4.9) 3 (1.1) 11 (3.9)
Current smoker 191 (67.0) 80 (28.1) 111 (38.9)
Comorbidities
COPD 74 (26.0) 34 (11.9) 40 (14.0)
IHD 71 (24.9) 43 (15.1) 39 (13.7)
Arrythmias 40 (14.0) 23 (8.1) 17 (6.0)
Type of operation
Pneumonectomy 24 (8.4) 10 (3.5) 14 (4.9)
Lobectomy/bilobectomy 224 (78.5) 95 (33.3) 129 (45.2)
Wedge/segmentectomy 37 (13.0) 18 (6.3) 19 (6.7)
COPD, chronic obstructive pulmonary disease; IHD, ischemic heart disease.
Table 2. Pathologic TNM stage according to the 7th revision of the TNM classiﬁcation and the histologic subtype/variant
for patients with primary lung adenocarcinoma resected in Iceland 1991-2010. N(%)
Predominant
Subtype
Stage Total
IA IB IIA IIB IIIA
AIS 1 (0.4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.4)
MIA 1 (0.4) 0 (0) 0 (0) 0 (0) 1 (0.4) 2 (0.7)
Lepidic 23 (8.1) 16 (5.6) 8 (2.8) 3 (1.1) 5 (1.8) 55 (20)
Acinar 39 (13.7) 28 (9.8) 21 (7.4) 17 (6.0) 24 (8.4) 129 (46)
Micropapillary 0 (0) 0 (0) 0 (0) 1 (0.4) 2 (0.7) 3 (1)
Papillary 6 (2.1) 6 (2.1) 2 (0.7) 3 (1.1) 4 (1.4) 21 (7)
Solid 15 (5.2) 17 (6.0) 13 (4.6) 13 (4.6) 7 (2.5) 65 (23)
Mucinous 3 (1.1) 2 (0.7) 1 (0.4) 0 (0) 1 (0.4) 7 (3)
Colloid 1 (0.4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.4)
Fetal 0 1 0 0 0 1 (0.4)
Total 90 (31.5) 70 (24.6) 45 (15.8) 37 (13.0) 44 (15.4) 285 (100)
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma.
© 2016 APMIS. Published by John Wiley & Sons Ltd 387
HISTOLOGY OF RESECTED PRIMARY LUNG CARCINOMA
with MIA had a mixed-type MIA that was 1.7 cm
in maximum diameter. The patient had recurrent
disease 2 years later and died from distant metas-
tases 8 years after the operation.
Survival of adenocarcinoma patients compared to
other histological subtypes
For comparison with patients with AC the 5-year
survival for 156 patients with squamous cell carci-
noma and 32 with large-cell carcinoma operated
during the same period was 35% and 28%, respec-
tively (log-rank test, p = 0.02). When corrected for
stage the survival diﬀerence was no longer signiﬁ-
cant (p = 0.98).
Predictors of survival
Table 3 depicts the univariate analysis of OS
according to the clinico-pathologic parameters. The
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Fig. 2. Overall survival (Kaplan–Meier) of all patients (n = 285) with primary lung adenocarcinoma resected in Iceland in
1991–2010. The 95% conﬁdence interval is shown with broken lines.
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following factors were signiﬁcantly associated with
worse OS: Sex, higher TNM staging, increasing size
of tumor, dyspnea at diagnosis, suﬀering a major
postoperative complication, or having ischemic
heart disease. In multivariate analysis (Table 3)
only advanced age (HR 1.03, 95% CI 1.02–1.05,
p < 0.0001) and TNM staging (stage IIIb HR 3.91,
95% CI 2.37–5.98, p < 0.001) turned out to be
independent prognostic factors of OS. After cor-
recting for other factors in the model, including age
and stage, the diﬀerent subtypes of AC did not
signiﬁcantly impact survival (HR 0.58–1.32, CI
0.3–5.8, p = 0.7), neither in uni- nor multivariate
analysis.
DISCUSSION
In this study, we performed histologic subtyping
of all lung ACs operated on in Iceland during a
20-year period according to the new 2011 IASLC/
ATS/ERS international multidisciplinary lung ade-
nocarcinoma classiﬁcation and studied its impact
on survival. Numerous studies have shown that
the new histological classiﬁcation may be an inde-
pendent predictor of survival for patients with
primary AC of the lung, especially in early stages
of the disease (stages I and II) (21). We decided
to include patients in all stages of NSCLC disease
where surgical resection is an option to represent
the whole spectrum of patients operated for
NSCLC in a well-deﬁned population.
Almost half (46%) of the patients had the aci-
nar-predominant histological subtype, as has been
reported in several other studies (21–23). Second
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Table 3. The Uni- and multivariate analysis of survival in
patients with resected adenocarcinoma of the lung in 1991
–2010. Only the statistically signiﬁcant (p < 0.05) or
nearly signiﬁcant (p < 0.1) variables are shown
HR p-value
Univariate
Sex (ref: male) 0.74 0.07
Age 1.02 <0.001
TNM (ref: IA)
IB 1.35 0.1
IIA 2.19 <0.001
IIB 2.51 <0.001
IIIA 4.21 <0.001
Size 1 <0.001
Incidental detection 0.71 0.06
Dyspnea 1.41 0.02
Major complication 1.7 0.005
IHD 1.35 0.05
ARDS 2.25 0.05
PO pneumonia 1.51 0.07
ASA score 1.22 0.08
Multivariate
Age 1.03 <0.001
TNM (ref IA)
IIB 1.15 0.61
IIA 2.09 <0.01
IIB 2.24 0.01
IIIA 3.98 <0.001
TNM, Tumor, Node, Metastasis; IHD, ischemic heart
disease; ARDS, acute respiratory distress syndrome; PO,
post operative; ASA, American Society of Anesthesia;
HR, hazard ratio.
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came solid-predominant adenocarcinoma with
mucin (SPA) production in 23% of cases, followed
by lepidic-predominant (LPA, 20%), and papillary-
predominant (PPA) subtypes in 7% of patients.
Applying the IASLC/ATS/ERS Classiﬁcation, only
a small proportion of lesions, less than 2% of ACs,
belong in the ‘early’ group. This is in line with
other studies from western countries like Australia
(21), but a lot lower than in Asian population stud-
ies (24, 25).
With respect to overall survival for the diﬀerent
histological AC subtypes, there was not a statistical
diﬀerence between diﬀerent subtypes of ACs (log-
rank test p = 0.32). However, when subtypes with
similar survival are grouped together (LPA and
SPA vs APA and PPA), a trend toward a diﬀerence
in survival was seen between the groups (log-rank
test p = 0.08). These calculations were done for
exploratory purposes only and it is unclear whether
the results have any clinical relevance. Using a mul-
tivariate analysis only advanced age, and the TNM
stage turned out to be independent prognostic fac-
tors of OS. After correcting for other factors in the
model, including age and stage, the diﬀerent sub-
types of AC did not signiﬁcantly impact survival
(HR 0.58–1.32, CI 0.3–5.8, p = 0.7).
Recent studies have shown that the prognostic
signiﬁcance of the AC subtype is not always con-
clusive. In an Australian study that included 210
AC patients that underwent pulmonary resection,
the new classiﬁcation system was shown to be an
independent prognostic indicator of survival, even
for advanced stage disease (21). Similarly a French
study of 407 surgical patients in all stages showed a
diﬀerence in survival in all stages (26). However,
the study by Westaway et al. (22), that included
152 surgical AC patients in stages I–IIIA, the new
classiﬁcation was not shown to be an independent
prognostic factor of survival. The new classiﬁcation
system has been studied extensively in early stages
(27–30) and the evidence seems to provide suﬃcient
data for prognostic signiﬁcance. Only a few studies
have been published in more advanced stages (21,
22, 26) so more studies might be needed before the
new classiﬁcaton can replace the older one. In Aus-
tralia, 28% of the population are immigrants or
born outside of the country (31) and in France this
number is 19% (32). The Icelandic population is
ethnically much more homogenous and consists of
325 000 inhabitants, where only 6% are immigrants
or people born outside of the country (33).
The reason for better OS for acinar-predominant
AC in some previous studies is not obvious. This
subgroup often seems to have an intermediate
outcome (23, 27), ranging between 43% and 68%
in 5-year survival (21–23, 27), compared to the pre-
sent study where it was only 38%. Our ﬁndings
therefore suggest that acinar-predominant ACs
should be grouped together with poor prognosis
AC subtypes, along with micropapillary and muci-
nous ACs. Because acinar-predominant histology
represents a large proportion of patients with AC,
it might also suggest that this is a heterogenous
subgroup of AC that needs to be further subclassi-
ﬁed according to nuclear features, architecture or
proliferative indices, e.g. Ki-67.
There was no diﬀerence between survival in the
papillary group if we divided the period into four
5-year periods (p = 0.3).
No diﬀerences in OS were detected between
patients with SCL, LCC, and AC in our study after
correcting for TNM-stage in the multivariate analy-
sis. The AC subtype had better OS in univariate
analysis, however, after correcting for disease stage
in multivariate analysis, the diﬀerence was not sta-
tistically signiﬁcant. This suggests that ACs are
more often diagnosed in early stages.
This is the ﬁrst study on the impact of subtyping
of pulmonary AC to be performed on a nationwide
basis. The cohort represents a well-deﬁned popula-
tion of patients with a relatively homogenous back-
ground. Further strengths are that the patients with
AC were found using two separate registries and
that all of the histological slides were reviewed by a
senior pathologist who was blinded to the postop-
erative clinical outcome. All the patients were oper-
ated on and treated at a single center, and they
were therefore less likely to be aﬀected by selection
bias and none of the patients were lost to follow-
up. The weakness of the study was its retrospective
design and inadequateness of the statistical power
for multivariate analysis with only 285 patients
analyzed.
In summary, this study shows that in a popula-
tion-based homogenous Caucasian cohort there is
not a big diﬀerence in survival according to diﬀer-
ent subtypes of AC. Only a minority of the cases
was non-invasive. The major histological types of
NSCLC also did not show a diﬀerence.
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Abstract
OBJECTIVES: An increasing number of elderly patients are diagnosed with non-small cell lung cancer (NSCLC). We compared the surgical
resection rate, operability and survival in this age group (>_75 years) to younger patients using centralized databases in Iceland.
METHODS: The study population comprised all patients diagnosed with NSCLC in Iceland from 1991 to 2014. A total of 140 elderly pa-
tients (>_75 years) with NSCLC underwent pulmonary resection and were compared with 550 surgically resected patients less than 75 years,
with respect to resection rate, short and long-term survival and complications of surgery. Reasons for exclusion from surgery were regis-
tered for elderly surgical candidates (stages IA–IIB).
RESULTS: Surgical resection rate in the elderly group was 18% compared to 32% in the younger age group (P < 0.001). The most frequent
reasons for not operating on elderly patients in stages IA–IIB were poor pulmonary function (58%), heart disease (17%) or multiple comor-
bidities (17%). The rate of major complications following surgery was comparable in the elderly versus the younger age group, 13 vs 11%,
respectively (P = 0.578). The same was true for 30 day mortality (2 vs 1%, P = 0.397). Five-year overall survival was 40% vs 44% (P = 0.019)
and cancer-specific survival 51% vs 50% (P = 0.802).
CONCLUSIONS: Elderly patients with resectable NSCLC according to stage are frequently excluded from surgery due to comorbid condi-
tions. Although the operated patients may represent a selected group, their favourable 30-day and long-term survival indicate that more
elderly patients with NSCLC could be operated on.
Keywords: Non-small cell lung cancer • Elderly • Resection rate • Operability and survival
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths in the
Western world [1]. In many European countries, including
Iceland, the mortality from lung cancer is similar to that of breast,
prostate and colon cancer combined. Surgery is the best curative
treatment for non-small cell lung cancer (NSCLC), which ac-
counts for about 85% of all lung cancer cases [2].
With an ageing population the number of elderly patients
diagnosed and treated for NSCLC is expected to increase. Until
recently the survival benefit of surgical treatment for elderly pa-
tients has been unclear. Recent studies have reported acceptable
surgical outcomes and favourable long-term survival for elderly
patients after pulmonary resections [3–7]. These studies suggest
that age alone should not be a contraindication for surgery, al-
though careful individual preoperative assessment is needed.
Still, surgical resection rates (SRR) in the elderly population are
lower compared to younger patients [8, 9], and elderly patients
seem to be more frequently excluded from surgery due to age
alone [10].
The aim of this study was to investigate the outcomes of pul-
monary resections for NSCLC in the elderly (>_ 75 years of age)
and compare them to younger patients, assess SSRs, operability
and reasons for exclusion from surgery, using centralized data-
bases in a well-defined nationwide cohort of patients.
MATERIALS AND METHODS
This was a retrospective whole-population study focused on all elderly
patients who underwent pulmonary resection in Iceland with curative
intent for NSCLC from January 1, 1991 to December 31, 2014.
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At present Iceland has 330,000 inhabitants with an average life
expectancy of 81.6 years for males and 84.3 for females.
Currently, only 11% of adults smoke but after the second world
war the smoking rate was close to 50% [11]. The health care is a
single payer system with one major tertiary care hospital where
all lung cancer surgery is provided.
The Icelandic Cancer Registry is a centralized database includ-
ing all cancer cases diagnosed at hospitals and other healthcare
facilities in Iceland since 1955. This registry was used to identify
all pulmonary tumours diagnosed in Iceland during the study
period. Pulmonary tumours that were not NSCLC (n = 160) were
excluded from the study. Another 77 elderly patients had to be
excluded for various reasons, as they were lost to follow-up, their
patient charts were not found or diagnosis was made post mor-
tem. To ascertain that no cases were missing, all cases of NSCLC
in the Icelandic Cancer Registry were cross-referenced against a
central, computerized histology database from the Department
of Pathology, Landspitali University Hospital, containing details of
all lung histology specimens in Iceland.
SRR was calculated by dividing the number of pulmonary re-
sections performed with curative intent by the number of con-
firmed cases of NSCLC within the same period. Baseline
demographic information and clinical data, for both elderly and
younger patients, were collected from hospital records and sur-
gical reports using a standardized data sheet. Comorbidities and
presenting symptoms were recorded along with operation type
and surgical complications. Tumours were classified according
to the 7th edition of the American Joint Committee on Cancer
TNM staging system [12]. The patients who had a surgical pro-
cedure were staged postoperatively (pTNM-staging). Their clin-
ical (cTNM) staging before surgery, however, was not uniformly
recorded and therefore not used for analysis of the surgical
patients.
All surgical procedures were performed under general anaes-
thesia with double lumen intubation and thoracic epidural
anaesthesia, most often performed through posterolateral or an-
terolateral thoracotomy. All cases were performed by 6 surgeons
using standardized techniques with intraoperative lymphade-
nectomy of enlarged hilar or ipsilateral mediastinal lymph
nodes, but during the last 10-year period these lymph nodes
were routinely removed or sampled.
Major complications were defined as heart failure, adult re-
spiratory distress syndrome, myocardial infarction, empyema,
stroke, bronchopleural fistula, pneumonia and major bleeding
defined as intraoperative bleeding over 1 litre or reoperation for
bleeding. Minor complications were defined as air leakage for
more than 7 days, new new-onset of atrial fibrillation/flutter,
wound infection, and recurrent laryngeal nerve paralysis.
Operative mortality was defined as death within 30 days of sur-
gery. To assess trends, the 24-year study period was divided into
four 6-year periods.
For elderly patients who did not undergo surgery, clinical data
was collected from patient records from health care centres all
over the country using a standardized data sheet. These patients
were clinically staged (cTNM) retrospectively and reasons for ex-
clusion from surgery were determined for patients in stages IA–
IIB. In some cases more than one reason for exclusion was deter-
mined. Stages IA–IIB were chosen since multi-modality treatment
is usually recommended for stage IIIA according to the latest
international guidelines [13, 14].
Statistics
Microsoft Excel was used for descriptive statistics, and R version
2.10.1 for survival calculations. The Student’s t-test (t) was used to
compare continuous variables between the two groups. The
Kolmogorov–Smirnov test (KS-test) assess the normal assumption
for continuous data. The Chi-square (v2) and Fisher exact test
(FET) were used to compare categorical variables. The Chi-square
with yates correction was used if expected cell frequency was
equal to or greater than 5. A P-value of less than 0.05 was con-
sidered statistically significant. Overall survival (OS) and cancer-
specific survival (CSS) was analyzed by the Kaplan–Meier
method, and the log-rank test was used to compare survival be-
tween groups. Patients could be assigned a date of death or were
identified as living on December 31, 2014 using data from the
Icelandic National Population Registry. To calculate CSS, the
cause of death was determined as either lung cancer or other
causes. Mean follow-up time was 5 years (range: 0–23 years).
The study was approved by the Icelandic National Bioethics
Committee and the Data Protection Authority. As individual pa-
tients were not identified, individual consent was waived.
RESULTS
Demographics of elderly patients diagnosed with
NSCLC
A total of 2556 patients were diagnosed with NSCLC in Iceland dur-
ing the 24-year study-period; 859 (34%) of them were classified as
elderly (>_75 years), but 77 of these had to be excluded, most often
due to missing long-term data; leaving 782 elderly (32%, 782/2479)
for further analysis. Out of these 782 elderly patients, 140 underwent
pulmonary resection and they were compared with 550 operated
NSCLC patients less than 75 years of age (younger group). The aver-
age/median age for all elderly diagnosed with NSCLC was 80/79 re-
spectively compared to 65/63 in the younger group. During the 24-
year study the proportion of elderly patients diagnosed with NSCLC
increased steadily from 29% (n= 159) in the first study period to
37% (n= 232) in the last (P= 0.006).
Table 1 shows information on tumour histology and clinical
staging of all elderly patients with NSCLC stage I and II.
Adenocarcinoma (48%) and squamous cell carcinoma (33%) were
the most common histological tumour types. The proportion of
adenocarcinoma rose significantly during the last two 6-year
periods (P = 0.013), but the rate of other histological types such
as squamous cell, large cell carcinoma and other unspecified
NSCLCs remained statistically unchanged. According to clinical
staging, 29% of the elderly patients were diagnosed in stage I or
II (18% and 11%, respectively). The rate of elderly with stage IA
disease rose significantly during the last study period while the
rate of stage IIB decreased (P < 0.001 and P = 0.035, respectively).
The number of patients with disease in stage III or IV was 485
(62%) and the number of patients where clinical stage could not
be determined retrospectively was 68 (9%).
Surgical resection rate and causes for non-
operability
The SRR in the elderly group was 18% (n = 140) compared to 32%
(n = 550) in the younger group (P < 0.001). SRR for elderly patients
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in different stages is shown in Table 2; it was 54% for stage IA,
63% for stage IB, 55% and 43% for stages IIA and IIB, and 15% for
stage IIIA.
Reasons for not operating on elderly patient are shown in
Table 3. Insufficient pulmonary function was the most common
reason for not operating on elderly patients diagnosed in stages
IA–IIB (58%), followed by cardiovascular disease (17%), multiple
comorbidities (17%), patient refusal of treatment (16%), frailty or
poor performance status (13%).
A total of 68 elderly patients had incomplete staging. Usually
further workup was not considered necessary in these cases since
it was known beforehand that these patients would not be
offered surgery for various reasons listed in Table 3.
Outcome of pulmonary resection in the elderly
Between 1991 and 2014 a total of 690 patients with NSCLC
underwent surgery with curative intent. Of these 690 patients,
140 (20%) were defined as elderly (>_ 75 years of age). When com-
paring preoperative patient demographics and risk factors, there
were more males in the elderly group (59% vs 45%, P = 0.007)
and a higher proportion of patients had a previous history of cor-
onary heart disease (45% vs 20%, P < 0.001) and arrhythmias (23%
vs 9%, P < 0.001). Elderly patients were also more likely to be
diagnosed incidentally (without symptoms of NSCLC), or in 46%
vs 30% of cases (P < 0.001) (Table 4).
Forced expiratory volume in 1 second (FEV1) in preoperative
pulmonary function tests was significantly lower in the elderly
compared to the younger patients (mean 2.02 l vs 2.31 l,
P < 0.001), see Table 4. The results of 62 pulmonary function tests
were missing and, therefore, not used in calculations of lung
function, 9 of them in elderly patients and 53 in the younger
patients.
The most common type of surgery performed was lobectomy
for both elderly and younger patients (75% and 70%, P = 0.284).
However, sublobar resections were more often performed in the
elderly (24% vs 3%, P < 0.001) and pneumonectomies were less
common compared to younger patients (3% vs 15%, P < 0.001)
(Table 5).
Neoadjuvant chemotherapy was administrated to 16 younger
patients (3%) but none of the elderly patients (see Table 4).
Furthermore, 7 (5%) elderly patients received adjuvant chemo-
therapy and 86 (16%) patients in the younger group (P = 0.002).
No difference was found between adjuvant radiotherapy in older
versus younger patients.
Surgical outcome, in terms of 30-day mortality (2% and 1%,
P = 0.397) and the median length of hospital stay (10 vs 9 days,
range: 1–144, P = 0.22), was comparable in both age groups (KS-
test, P = 0.08) (Table 5).
Postoperative complications are shown in Table 5. There was
no statistical difference in the rate of major or minor complica-
tions between older and younger patients (P = 0.578 and
P = 0.135, respectively). The most common major complication in
both groups was profound bleeding, defined as perioperative
bleeding exceeding 1 litre and/or reoperation for bleeding. Air
leakage extending more than 7 days and new-onset atrial fibrilla-
tion were the most common minor complications. Heart failure
was the only complication that was significantly more common
in the elderly (4 vs 1%, P = 0.012).
OS and CSS are shown in Figs 1 and 2. OS for the elderly was
40% at 5 years compared to 44% in the younger group. A
Table 1: Resection rate, tumour histology and TNM-stage
1991–1996
(n = 32)
1997–2002
(n = 36)
2003–2008
(n = 76)
2009–2014
(n = 85)
Total
(n = 229)
P-value
v2
Resection rate 17 (53) 17 (47) 41 (54) 51 (60) 126 (55) 0.611
Histology
Squamous cell 14 (44) 16 (44) 21 (28) 25 (29) 76 (33) 0.153
Adenocarcinoma 10 (31) 12 (33) 38 (50) 50 (59) 110 (48) 0.013
Large cell 2 (6) 2 (6) 2 (3) 2 (2) 8 (3) 0.644
Other non-small cell 1 (3) 2 (6) 7 (9) 5 (6) 15 (7) 0.657
Primary tumour of lung without histological verification 5 (16) 4 (11) 8 (11) 3 (4) 20 (9) 0.147
Stage
IA 10 (31) 6 (17) 14 (18) 38 (45) 68 (30) <0.001
IB 10 (31) 13 (36) 24 (32) 26 (31) 73 (32) 0.946
IIA 7 (22) 8 (22) 17 (22) 12 (14) 44 (19) 0.518
IIB 5 (16) 9 (25) 21 (28) 9 (11) 44 (19) 0.035
Resection rate, tumour histology and TNM-stage for all elderly patients diagnosed with stages I and II NSCLC (n = 229), during the study period 1991–2014,
divided into four 6-year periods. Not included in the table are patients diagnosed with stage III–IV disease (n = 465) or when staging was incomplete (n = 68).
The numbers of patients are given with percentages in parentheses. Statistically significant difference between groups was set at P < 0.05.
Table 2: Surgical resection rate (SSR) in elderly patients in
different TNM stages
TNM stage SSR
IA (n = 68) 37 (54)
IB (n = 73) 46 (63)
IIA (n = 44) 24 (55)
IIB (n = 44) 19 (43)
IIIA (n = 87) 13 (15)
IIIB (n = 37) 0 (0)
IV (n = 327) 0 (0)
Information regarding staging was unknown for 68 patients and in-
accurate for 34 patients regarding stages IIIA–IV and are not shown.
The numbers of patients are given with percentages in parentheses.
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significant statistical difference was found between the groups
(P = 0.019). However, 5-year CSS for the elderly patients was 51%
vs 50% for the younger group (P = 0.802) (Fig. 2).
DISCUSSION
This is the first study on the resectability and outcomes of elderly
patients with NSCLC performed in a whole population. Our re-
sults show that younger and elderly patients who underwent sur-
gery with curative intent for NSCLC had similar short-term
outcomes. The low 30-day mortality (2%) observed for elderly
patients, compares favourably with the 30-day mortality for
younger patients previously reported, however, most studies
have shown higher 30-day mortality rates in the elderly [3, 5],
whereas others have not shown significant differences [6, 7, 15].
There was no significant difference in rates of minor or major
complications between the groups; a finding that is in line with
some previously published studies [3, 6, 16]. When comparing
the rate of complications and comorbidities between studies it is
important to remember that different definitions have been
used. Still, most studies have shown a slightly higher rate of
Table 3: Reasons indicated for not operating on elderly patients with NSCLC on cTNM-stages IA–IIB and for not performing a com-
plete staging workup
IA–IIB (n = 103) Incomplete staging (n = 68) P-value
Heart disease 17 (17) 11 (16) 0.888a
Insufficient lung function 60 (58) 32 (47) 0.2a
Dementia 3 (3) 6 (9) 0.158b
Multiple comorbidities 17 (17) 9 (13) 0.718a
Frailty or poor performance status 13 (13) 14 (21) 0.237a
Unresectable tumour location 4 (4) 6 (9) 0.198b
Patients who refused treatment 16 (16) 8 (12) 0.639a
Death of other causes before complete workup/treatment 4 (4) 2 (3) 1b
Other life threatening or terminal disease 4 (4) 3 (4) 1b
Reason for not operating could not be determined 3 (3) 3 (4) 0.683b
aChi-square test.
bFischer’s exact test.
Note that patients could have multiple indications. The numbers of patients are given with percentages in parentheses. Statistically significant difference be-
tween groups was set at P < 0.05.
Table 4: Preoperative comparison of demographics and risk factors for elderly and younger patients
<75 years (n = 550) >_75 years (n = 140) P-value
Male sex 250 (45) 82 (59) 0.007a
History of smoking 526 (96) 131 (94) 0.424a
Incidental detection 167 (30) 65 (46) <0.001a
Chronic obstructive pulmonary disease 140 (25) 46 (33) 0.1a
Coronary heart disease 112 (20) 63 (45) <0.001a
Arrhythmia 52 (9) 32 (23) <0.001a
pTNM stage
IA 166 (30) 37 (26) 0.442a
IB 103 (19) 46 (33) <0.001a
IIA 99 (18) 24 (17) 0.92a
IIB 64 (12) 19 (14) 0.632a
IIIA 91 (17) 13 (9) 0.044a
IIIB 4 (1) 0 (0) 0.588b
IV 21 (4) 0 (0) 0.022b
Unclear 2 (1) 0 (0) 1b
FEV1 (l) 2.31 2.02 <0.001c
Neoadjuvant chemotherapy 16 (3) 0 (0) 0.05b
Neoadjuvant radiotherapy 16 (3) 1 (1) 0.219b
Adjuvant chemotherapy 86 (16) 7 (5) 0.002a
Adjuvant radiotherapy 55 (10) 7 (5) 0.09a
aChi-square test.
bFischer’s exact test.
cStudent’s t-test.
pTNM: postoperative Tumour Node Metastasis; FEV1: forced expiratory volume in 1 second.
The numbers of patients are given with percentages in parentheses. Statistically significant difference between groups was set at P < 0.05.
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postoperative complications in elderly patients [5, 17]. In the pre-
sent study, this was only seen for heart failure.
Interestingly the long-term outcome for CSS at 5 years was
not significantly different. However, the results for the OS was
statistically different. Interestingly, when the Wilcoxon test was
used for comparing OS of the groups, a statistical difference was
not observed (P = 0.109), but this test emphasizes early events of
the survival curve. This may indicate that initially the OS in both
groups was similar, but due to the higher chronological age and
the long follow-up time, the survival curve drops in the elderly
group around year six and explains a significant difference in
the OS with the log-rank test. Several other studies have
Table 5: Comparison of operation type and surgical outcome for elderly and younger patients who underwent surgery for NSCLC
with curative intent
<75 years (n = 550) >_75 years (n = 140) P-value
Operation type
Pneumonectomy 80 (15) 4 (3) <0.001a
Lobectomy 412 (75) 98 (70) 0.284a
Sublobar resections 50 (9) 34 (24) <0.001a
Major complications
All major complications 71 (13) 15 (11) 0.578a
Bronchopleural fistula 3 (1) 0 (0) 1b
Myocardial infarct 3 (1) 3 (2) 0.102b
Adult respiratory distress syndrome (ARDS) 10 (2) 3 (2) 1b
Major bleeding 55 (10) 8 (6) 0.159a
Empyema 9 (2) 1 (1) 0.49b
Pneumonia 44 (8) 17 (12) 0.169a
Minor complications
All minor complications 162 (29) 51 (36) 0.135a
New-onset atrial fibrillation 41 (7) 18 (13) 0.061a
Heart failure 5 (1) 6 (4) 0.012b
Recurrent laryngeal nerve paralysis 10 (2) 0 (0) 0.135b
Wound infection 11 (2) 0 (0) 0.133b
Air leakage >_ 7 days 75 (14) 21 (15) 0.777a
Median length of hospital stay 9 10 0.22c
30-day mortality 6 (1) 3 (2) 0.397b
aChi-square test.
bFischer’s exact test.
cStudent’s t-test.
The numbers of patients are given with percentages in parentheses. Statistically significant difference between groups was set at P < 0.05.
Figure 1: Kaplan–Meier graph showing OS of patients operated for NSCLC from 1991 to 2014. Five-year survival was 40% for elderly patients compared to 44% for
younger patients, a significant difference was found between the two groups (P = 0.019).
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reported similar findings [15, 16, 18, 19], but these studies often
represent material from single institutions as compared with a
whole population in the present study.
Our favourable results on surgical outcome and survival may in
part be influenced by the fact that resection rate was significantly
lower for elderly compared to younger patients. This has also
been shown in other studies [19, 20]. These findings might also re-
flect appropriate selection of elderly patients for surgery, con-
sidering the rate of pneumonectomies and sublobar resections in
this group of patients. Our results might also suggest that more
elderly patients could tolerate surgery, especially limited resec-
tions, as a higher complication rate may be accepted in elderly
patients [21–23]. Fewer elderly than younger patients had adjuvant
chemotherapy (5% vs 15.6%, P < 0.001), but adjuvant therapy was
not introduced as a routine in Iceland until 2005.
Sublobar resection, as well as less invasive surgery (video-
assisted thoracic surgery, VATS), has in previous studies resulted in
lower complication rates and mortality [17, 24–29]. An abstract on
a new randomized controlled trial on sublobar resection versus
lobectomy in the elderly has recently been published [30], so more
information about this is pending. Therefore, it could be argued
that the SRR in elderly patients with NSCLC could be increased by
offering less invasive surgery or limited resections and reduce the
number of patients who are denied surgery because of insufficient
pulmonary function, heart disease and multiple morbidities, all
common reasons for not offering surgery to the elderly NSCLC pa-
tients in the present study. We noticed a significant increase in the
number of elderly patients with stage IA disease during the last 6-
year period, as well as a decrease in stage IIB. The reasons for this
increase are unclear, but more frequent use of CT might play a
role. PET scans were not available in Iceland until after the study
period ended. This may further strengthen the need for less inva-
sive surgery for elderly comorbid patients.
The main strength of this study was that the cohort included
all elderly NSCLC patients from a whole country, reducing the
risk of selection bias. A further strength was the complete dataset,
with patients identified in three separate registries, including the
population-based Icelandic Cancer Registry. All patients were
operated on and treated in a single centre, decreasing the risk of
referral bias. Information on follow-up and survival was relatively
complete. One of the main drawbacks, was the study’s observa-
tional design. Another drawback is the limited power due to the
small patient cohort (see above). As the study is retrospective it is
susceptible to cases being excluded because of incomplete data
and medical record information. Unfortunately DLCO and VO2
max measurements were not performed routinely for all patients
and this information was therefore not included.
In conclusion, we have reported resection rate, complications,
and survival rates for all elderly patients operated for NSCLC in
the Icelandic population during a 24-year period. Our results
show that almost every other (45%) elderly patient with poten-
tially resectable NSCLC is excluded from surgery due to co-
morbid conditions. The favourable 30-day and long-term survival
of the elderly patients observed in this study may likely reflect a
careful selection of patients but could also indicate that more
elderly patients with NSCLC could be operated on given recent
advances in surgical technique and perioperative care.
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